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ABSTRACT
Cervical  in t raep i the l ia l  neop las ia  (CIN) les ions  of the same 
m orpho log ica l  grade show var iab le  c l in ica l  behaviour ;  some 
progress  and others regress .  Curren t ly ,  there  are no b iochemical  
or m olecu la r  markers which can d is t ingu ish  CIN les ions  with 
d i f fe ren t  p rognosis .  We have op t im ised  several  molecular  
methods on archival  cerv ica l  smears and screened  a number  of 
m olecu la r  markers  that  may aid p rognosis  of  CIN.
By sys tem at ica l ly  va l ida t ing  d if fe ren t  p ro toco ls ,  we have 
es tab l ished  that crude DNA prepa ra t ions  from a small number  of 
mic rod issec ted  cel ls  from cervical  smears  are adequate  for 
var ious  PCR-based  inves t iga t ions .  Fu r the rm ore ,  the crude DNA 
prepara t ions  could be fur ther  pur i f ied  and used for PCR-based  
c lonal i ty  analysis  of  the X-l inked genes.
Using PCR-based  c lona l i ty  analysis  of  the androgen recep to r  
gene, we have shown that  CIN3 and the m ajo r i ty  of  CIN2 les ions  
are monoclonal ,  whereas  CIN1 les ions  are po lyc lona l .  
Im portan t ly ,  pa t ien ts  with monoclonal  CIN2 show d isease  
pers is tence  or p rog res s ion ,  while  po ly c lo n a l  CIN2 regress  af ter  
t rea tment  and remain  nega t ive  during fo l low -up .
To fur ther  iden t i fy  m olecu la r  markers  that  are techn ica l ly  easy to 
apply and p o ten t ia l ly  su i tab le  for  prognosis  assessment  of all CIN 
grades ,  we have inves t iga ted  the p rognost ic  value  of gene
dele t ions .  In a p i lo t  s tudy,  we screened 12 m ic rosa te l l i te  
markers ,  which  showed high f requencies  of loss of he te rozygos i ty  
(LOH) in cerv ica l  carc inom as ,  and iden t i f ied  four, inc lud ing
D3S1300,  D3S1260,  D11S35 and D11S528,  that  were
s ign if ican t ly  a ssoc ia ted  with CIN pers is tence  or p rogress ion .  The 
4 markers  were fu r ther  inves t iga ted  in a larger  cohort .
Combined ana lys is  of LOH at these 4 loci  perm it ted  the 
iden t i f ica t ion  of 22-47% of  CIN les ions  of var ious  h is to log ica l  
grades ,  that  were a ssoc ia ted  with disease  pe rs is tence  or 
progress ion  with 100% spec i f ic i ty .  LOH at these  loci  was
s ign if ican t ly  a ssoc ia ted  with HPV16 infec t ion .  B io in fo rm at ics  
analysis  iden t i f ied  severa l  candidate  genes inc lud ing  the f rag i le  
h is t id ine  t r iad  and p roges te ro n e  recep to r  gene that  may be the 
target  of de le t ions .
CHAPTER 1 
GENERAL INTRODUCTION
Carcinoma of  the uterine cervix  is the second leading  cause of 
carc inom a re la ted  death  in women worldwide,  w i th  an es t im ated
470,000 newly diagnosed cases per year (Drain  et a l , 2002).  The 
age of peak  incidence  is be tween 45-59 years  (S tock ton  et al,  
1997;Schoel l  et al,  1999). There  are two main types of  cerv ica l  
carc inom a,  squamous cell carc inom a and adenocarc inom a,  with 
the form er  accounting  for about 75%. Most of cerv ica l  squamous 
carc inom as are preceded by the p re -n eo p las t ic  s tage,  re fe r red  to 
as cerv ica l  in t raep i the l ia l  neop las ia  (CIN). CIN is the research  
subject  of  th is  thesis .
1.1 Epidemiology
1.1.1 Incidence
A pprox im ate ly ,  470 ,000  women are d iagnosed  with cerv ica l  
carc inom a worldwide  each year ,  accounting  for  10% of  all 
ca rc inom as  d iagnosed  in women (Drain  et al ,  2002) .  Around ,  80% 
of cases occur  in the deve lop ing  world ,  where  the d isease  is 
usual ly  de tec ted  at advanced  s tages  causing  190,000 deaths  each 
year (P isan i  et  al,  1999 ;Pa tn ick ,  2000 ;D ra in  et al ,  2002).
The incidence  of  invasive  cervical  carcinoma in many W estern  
countr ies  has fa l len  due to the in troduct ion  of cerv ica l  carc inom a 
screening  programmes.  In England,  s ince in t roduc t ion  of the 
Nat ional  Heal th  Service  Cervical  Screening  Programme 
(NHSCSP) in 1988, the inc idence  of invasive cerv ica l  carc inom a 
had dropped from 16/100,000 in the mid-1980s ,  to 10/100,000 in 
1995 with an overa l l  decl ine  of 35% (Quinn et a l , 1999;Levi  et  
al,  2000). The drop of the incidence occurred in every age group 
from 30-34 to 70-74, in pa r t icu la r  in 50-54 age group (Quinn et  
al,  1999;Levi  et  al,  2000).
In con tras t ,  the inc idence  of cervica l  carc inom a in develop ing  
coun tr ies  remains  high. For example , in India  the rate was 
99 .1 /10 ,000  in the period  of 1982-1995, and in Cali Colombia  it 
was 77 .4 /100 ,000  in the period  of 1987-1991 (Soler  et al,  2000; 
Shanta  et al,  2000).
In contras t  to the  dram atic  drop of the inc idence  of cerv ica l  
carc inoma during  late 1980s and 1990s in the W estern  coun tr ies ,  
the incidence  of  CIN appears  to have increased .  In England,  it 
rose from about 55 / 100,000 in 1985 to 80 / 100,000 cases in the 
1995 (Quinn et al ,  1999). This increase  was p a r t icu la r ly  
p rom inent  in wom en aged 20-29 (Quinn et al,  1999), whereas  
women in the age 30-49 group showed no overal l  increase  and the 
older  women group (aged 50-84) d isp layed  a decl ine  (Quinn et al ,  
1999).  The p r im ary  reason for the increase  of CIN in women aged 
2 0 -2 9  might  be re la ted  to the change in sexual  behav iou r  in
women including  the early onset  of sexual ac t iv i ty  and 
consequent ly ,  ear l ie r  age of HPV infect ion .
1.1.2 Mortality
The worldwide  cerv ica l  carcinoma m orta l i ty  rate  of  nearly
200,000 deaths / annum (Drain  et a l , 2002) has been decl in ing  in 
developed countr ies  by up to 70% over the las t few decades  since 
in t roduc t ion  of  the cerv ica l  carcinoma screening  p rogram m es .  In 
the UK, before  the in t roduc t ion  of the NHSCSP in 1988, cerv ica l  
carcinoma caused  11 .2 /100 ,000  deaths /  annum (Pa tn ick ,  2000; 
Quinn et al,  1999). By 1997, the m orta l i ty  rate  had fa l len  to 
3 .7 /100 ,000 ,  accounting  for  2% of carcinoma rela ted  death  in 
women (Pa tn ick ,  2000 ;Q uinn  et al,  1999).  The cerv ica l  carc inom a 
m orta l i ty  rate  con t inues  to fal l ,  by approxim ate ly  7% per annum 
(Patn ick ,  2000;Quinn  et  al,  1999).
In deve lop ing  coun tr ies  where  cerv ica l  carcinoma is s t i l l  the 
major  heal th  prob lem , the magni tude  of  this  d isease  is p robably  
much g rea ter  than recorded  because  there  are no comple te  and 
durable  tumour reg is t r ie s .  The h ighes t  morta l i ty  rate  has been 
repor ted  in A fr ica  (15 .3 /100 ,000) ,  fo l lowed by Latin  A m erica  
(14 .3 /100 ,000)  (Drain  et al,  2002).
1.2 Etiology
Based on both  ep idem io log ica l  and labora to ry  s tudies ,  it is now 
unders tood  that  the development  of  cerv ica l  carc inom a is 
a ssoc ia ted  with  severa l  r isk factors .
1.2.1 Human Papilloma Virus Infection
In the last  20 years ,  Human Papi l lom a Virus (HPV) has been at 
the centre  of  in v es t ig a t io ns  in re la t ion  to the e t io logy  of cervica l  
carc inoma.  The p reva len ce  of HPV-DNA found in cerv ica l  
carc inom a has d ram a t ica l ly  increased  with the improvement  of 
the de tec t ion  m ethods.  In the 1980s, the use of  Southern  blot  
analys is  iden t i f ied  HPV in 40-70% of cases (B o schb et al  , 2002).  
Fur ther  im provem en t  in the probe design and tes t ing  condit ions  
enabled  the de tec t ion  of HPV in near ly  100% of  cases (B oschb et  
al,  2002). Recent  s tud ies ,  us ing PCR on a large ser ies  of cases,  
have shown that  HPV in fec t ion  is p resen t  in 93-99% of cases 
(Bosch  et al ,  1995; W alboom ers  et al,  1999).
HPV represen ts  a h e te rogeneous  group of DNA viruses  
encom pass ing  a fam ily  of  more than 80 geno types ,  of  which 
about  40 are found in the  gen i ta l  t ract .  The curren t  HPV typing  is 
based  on sequence  d i f f e ren c e s ,  in pa r t icu la r  in the E6/E7 and LI 
reg ions  (Sou the rn  et  al ,  1998;Soler  et al,  2000;Sonnex ,  
1998 ;S tew art  et  al,  19 96) . .  HPV types can also be d iv ided  into 
cu taneous  or m ucosa l .  From a c l in ica l  pe rspec t ive ,  mucosal  HPV
types are fu r ther  subdiv ided  into low, in te rm edia te  and h igh-r isk  
groups depending  on the les ions  they are assoc ia ted  with.  Low- 
r isk  types such as HPV6 and 11, are a ssoc ia ted  with benign 
genita l  warts  and low-grade  CIN les ions (CIN1),  and are rare ly  
found in CIN2, CIN3 and invas ive  les ions .  On the o ther  hand, 
in te rm ed ia te - r i sk  types such as HPV31, 39, 52, and 58 and high- 
r isk  types, for  example  HPV16, 18, 33, 45 and 56, are more often 
seen in CIN2, CIN3 and cerv ica l  carc inom a than in CIN1 and 
border l ine  les ions  (Chan et al,  20 0 2 ;Ja s t reb o f f  et al,  2002;Lazo ,  
1999).
Evidence  from ep id em io lo g ica l  s tudies  s t rongly  ind ica tes  that  
HPV infec t ion  is a c r i t ic a l  fac to r  in the deve lopm ent  of cerv ica l  
carc inom a (Bosch et  al ,  1995). Nearly  all cervica l  carc inom as  
have de tec tab le  HPV (W alboom ers  et al,  1999).  H igh-r isk  HPV 
types are more of ten  seen  in CIN2, CIN3 and invas ive  cerv ica l  
carc inom a than CIN1 and bo rder l ine  les ions  (Chan et  al,  
2 0 0 2 ;Ja s t rebo f f  et al,  2002 ;Lazo ,  1999). Longitud inal  s tudies  
have shown that  HPV in fec t ion  precedes  the deve lopm ent  of 
cerv ica l  carc inom a (D i l ln e r  et al ,  1997). The p rospec t ive  case- 
contro l  s tud ies  show that  women with normal  Pap smear  tes t 
resu l t  but pos i t ive  for  high r isk HPV types had a 16.4 times 
h igher  r isk  of d eve lop ing  cerv ica l  carc inom a than those nega t ive  
for high r isk  HPV (W al l in  et al ,  1999). P re l im inary  resu l ts  of  a 
recent  HPV 16 vacc ine  t r ia l  showed decrease  in the inc idence  of
both HPV-16 in fec t io n  and HPV rela ted  CIN les ions  in women 
who received the vacc ine  but  not in the control  group (Koutsky et  
al,  2002) .
The s trong ep idem io log ica l  evidence in favour  of a causa t ive  role 
of HPV in fec t ion  in development  of cervica l  carcinoma is 
supported  by m olecu la r  s tudies  of the oncogenic  act iv i ty  of 
m olecu les  a ssoc ia ted  with the virus. Two viral  oncopro te ins  
namely E6 and E7 have been shown to play an important  role in 
the process  of  m al ignan t  t ransfo rm at ion .  Both p ro te ins  are 
cons is ten t ly  expressed  in cerv ica l  carcinoma cell l ines  and can 
im m orta l ize  p r im ary  cerv ica l  ep i the l ia l  cel ls  and human 
ke ra t inocy tes  in v i t ro  (zur Hausen,  1999;Southern  et al,  1998). 
T ransgen ic  mice with E6/E7 of HPV16 show hyperp la s t ic  and 
dysp las t ic  squam ous les ions  (Arbe it  et al,  1994;Coussens  et al,  
1996). M olecu lar  s tud ies  demons tra te  that  the HPV E6 pro te in  
b inds the p53 gene p roduc t  and the E7 pro te in  forms complexes 
with Rb gene (Dyson et  al,  1989;Werness  et al,  1990), thus 
b lock ing  the ir  tumour  supp re sse r  ac t iv i ty  (as de ta i led  in sect ion  
1 .8 . 1 . 1).
1.2.2 Sexual Behaviour And Other Infectious Agents
E pidem io log ica l  s tud ies  conducted  during the past  30 years  have 
cons is ten t ly  iden t i f ied  sexual  behav iour  as a major  r isk  fac to r  for 
cerv ica l  ca rc inom a and its assoc ia t ion  with this d isease  is in
many ways s imilar  to that  of  o ther  sexually  t ransm it ted  d iseases .  
Age at f i rs t  in te rcou rse ,  num ber  of sexual  pa r tne rs ,  c igare t te  
smoking,  low soc ioeconom ic  s ta tus ,  and the acqu is i t ion  of HPV 
are cons is ten t ly  l inked  to sexual  behav iour .  With the exception  
of HPV in fec t ion ,  none of  the others  have been shown to be 
s ign i f ican t  independen t  r isk  fac to r  (Rock et al,  2 0 0 0 ;Ja s t rebo f f  et 
al,  2002;Schoel l  et al ,  1999 ;Leh t inen  et al,  2002 ;C as te l lsague  et  
al,  2002). Cervical  ca rc inom a  rare ly  occurs  in nuns and v i rg ins  
(Morin  et al,  2000;  Ju ssaw a l la  et  al,  1984).  In Israe l ,  where  the 
lowest  worldwide  inc idence  of  cerv ica l  carc inom a is reg is te red ,  
this is most  l ikely re la ted  to the i r  conserva t ive  sexual  li fe  style  
(Sadan et al,  2003).
Chlamydia  t rachom at is  is the m ost  common sexual ly  t ransm it ted  
bac te r ia l  in fec t ion ,  and has been  cons is ten t ly  assoc ia ted  with 
cerv ica l  carcinoma and its p recu rso rs .  In a case control  s tudy, 
A n t t i la  et al showed tha t  the p resence  of serum an tibodies  to 
Chlamydia  t rachom at is  was a ssoc ia ted  with 6.6 fold increase  in 
r isk of cerv ica l  ca rc inom a  developm ent  as compared to 
se ronega t ive  women (A n t t i la  et  al,  2001). However this 
assoc ia t ion  has com m only  been  a t t r ibu ted  to be confounded  by 
HPV in fec t ions  (W al l in  et al,  2002 ;Sm ith  et al,  2002).
Herpes s implex virus  type  2 (HSV-2)  is another  in fec t ious  agent  
assoc ia ted  with sexua l ly  t r an sm i t ted  d iseases  (Cherpes et  al,
2003). The role of  HSV-2 in fec t ion  in development  of cervical  
carcinoma is unc lear .  HSV-2 assoc ia ted  oncogenes are capable  of 
t ransform ing  cel ls  in cu lture  (Tran-Thanh et al,  2003). However, 
the recent  s tudy with a h ighly  sensi t ive  and specif ic  PCR method 
fa i led  to de tec t  HSV-2 DNA in high grade CIN and invasive 
cervica l  carc inom a (Leht inen  et al ,  2002). The role of  HSV-2 in 
development  of  cerv ica l  carc inom a,  is thought  to be through the 
induced in f lam m atory  response  (Caste l lsague  et al,  2002).
Human Im m unodef ic iency  Virus (HIV) pos i t ive  women have 
consis ten t ly  been shown to be at an increased  risk of 
development  of cerv ica l  carc inom a (Francesch i  et al ,  1998;Selik  
et al ,  1998).  Since HPV and HIV share the same route of 
t ransm iss ion ,  it is d i f f icu l t  to de termine  their  respec t ive  
con tr ibu t ions  to the e t io logy  of the d isease .  Hence, the 
re la t ionsh ip  be tw een  HIV in fec t ion  and cervical  carc inoma could 
be exp la ined  e i the r  by the f requen t  occurrence  of HPV infec t ion  
in H IV -pos i t ive  women and /or by a d irec t  suppress ive  e ffec t  of 
HIV in fec t ion  on the immune system which may promote  the 
pe rs is tence  of  HPV in fec t ion  (Serra ino  et  al,  1999).
1.2.3 Hormones And Oral Contraceptives
An increased  inc idence  of  cerv ica l  carcinoma and its p recursors  
has been repor ted  in women using oral con tracep t ive  (Moreno et  
al,  2002). A case con tro l  s tudy carr ied  out by In te rna t iona l
Agency For  Research  on Carcinoma (IARC) (cases and controls  
were  pos i t ive  for  HPV DNA), showed tha t  the use of oral 
con tracep t ives  for f ive  or more years is a co fac to r  that  increases  
the risk of  cerv ica l  carcinoma up to four fo ld  (Boscha et al, 
2002;M oreno  et al,  2002). Mit ta l  et al showed that HPV 
express ion  in human ectocerv ica l  cel ls  l ines  was enhanced when 
p roges te rone  or g lucocor t ico ids  were added to the culture  (Mitta l  
et al,  1993). It has been shown by both in v i tro  and in vivo 
s tudies  that  s te ro id  hormones enhance the t ranscr ip t ion  of  the 
HPV E 6/E7genes  (Moodley et al ,  2003).
1.2.4 High Parity
High par i ty  has cons is ten t ly  been  found to be assoc ia ted  with 
cerv ica l  ca rc inom a  in most case-  contro l  s tudies .  In the IARC 
m u lt icen te r  s tudy,  HPV pos i t ive  women who repor ted  seven or 
more full term p regnanc ie s  had a fourfo ld  increased  r isk of 
cerv ica l  ca rc inom a  compared  with  s im ila r  HPV posi t ive  women 
who were n u l l ip a ro u s  (Munoz et al,  2002 ;H i ldeshe im  et  al,  
2 001 ;Sch if fm an  et al ,  1993).
1.2.5 Smoking
E p id em io lo g ica l  s tud ies  have im p l ica ted  c igare t te  smoking as a 
poss ib le  co n tr ib u t in g  fac to r  in the deve lopm ent  of cervica l  
ca rc inom a (Sou the rn  et  al ,  1998;La Vecchia  et al ,  1986). It has 
been shown that  sm okers  have a 4 -fo ld  increased  r isk  of
developing  cerv ica l  carcinoma compared  to non-sm okers  
(W inkels te in ,  1990). The actual  m echanism by which smoking 
leads to an increased  risk of cerv ica l  carc inom a is not fu l ly  
unders tood.  The cons t i tuen ts  of smoke and the ir  de r iva t ives  can 
enhance the p ro l i fe ra t ion  of HPV t rans fo rm ed  cerv ica l  cel ls  
(Morel l i  et al,  1993;W aggoner  et al,  1994). N ico t ine  and co t in ine  
are found at high levels  in cerv ica l  mucus of smokers ,  and are 
be l ieved  to have local  im m unosuppress ive  and mutagenic  e f fec ts  
(C as te l lsague  et al,  2002).  Reduct ion  in number  and func t ion  of 
Langerhans  cells  and he lpe r / inducer  T lym phocy tes  has been 
observed  in the squamous ep i the l ium  of the ce rv ica l  
t ransfo rm ation  zone in female  smokers  (M ore l l i  et  al,  
1993;Waggoner  et al,  1994).
1.3 Histology
1.3.1 The Normal Cervix
The uterus consis ts  of  the corpus and the cervix .  The cerv ix  is 
covered  on its outer  surface  (ec tocerv ix )  by s t ra t i f ied  squam ous 
ep i the l ium  (Figure  1.1),  and on its inner  surface  (endocerv ica l  
canal)  by the mucus secre t ing  co lum nar  ep i the l ium  (Figure  1.2) 
and assoc ia ted  crypts .
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A B
Fi g u r e  1.1: N o r m a l  e c t o c e r v i c a l  s q u a m o u s  e p i t h e l i u m ,  A: H i s t o l o g i c a l  
s e c t i o n ,  s h o w s  s t r a t i f i e d  s q u a m o u s  e p i t h e l i u m .  B: Pap s m e a r  
s h o w s  s u p e r f i c i a l  s q u a m o u s  e p i t h e l i a l  c e l l  and i n t e r m e d i a t e  
c e l l s .
B
Fi gure  1.2: N o r m a l  e n d o c e r v i c a l  c o l u m n a r  e p i t h e l i u m .  A: H i s t o l o g i c a l  
s e c t i o n  s h o w s  n o r m a l  e n d o c e r v i c a l  c o l u m n a r  e p i t h e l i u m ,  B:  
Pap s m e a r  s h o w s  e n d o c e r v i c a l  c o l u m n a r  e p i t h e l i u m .
T h e  j u n c t i o n  b e t w e e n  t he  t w o  d i f f e r e n t  e p i t h e l i a  is k n o w n  as the  
s q u a m o c o l u m n a r  j u n c t i o n  ( F i g u r e  1.3) .
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F i gu r e  1.3: H i s t o l o g y  s e c t i o n  s h o w i n g  s q u a m o c o l u m n a r  j u n c t i o n ,  wi t h  
s t r a t i f i e d  s q u a m o u s  e p i t h e l i u m  and e n d o c e r v i c a l  g l a n d s .
T h e  l o c a t i o n  o f  t he  s q u a m o c o l u m n a r  j u n c t i o n  v a r i e s  t h r o u g h o u t  
l i f e .  B e f o r e  p u b e r t y ,  i t  is u s u a l l y  l o c a t e d  w i t h i n  t he  e n d o c e r v i c a l  
c a n a l .  W i t h  t he  o n s e t  o f  t he  m e n s t r u a t i o n  o r  at  t he  t i m e  o f  t he  
f i r s t  p r e g n a n c y ,  i n c r e a s e  in v o l u m e  o f  t he  c e r v i x  l e a d s  to 
e v e r s i o n  o f  t he  c o l u m n a r  e p i t h e l i u m  ( e c t o p y ) ,  so t h a t  t he  
s q u a m o c o l u m n a r  j u n c t i o n  is l o c a t e d  d i s t a l  to t he  e x t e r n a l  os .  In 
t he  s e c o n d  a nd  t h i r d  d e c a d e  o f  l i f e ,  t he  s q u a m o c o l u m n a r  j u n c t i o n  
is l o c a t e d  n e a r  t he  e x t e r n a l  o s ,  b e c a u s e  t he  e c t o p i c  c o l u m n a r  
e p i t h e l i u m  u n d e r g o e s  m e t a p l a s t i c  c h a n g e  to a n o n - k e r a t i n i z i n g
s t r a t i f i e d  s q u a m o u s  e p i t h e l i u m .  T h e  p r o c e s s  o f  m e t a p l a s t i c
c h a n g e  is p a t c h y ,  o c c u r r i n g  at  s e v e r a l  s i t e s  in t he  e c t o p i c
c o l u m n a r  e p i t h e l i u m  at  d i f f e r e n t  t i m e s .  As  t he  m e n o p a u s e
a p p r o a c h e s ,  t he  c e r v i x  a t r o p h i e s  a n d  the  l o c a t i o n  o f  t he  
s q u a m o c o l u m n a r  j u n c t i o n  r e c e d e s  i n t o  t he  e n d o c e r v i c a l  c a n a l .
T h e  c o l u m n a r  e p i t h e l i u m  o f  t he  e x t e r n a l  os  is s u s c e p t i b l e  to 
m e t a p l a s t i c  c h a n g e s .  Th i s  m e t a p l a s t i c  c h a n g e  is a n o r m a l
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physio log ica l  p ro tec t ive  mechanism, where the f ragi le  m onolayer  
of the co lum nar  ep ithel ium is replaced by a pro tec t ive  
m ult i layered  squamous epi the l ium, upon exposure  to the acidic  
pH of the vagina  or chronic infec t ions .  During  this m etap las t ic  
process ,  the ep i the l ium  seems to be pa r t icu la r ly  vu lnerab le  to 
m al ignant  t rans fo rm at ion  and the region showing m etap las t ic  
changes is commonly refereed to as the t rans fo rm at ion  zone (TZ).
The ec tocerv ix  (Figure  1.1) is covered by s t ra t i f ied  squamous 
ep i the l ium , which is composed of four d is t inc t  layers .  Basal  layer  
cons is ts  of a s ingle  row of cells  and rests on a thin  basem ent  
m em brane .  It is responsible  for the cont inuous  ep i the l ia l  
regenera t ion  through active mitos is .  Midzone is the dom inan t  
por t ion  of  the epi thel ium, the lower  one th ird  of the m idzone  
known as parabasal  layer, also con tr ibu te s  to the ep i th e l ia l  
growth.  Cells  that  are involved in ascending  m atu ra t ion  occupy  
the upper  port ion  of the midzone.  These  cel ls  appear  in the Pap 
smear as large cells  and known as in te rm ed ia te  cel ls .  S u p e r f ic ia l  
zone conta ins  mature cel ls ,  which appear  in the Pap smear  as 
large cel ls  with large amount of  cy top lasm  and small ,  pykn o t ic  
nuc le i ,  they are known as superf ic ia l  squam ous ep i the l ia l  cel ls .
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1.3.2 Pre-Neoplastic Lesions
Most cerv ica l  carc inom as are be l ieved  to derive from p re ­
neop las t ic  ep i the l ia l  les ions  known as CIN, in which the 
abnormal cel ls  are confined  to the ep i the l ia l  layer . The 
in t raep i th e l ia l  neoplasm  may be of squamous or co lumnar  cell 
type.  Early  s tud ies  on mapping of CIN and the surrounding  
ep i the l ium  in cone b iops ies  showed that  only 3.1% of  CIN were 
found in the ec tocerv ix ,  9.7% were su rrounded  by endocerv ica l  
ep i the l ium  and the rem ain ing  87.2% occurred  within the 
t rans fo rm a t ion  zone (Abdul-K ar im  et al,  1982).
In Europe,  CIN is c la ss i f ied  using a th ree - t ie r  (CIN1-3)  (Arends 
et al,  1998) system c la ss i f ica t io n .  The d iv is ion  of CIN into 
d i f fe ren t  grades  is pure ly  on m orpho log ica l  g rounds .  The grading 
depends on the p ropor t ion  of  ep i the l ia l  th ickness  occupied  by 
d yska ryo t ic  cel ls  and the level  of  their  p leom orph ism  and 
m itoses .  The h is to log ica l  c r i te r ia  used for d iagnos is  of  d i f fe ren t  
g rades  of  CIN les ions  are sum m arized  below:
CIN1 (mild  dysp las ia ) :  CIN is a full  th ickness  change but 
p ro l i fe ra t in g  cells  and m itoses  are confined  to the lower one 
th ird  of the ep i the l ium  (F igure  1.4).
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Fi gure  1.4: H i s t o l o g y  o f  C I N 1 :  A b n o r m a l  c e l l s  are r e s t r i c t e d  
to t he l o w e r  o n e  t hi r d  o f  t he e p i t h e l i u m .
C I N 2  ( m o d e r a t e  d y s p l a s i a ) :  C I N  is a fu l l  t h i c k n e s s  c h a n g e  but  
p r o l i f e r a t i n g  c e l l s  and  m i t o s e s  a r e  c o n f i n e d  to t he  l o w e r  t w o -  
t h i r d s  a nd  ma y  be a b n o r m a l  ( F i g u r e  1.5) .
Fi gure  1.5: H i s t o l o g y  o f  C I N 2 :  A b n o r m a l  c e l l s  are  r e s t r i c t e d  
to t he b a s a l  t wo  t h i r d s  o f  t he  e p i t h e l i u m .
C I N 3  ( s e v e r e  d y s p l a s i a  a nd  c a r c i n o m a  in s i t u ) :  A t y p i c a l  c e l l s  
t r a n s e c t  t he  e n t i r e  e p i t h e l i u m  a nd  p r o l i f e r a t i n g  c e l l s  are  f o u n d  in 
al l  t h r e e  l a y e r s  bu t  do  n o t  i n v a d e  t he  b a s e m e n t  m e m b r a n e  ( F i g u r e  
1 .6) .  N u c l e a r  c r o w d i n g  and  p l e o m o r p h i s m  a r e  u s u a l l y  m o r e
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m a r k e d  t ha n  t h o s e  o f  CI N1  a n d  C I N 2 .  M i t o s e s  a re  f r e q u e n t ,  
p r e s e n t  in t he  u p p e r  one  t h i r d  o f  t he  e p i t h e l i u m  a nd  a r e  o f t e n  
a b n o r m a l .
Fi g u r e  1.6: H i s t o l o g y  o f  C I N 3 :  A b n o r m a l  c e l l s  t r a n s e c t  
t he e n t i r e  e p i t h e l i u m .
C y t o l o g i c a l  g r a d i n g  o f  C I N  l e s i o n s  r e l i e s  m a i n l y  on t he  ce l l  
m o r p h o l o g y ,  a s s u m i n g  t h a t  t he  s a m p l e  c o l l e c t e d  f r o m  t he  s u r f a c e  
r e f l e c t s  the  c h a n g e s  t h a t  o c c u r  t h r o u g h o u t  t he  e p i t h e l i u m .  T h e s e  
a b n o r m a l  c y t o l o g i c a l  c h a n g e s  are  t e r m e d  “ d y s k a r y o s i s ” . 
D y s k a r y o t i c  c e l l s  a r e  c l a s s i f i e d  i n t o  s u b g r o u p s  to e n a b l e  
c y t o p a t h o l o g i s t s  to p r e d i c t  t he  u n d e r l y i n g  h i s t o l o g i c a l  c h a n g e s  o f  
t he  c e r v i x .  T h r e e  g r a d e s  o f  d y s k a r y o s i s  ( m i l d ,  m o d e r a t e  and  
s e v e r e )  a re  r e c o g n i z e d  a c c o r d i n g  to  t he  n u c l e o - c y t o p l a s m i c  r a t i o .  
M i l d  d y s k a r y o s i s  c o r r e l a t e s  to C I N 1 .  D y s k a r y o t i c  c e l l s  s h o w  
e n l a r g e d  n u c l e i ,  w h i c h  o c c u p y  l e s s  t h a n  h a l f  o f  t he  c e l l  d i a m e t e r ,  
w i t h  i r r e g u l a r  n u c l e a r  o u t l i n e ,  a b n o r m a l  c h r o m a t i n  p a t t e r n  a n d  
h y p e r c h r o m a s i a  ( F i g u r e  1.7) .
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F i gu r e  1.7: C y t o l o g y  o f  mi l d  d y s k a r y o s i s :  D y s k a r y o t i c  c e l l s  s h o w
e n l a r g e d  h y p e r c h r o m a t i c  n u c l e i ,  w h i c h  o c c u p y  l e s s  than  
h a l f  o f  t he  c e l l  d i a m e t e r .
M o d e r a t e  d y s k a r y o s i s  c o r r e l a t e s  to C I N 2 .  T h e  n u c l e u s  o f  
d y s k a r y o t i c  c e l l s  o c c u p i e s  h a l f  to t w o - t h i r d s  o f  t he  ce l l  d i a m e t e r  
( F i g u r e  1.8) .
F i g u r e  1.8: C y t o l o g y  o f  m o d e r a t e  d y s k a r y o s i s :  D y s k a r y o t i c  c e l l s  
s h o w  e n l a r g e d  h y p e r c h r o m a t i c  n u c l e i ,  w h i c h  o c c u p y  
h a l f  to t w o - t h i r d s  o f  t he  c e l l  d i a m e t e r .
S e v e r e  d y s k a r y o s i s  c o r r e l a t e s  to C I N 3 .  T h e  n u c l e i  o f  d y s k a r y o t i c  
c e l l s  o c c u p y  m o r e  t ha n  t w o - t h i r d s  o f  t he  c e l l  d i a m e t e r  w i t h  o n l y
a t h i n  r i m o f  c y t o p l a s m  r e m a i n i n g  ( h i g h  n u c l e o -  c y t o p l a s m i c  
r a t i o )  ( F i g u r e  1.9) .
Fi g u r e  1.9: C y t o l o g y  o f  s e v e r e  d y s k a r y o s i s :  D y s k a r y o t i c  
c e l l s  s h o w  e n l a r g e d  h y p e r c h r o m a t i c  n u c l e i ,  
w h i c h  o c c u p y  m o r e  t han t w o - t h i r d s  o f  t h e  c e l l  
d i a m e t e r  w i t h  o n l y  a t hi n  r i m o f  c y t o p l a s m  
r e m a i n i n g .
In a d d i t i o n ,  a s e p a r a t e  c a t e g o r y  d e s c r i b i n g  c h a n g e s  l e s s e r  t ha n  
CI N1  is  c a l l e d  b o r d e r l i n e  c h a n g e s .  T h e  t e r m  b o r d e r l i n e  is u s e d  
w h e n  t h e r e  is u n c e r t a i n t y  i f  the  n u c l e a r  c h a n g e s  a r e  r e a c t i v e  or  
d y s p l a s t i c ,  fo r  e x a m p l e  d i s t i n c t i o n  b e t w e e n  b o r d e r l i n e  n u c l e a r  
c h a n g e s  and  m i l d  d y s k a r y o s i s  w h e n  H P V  i n f e c t i o n  is p r e s e n t .
1 .3 .3  I n v a s i v e  C e r v i c a l  C a r c i n o m a
M o s t  i n v a s i v e  c a r c i n o m a s  o f  t he  c e r v i x  d e v e l o p  w h e n  the  
d y s k a r y o t i c  c e l l s  f r o m  an i n t r a e p i t h e l i a l  l e s i o n  i n v a d e  t he  
b a s e m e n t  m e m b r a n e  as a c o n s e q u e n c e  o f  u n c o n t r o l l e d  c e l l  
d i v i s i o n .  H i s t o l o g i c a l l y ,  i n v a s i v e  c e r v i c a l  c a r c i n o m a s  are  
c l a s s i f i e d  as s q u a m o u s  ce l l  c a r c i n o m a ,  a d e n o c a r c i n o m a ,  
a d e n o s q u a m o u s  c a r c i n o m a  and  u n d i f f e r e n t i a t e d  c a r c i n o m a .
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Among these  d i f fe ren t  types ,  squamous cell  carcinoma is the 
most common, accounting  for 75% of  all  cases. As this thesis  
focuses  on the squamous les ions ,  only the h is to logy  of squamous 
carc inom a is descr ibed  below.
1.3.3 .1  H is to logy  Of Squamous Carcinoma
WHO c lass i f ied  cerv ica l  squamous cell  carc inom a into two 
ca tegor ies ,  ke ra t in iz ing  and non-kera t in iz ing .
Kera t in iz ing  carc inomas:  The tumours  are composed of
charac te r i s t ic  ep idermoid  cel ls ,  the most  s t r ik ing  fea tu res  of 
which are the c i rcu la r  whorls  of cel ls  with  central  nests  of 
kera t in  (ep i the l ia l  pear ls) .  The nucle i  are large  and 
h yperchrom at ic  with coarse  chrom atin .  M ito t ic  f igures  are not 
f requent .
N on-ke ra t in iz ing  carc inom as:  The tumour cel ls  are gene ra l ly  
recogn izab le  as squamous by the ir  po lygonal  shape and ev idence  
of kera t in  fo rm at ion  and ind iv idua l  cell ke ra t in iza t io n ,  but  
kera t in  pear ls  are not seen.  M ito t ic  f igures  are usual ly  num erous .
1.3 .3 .2  H is to log ica l  Features  That Suggest  Invasive  C arcinom a
Invas ion  of  the basem ent  mem brane  and beyond by n eo p la s t ic  
cells .
P leomorphism : The m orpho logy  of  carc inom a cel ls  is u sua l ly  
d i f fe ren t  from that  of CIN3 cel ls .  They usual ly  vary in size and 
shape and show giant  ce l ls  with one or more nucle i .  The nuc leus
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of a carc inom a cell  is of ten  la rger  and hyperchrom at ic ,  and 
usual ly  con ta ins  one or more p rom inen t  nuc leo l i .  Some m al ignant  
ce l ls  may con ta in  large cy top lasm ic  vacuo les ,  which  produce  a 
“ s igne t  r i n g ” appearance.
High m ito t ic  ac t iv i ty :  Invas ive  carc inom a cel ls  usua l ly  have high 
mito t ic  ac t iv i ty  and of ten show abnormal  m ito t ic  f igures  such as 
t r ipo la r  m itos is .
1.3.3 .3  S tag ing  Of Cervical  Carcinoma
Cervical  carc inom a is commonly  s taged accord ing  to the 
in te rn a t ion a l  Federa t ion  of  Gyneco logy  and O bs te t r ics  (FIGO) 
system (Nguyen et al,  1999):
Stage I: Tumour  is s t r ic t ly  confined  to the cerv ix ,  and is fu r ther  
subd iv ided  into:
Stage la: P rec l in ica l  carc inom a of the cerv ix ,  d iagnosed  only by
h is to lo g ica l  exam ina t ion  of b iops ies .
Stage Ia l :  Les ions with  m in im al  m ic roscop ic  ev idence  of st romal  
invas ion .
Stage Ia2: M icroscop ic  les ions  with  the depth  of  invas ion  less
than 5mm and the ho r izon ta l  spread  less  than 7mm.
Stage lb: Les ions g rea te r  than s tage Ia2, w he ther  seen c l in ica l ly
or not .
Stage II: Tumour ex tends beyond  the cervix ,  but  not  yet involves 
the pe lv ic  wall.  The ca rc inom a may involve  the vagina ,  but  not 
the lower  third.
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Stage Ila: No obvious param etr ia l  involvement .
Stage lib: Obvious param etr ia l  involvement .
Stage III: Tumour extends to the pe lv ic  s idewal l  or the lower
third of the vagina  and all cases inc lud ing  those  with
hydronephros is  or nonfunct ion ing  kidney.
Stage Ilia: No involvem ent  of the pelvic  wall.
Stage Illb: Involvement  of the pelvic  wall,  hyd ronephros is  or 
nonfunct ion ing  kidney.
Stage IV: Tumour extends beyond the pe lv is  or c l in ica l ly
involves  the mucosa of the b ladder  or rectum.
Stage IVa: Spread to ad jacent  organs.
Stage IVb: Spread to d is tan t  organs.
1.4 Detection Of CIN By Cytology
In 1928 George Papan ico laou ,  reported that  tumour  cells  from 
women with cerv ica l  carc inom a could be de tec ted  in vaginal  
smears. The idea was not readily  received  unti l  1941 when 
Papan ico laou  and Trout  pub l ished  their  monograph,  in which he 
and his co l league  descr ibed  the range of cel ls  seen in vaginal  
smears.  The po ten t ia l  of this  technique  as a sc reen ing  method 
for cerv ica l  carc inom a and de tec t ing  it at its ea r l ie s t  and most 
t rea tab le  stage was rea l ized  and the cervical  carc inom a screening  
programme was in troduced  in Europe and North A m erica  in 1960.
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1.4.1 Specimen Collection And Preparation Of Cervical 
Smears
The most  common tool for sampling  the cervix  is the cerv ica l  
scrape, which is done by a specia l ly  designed wooden or p las t ic  
spatula .
The cervix  is c lear ly  v isua l ized  and the end of the spa tu la  is 
inser ted  into the cervica l  os and ro ta ted  for  360°. The cerv ica l  
mucus and cells  adhering to the spa tu la  are spread evenly across  
a glass sl ide. The sl ide is f ixed imm edia te ly  e i ther  by imm ers ion  
in 95% ethanol  for at least  30 min or by spray f ixa t ive  
(po lye thy lene  coat ing f ixa t ive) .  The sl ides are then s ta ined  with 
Papanico laou  stain  (Pap).
1.4.2 The NHS Cervical Screening Programme (NHSCSP)
The appl ica t ion  of Papanico laou  smear  tes t as a sc reen ing  method 
for cerv ica l  carcinoma in the past  decades  has led to a d ram atic  
decrease  in both its incidence  and m orta l i ty .  The s teady decl ine  
is la rge ly  a t t r ibu ted  to early d iagnos is  and success fu l  t rea tm en t  
of CIN les ions thus p reven t ing  them to develop  into invas ive  
carc inom as.  Papanico laou  smear sc reen ing  is capable  of de tec t ing  
precarc inom aous  les ions  as well  as asym ptom at ic  invas ive  
squamous carc inomas,  both of which  can be t rea ted  e f fec t ive ly .  
The NHSCSP was in troduced  in 1988 in the UK (Cuzick  et  al, 
1999 Herbert ,  1997).
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1.4 .2.1 The Targeted Population
In England and Wales , women aged between 20 and 64 years are 
invited  for  cerv ica l  screening  every 3-5 years .  In Scotland  the 
ta rge ted  age group is be tween 20 and 60 years ,  at 3 yearly 
in te rva ls  (Cuzick et al,  1999;Pa tn ick ,  2000).  There are 
approxim ate ly  15 mil l ion women within  these age groups in 
Bri ta in  (Patn ick ,  2000).
1.4 .2 .2  The Screening Interval
The e ffec t iveness  of the screen ing  programme can be judged  by 
coverage .  This is the percen tage  of women in the target  age 
group (25-64) who have been screened in a g iven f ive-year  
period .  The coverage has improved from about 50% in the mid- 
1980s to 85% in 1998 and has s tab i l ized  at this  level  (Cuzick  et 
al,  1999;Patn ick ,  2000).
1.4.2.3 Evidence That Cervical  Screening Reduces  Cervical  
Carcinoma
Both the inc idence  and m orta l i ty  rate  of cerv ica l  carc inom a in 
the UK have fa l len  since the in t roduc t ion  of the NHSCSP. The 
incidence  fel l from 16/100,000 in the m id-1980s to 10/100,000 in 
1995, whi ls t  the m orta l i ty  rate  dropped from 11 .2 /100 ,000  in the 
mid-1980s to 3 .7 /100 ,000  in 1997 (Patnick,  2000 ;Q uinn  et al,  
1999).
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1.4 .2.4 Problems With The Cervical  Smear Test
Although it has proved to be success fu l ,  cerv ica l  cytology 
screening  is not wi thout  its problems.  It is h ighly  labour 
in tensive  and requires  highly skil led personal  (Baldwin  et al,  
2003).  Some pract ical  d i f f icu l t ies  assoc ia ted  with convent iona l  
cy to log ica l  screening  are summarized below.
1) Sampling  errors:  A l imited  number of cells  are co l lec ted  which 
may not be rep resen ta t ive  of the lesion ( les ions  high up in the 
endocerv ica l  canal  should be sampled by endocerv ica l  brush).
2) Errors  rela ted  to smear preparat ion:  Uneven spreading  of the 
mater ia l  on the sl ide,  poor ce l lu la r  p reserva t ion  due to delay in 
f ixa t ion  may lead to a ir -d ry ing  art i fac t  or poor quali ty  s ta in ing .
3) Errors  re la ted  to in te rp re ta t ion :  False negat ive  and false
pos i t ive  resul ts  are the main concern.  Excess ive  presence  of 
in f lam m atory  cel ls  can obscure  the abnormal  cells .  High 
work load  may affect  the performance  of indiv idua l  cy to log is ts .  
The repor ted  sens i t iv i ty  of a single cerv ica l  smear tes t (the 
p ropor t ion  of disease  pos i t ives  that  are test  pos i t ive )  is low and 
shows a wide var ia t ion  (30-87%),  and the spec i f ic i ty  of a s ingle  
Pap test  (the p ropor t ion  of d isease negat ives  that  are test 
negat ive)  might be as low as 86% (Baldwin et al,  2003). 
Sens i t iv i ty  and spec i f ic i ty  could be improved by reducing  false 
pos i t ive  and false negat ive  resul ts  through improving  the 
sampling quali ty ,  reduc ing  the labora tory  errors and e l im ina t ion  
of in te robse rver  va r ia t ions .
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1.4 .2 .5  Im provem ent Of Cervical  Smear Test
To reduce the false pos i t ive  and false negat ive  resul ts  of 
conven t iona l  smears sc reening ,  several  new techno log ies  have 
been  developed and some of them are a lready incorpora ted  into 
c l in ica l  prac t ice .
1.4 .2 .5 .1  M onolayer  (Liquid-Based)  Cytology Preparat ions
The cells  co l lec ted  from the cervix are f i rs t  put into a l iquid  
t ranspor t  medium and la ter  p la ted  out as a th in - laye r  of cel ls  on 
g lass  sl ides  in labora to r ies .  There are a number of advantages  for 
this  approach.
1) A uniform th in - layer  of approxim ate ly  80000 cel ls  provides  
be t te r  morphology;
2) Smaller  sl ide area to be screened:  17x20mm2 versus  
24x50m m 2 for convent iona l  sl ides;
3) Sui tab le  for au tomated  screening:  It is hoped that  a h igh-speed  
camera  can be used to scan about 200 convent iona l  smears daily. 
The advantage  of  this method is that it is cost e ffec t ive .
4) Excess  blood and in f lam m atory  cel ls  are lysed;
5) Several  s l ides  can be genera ted  from one sample ,  thus 
a l lowing  for addit ional  tes ts ,  such as im m unocy tochem is t ry  and 
m olecu la r  inves t iga t ion  (L ina et al,  2000).
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1.4 .2 .5 .2  HPV Typing
HPV typing is now increas ing ly  used to ass is t  the in te rp re ta t ion  
of  a smear test.  HPV infec t ion  is s t rongly  assoc ia ted  with 
deve lopm ent  of CIN. The HPV is posi t ive  in 80% CIN les ions but 
only in 11-20% of normal smears (Kjaer  et  al ,  2002;Stan ley ,  
2001). Moreover  high risk HPV is assoc ia ted  s ign i f ican t ly  with 
h igh-grade  CIN les ions  and cervical  carc inom a (Chan et al,  
2 0 0 2 ;Ja s t rebo f f  et al,  2002;Lazo,  1999). A l though  HPV infec t ion  
may be t rans ien t ,  pe rs is ten t  infec t ion  of high r isk HPV has been 
shown to be c losely  assoc ia ted  with pers is tence  and p rogress ion  
of  CIN les ions  (Nobbenhuis  et al,  1999).
Conven t iona l  smear tes t  together  with HPV typ ing ,  de tects  90- 
100% of h igh-grade  CIN les ions  (Rock et al,  2000). When l iquid-  
based  cyto logy is combined with HPV typing,  100% of h igh-grade  
CIN les ions  are hoped to be detec ted  (Rock et  al,  2000).
1.4 .2 .5 .3  Im m unocytochem istry  Of Cell P ro l i ferat ion  Markers
1) P ro l i fe ra t ing  cell nuc lear  antigen (PCNA) express ion ;  PCNA 
funct ions  as an auxil ia ry  fac tor  for DNA po lym erases ,  and is
invo lved  in DNA repa ir  and rep l ica t ion .  However ,  PCNA
express ion  in normal cervix is res t r ic ted  to the basal  layer . In 
CIN, PCNA is expressed  at various levels  of the epi thel ium
(Demeter  et  al,  1994;Baldwin  et al,  2003) . PCNA express ion
genera l ly  corre la tes  with  the grade of CIN, m itos is  and the copy 
number  of HPV infec t ion  as well as the E6/E7 t ranscr ip t  level
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(Dol lard  et al,  1992;Shurbaji  et al,  1993;Baldwin  et al,  
2003;Dem ete r  et al,  1994).  Sta in ing for PCNA can be affected by 
a var ie ty  of fac tors ,  including  f ixat ion  time (Rowlands  et al,  
1991).  The sens i t iv i ty  and specif ic i ty  of PCNA sta in ing  for 
de tec t ion  of  dyskaryo t ic  cells  have been shown to be low v/hen 
applied  to cerv ica l  smears (Wil l iams et al,  1998).
2) Ki-67 express ion ;  Ki-67 is a nuclear  an t igen ,  which is used as 
cell p ro l i fe ra t ion  marker .  Similar  to PCNA, Ki-67 is expressed  
only in basal  cel ls  of  normal cervix,  but shows increased  
f requency and p e rs i s tence  of express ion  in CIN and squamous 
cell carc inom a (Konish i  et al,  1991). A l though  some studies  
showed that  Ki-67 express ion  in superf ic ia l  ep i the l ia l  layers  
pos i t ive ly  corre la tes  with  the grade of CIN and presence  of high 
risk HPV (K ru sea et al,  2001 ;K ruseb et al ,  2001;Baisch ,  
1987;Verhe i jen  et al,  1989), the sens i t iv i ty  and spec i f ic i ty  of Ki- 
67 s ta in ing  for de tec t ion  of dyskaryo t ic  cells  have been shown to 
be low, when applied  to cerv ica l  smears (W il l iams et al,  1998).
3) M in ichrom osom e m ain tenance  pro te ins  (Mem) and Cdc6; The 
Mem and Cdc6 p ro te ins  are members of the p re - rep l ica t ion  
complex that  is essen t ia l  for l icens ing  DNA rep l ica t ion  (Lei  et  
al,  2001).  S ta in ing  for Mem and Cdc6 pro teins  have shown high 
sens i t iv i ty  and spec i f ic i ty  for de tec t ion  of dyskaryo t ic  cel ls  in 
both cerv ica l  smears and b iops ies  (Freeman et al,  1999;W il l iams 
et al,  1998).  In addit ion ,  the an t ibodies  for Mem and Cdc6 work
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on both fresh  and fixed specimens thus can be applied  to both 
cy to log ica l  and h is to log ica l  specimens.
A nt ibod ies  against  Mem and Cdc6 showed high percen tage  of 
im m unosta ined  cells  in high grade CIN (78-100%) and in low 
grade CIN (8-70%).  Whereas,  an tibodies  against  PCNA and Ki-67 
showed low percen tage  (5-20%),  (3-10%) in high and low grade 
CIN respec t ive ly  (Wil l iams et al,  1998).
1.5 Natural History Of Cervical Intraepithelial 
Neoplasia
Despite  the apparent  m orpho log ica l  hom ogeneity  w ith in  each su b ­
group, CIN les ions  show var iab le  c l in ica l  behaviour .  In rev iewing 
the l i te ra tu re  over the past  40 years,  Ostor ,  Duggan et al, found 
that  in absence  of any t rea tm ent ,  60% of CIN1 regressed ,  30% 
pers is ted ,  whereas  10% progressed  to a h igher -g rade  les ion 
(Duggan et al,  1998;Ostor ,  1993). Around 40% of CIN2
regressed ,  whereas  40% and 20% showed pers is tence  or 
p rog ress ion  to a h igher-g rade  les ion respec t ive ly  (Duggan et  al,  
1998;Ostor ,  1993). S im ila r ly ,  32% of CIN3 regressed ,  while  56% 
and 12% showed pers is tence  or p rogress ion  to carc inom a in situ 
or invas ive  carc inom a respec t ive ly  (Duggan et al ,  1998 ;Ostor, 
1993).
The risk of p rogress ion  from low to high grade CIN has been 
shown to be g rea ter  in pa t ien ts  with pers is ten t  h igh -r isk  HPV
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in fec t ion .  Follow up s tudies of women with and w ithout  cervical  
abnorm al i t ie s  have indicated that  the pe rs is ten t  presence  of high- 
r i sk  HPV infec t ion  is necessary  for the development ,  
m ain tenance ,  and progress ion  of CIN les ions  (Koutsky et al,  
1992;Nobbenhuis  et al,  1999). Moreover women with a low grade 
les ion ,  who are negat ive  for h igh-r isk  HPV DNA, are unl ike ly  to 
develop  CIN2/3 and their  cy to logica l  f inding is l ike ly  to return  to 
normal  (Nobbenhuis  et al,  2001;Z ie l insk i  et al,  2001).
The m al ignan t  potent ia l  of high grade CIN is s t rongly  supported  
by the study of Mclndoe WA, et al from the Nat iona l  W om e n ’s 
H osp i ta l  in New Zealand (M clndoe  et al,  1984). They fo l lowed up 
u n trea ted  women with pe rs is ten t  abnormal cy to logy  fo l lowing 
d iagnos is  of carcinoma in situ in 1970s, and showed that  22% of 
them developed invasive  cerv ica l  carcinoma.
The ep idem io log ica l  s tudies  show that  the mean age of pa t ien ts  
w i th  carcinoma in si tu is 15.6 years younger  than that  of pa t ien ts  
w i th  invas ive  carc inom a (Cramer et al,  1974). The data  suggest  
that  on average ,  it p robably  takes more than 10 years  for  a CIN 
les ion  to develop into an invas ive  carcinoma. R ichar t  and Barron 
repor ted  that  58 months were needed for a CIN1 les ion  to develop 
into  a carc inom a in si tu,  38 months for CIN2, and 12 months for 
CIN3 (Barron  et al  1970). They predic ted  that  66% of all 
dysp las ia  would p rogress  to CIS within  10 years in the absence of 
t rea tm ent .
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1.6 Management Of CIN Lesions
1.6.1 Management Of CIN1
There is no absolute  in te rna t iona l  agreem ent  on m anagement  of 
women with CIN1. In general ,  each case needs to be decided on 
an ind iv idua l  basis .  Due to the high spontaneous  regress ion  rate 
and a long incubat ion  period for CIN1 les ions  to progress  into a 
h igh-grade  les ion (Duggan et  al,  1998;Ostor ,  1993), a repeat  
cerv ica l  smear in 6 months is usual ly  recom mended  in the f i rs t  
ins tance .  Colposcopy is recommended if  the repeat  smear 
continues  showing abnormal cel ls  (NHS ABC decum ent ,  2000).  If  
2-3 consecu t ive  smears show negat ive  resu l ts  w i th in  12-18 
months of the fol low up, the women may be re turned  to a rout ine  
cerv ica l  screening .  High r isk  HPV typing has been  included in the 
managem ent  of CIN1. If  a h igh-r isk  HPV infec t ion  pers is ts ,  
pa t ien ts  who are under  30 years of age should  be fo l lowed by 
co lposcopy ,  whereas  those who are over 35 years  should be 
t rea ted .  Pa t ien t  may re turn  to a rout ine  screening  if  the fo l low-up 
smear and h igh-r isk  HPV are negat ive .
1.6.2 Management Of CIN2 And CIN3
There is no in te rna t iona l  agreem ent  on t rea tm ent  of CIN2 and 
CIN3 les ions ,  but the fo l low ing  gu ide l ines  are recommended.  
Pa t ien ts  with CIN2 or CIN3 les ions  are recom mended for 
co lposcop ic  exam ina t ion  w ith in  4 weeks of d iagnos is  and are
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usually  t rea ted  during co lposcopic  exam ina t ion  by “ se lect  and 
t r e a t” or “ see and t r ea t” s tra tegy.  In the s t ra tegy  of se lect  and 
treat ,  b iopsy  will be taken for h is to logy  and h igh-r isk  HPV 
typing.  If  the biopsy shows high-grade les ion ,  les ion should be 
removed using large loop excis ion of the t rans fo rm at ion  zone 
(LLETZ). On the other hand if  the b iopsy  shows a low-grade  
les ion,  pa t ien t  is recommended for co lposcopic  exam inat ion  in 6 
months. If  h igh-r isk  HPV infec t ion  pers is ts ,  the les ion  should  be 
t rea ted  by LLETZ. In see and treat  s t ra tegy ,  the les ion  is removed 
by LLETZ and sent for h is to log ica l  exam ina t ion  as well  as for 
h igh-r isk  HPV typing. The patien t  should be fo l lowed  up by 
co lposcopy in 6/12 months.
1.7 Treatment
1.7.1 Treatment Of CIN
Several  m odal i t ies  of t rea tm ent  are avai lab le  for  pa t ien ts  with 
CINs. The goal of these  t rea tm ent  m odal i t ies  is local  control  and 
p reven t ion  of invas ive  les ions .
1 .7 .1 .1 L a r g e  Loop E x c is io n  O f  The  T r a n s f o r m a t i o n  Zone  
( L L E T Z ) :  It is a w ide ly  used procedure  for d iagnosis  and 
t rea tm ent  of  CIN.
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Procedure :  During colposcopy,  a wire loop e lec trode  is p laced 
into the cervix to a depth of 5 to 6mm under  local  anesthesia .  
From one la tera l  margin of the t ransfo rm ation  zone, the loop is 
pul led  across and out at the opposi te  side so that  the enti re 
t rans fo rm at ion  zone can be removed (Cir isano,  1999).
Advantage:  It is a po ten t ia l ly  curat ive  procedure ,  which can be 
perform ed in an ou tpat ien t  c l inic.  It also prov ides  specimen for 
h i s to log ica l  d iagnosis  (Chan et al,  1997).
Disadvantage:  B leeding  during or pos t -ope ra t ion  has been
reported  in a range of 1% to 8%. Cervical  s tenos is  occurs  in 
approx im ate ly  1% of  pa t ien ts  t rea ted  by LLETZ (Bigr igg  et al,  
1990). LLETZ has a 97% cura t ive  rate and is the most  common 
method used for t rea tm ent  of CIN (Dey et al,  2002).
1.7 .1 .2  E x c is io n a l  Cone  B iopsy :  Several  types of  cone b iops ies  
inc lud ing  broad deep cone,  cy l indr ica l  cone and mini cone are 
used for t rea tm ent  of CIN. Coniza t ion  can be pe rform ed e i ther  
with a surg ical  scalpel  or with  a laser . Laser  cone biopsy  has 
fewer com pl ica t ions  than surg ical  (sca lpe l)  cone b iopsy ,  is far 
more prec ise  and causes less d is to r t ion  to the cerv ix .
Procedure:  An inc is ion  is made into the mucous mem brane  of the 
ec tocerv ix ,  which inc ludes  all the abnormal  area.
Advantage :  The method can be used as both d iagnos t ic  and 
t rea tm ent  p rocedure ,  with approx im ate ly  96% success  rate. 
D isadvantage:  This t rea tm ent  method is assoc ia ted  with  a high 
rate  of  com pl ica t ions  inc lud ing  haem orrhage ,  in fec t ion ,  and
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subsequent  deformity  or incompetence  of the cervix ,  which  has 
been repor ted  in up to 12% of the pat ien ts  (Luesley  et a l , 1985).
1.7.1.3  E lectrocoagulat ion  Diathermy
Procedure:  Under general  anesthesia ,  the cervix  is d i la ted  to 
expose the dis tal  canal; an e lectrode  is applied  to the abnormal  
t issue ,  a l lowing thermal destruct ion .
Advantage :  The method has 90% success  rate in t rea tm ent  of  CIN 
les ions  (Chanen,  1983;Benedet  et al, 1987;Creasman et al,  1984). 
D isadvantage:  General  anesthesia  and its com pl ica t ions .  Vag ina l  
d ischarge  or frank b leeding  may happen 3-4 weeks fo l low ing  the 
procedure .  Minor burn to the vulvar  skin may occur. No h is to logy  
is avai lab le .
1.7.1.4 Cryosurgery:
This technique  can be pe rform ed as an ou tpa t ien t  p rocedure .  
P rocedure:  A l iquid  re f r igeran t  such as n i trous  oxide is app l ied  to 
the CIN les ion through c ryoprobe .  An ice ball wil l  develop  after  
a f reeze period  of several  minutes .  This  can be repea ted  unt i l  the 
abnormal  t issue  is des t royed  complete ly .
Advantage :  The method is s imple  and eff ic ien t ,  with  a 94% of 
success  rate  (Benedet  et al,  1987;Creasman et al,  1984).
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Disadvantage:  Pa t ien ts  may feel fa in tness ,  mild abdominal  cramps 
during the procedure .  Watery  vaginal  d ischarge  may occur 2 to 3 
weeks fo l low ing  the opera t ion  (Paraskeva id is  et al,  2001). No 
h is to logy is avai lable .
1.7.1.5  Carbon Dioxide Laser  Ablation:
Procedure:  The carbon d ioxide  laser  beam is inv is ib le  and is 
usual ly  guided by a second laser  that  emits  v is ib le  l ight . The 
energy of the laser  is absorbed by water ,  and the t issue  is 
des troyed by vapor iza t ion .  The laser  is mounted  to and d irec ted  
by a co lposcope .
Advantage :  The method can be used for large  les ions  (Gunasekera  
et al,  1990). Success  ra tes  are ranged from 83% to 97% for CIN1- 
2, and 77% to 96% for CIN3.
Disadvantage:  It is a pa in fu l  procedure ,  and b leed ing  can be a 
problem as the depth of t issue  des truct ion  increases .
1.7 .1 .6  H ysterectomy:
Total hys te rec tom y may be perform ed for p re - invas ive  les ions  of 
the cervix,  i f  c l in ica l  c i rcum stances  are so negat ive .
Procedure:  The surg ica l  approach is based on pa t ien t  se lec t ion  
and may be e i ther  to ta l  vaginal  hys te rec tom y or abdominal  
hys te rec tom y.  If  ovar ian  removal  is ind ica ted ,  pa t ien ts  may be 
considered  for  lapa rosco p ic  ass is ted  vaginal  hys te rec tom y.
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Advantage:  This t rea tment  procedure  has the lowest  rate  of CIN 
recurrence.
D isadvantage:  It is too radical .  Fer t i l i ty  is lost  and the pat ien ts  
st i ll  need to be fo l lowed up by cerv ica l  smears because 
recurrence  does occur,  a l though the rate is low.
Because of  the concern over the poss ib i l i ty  of miss ing  invasive 
cerv ica l  carcinomas,  excis ional  methods for  CIN trea tm ent  
a l lowing exam inat ion  of t issue  are now being wide ly  used and 
replaced  the abla t ive  techn iques .  LLETZ is the most  common 
method used,  with its high success  rate.  (B igr igg  et a l , 1994; 
Luesley et al,  1990).
A l though  CIN les ions  can be e ffec t ive ly  t rea ted  by the ment ioned 
methods,  10-15% of cases show disease  recurrence  (B is to le t t i  et  
al,  1988;Elfgren  et al,  1996). One of the major  d i f f icu l t ie s  in the 
c l in ica l  management  of pa t ien ts  with CIN les ions  is to d is t inguish  
be tween those that  wil l  p rogress  or pers is t  from those that  wil l be 
cured.
1.7.2 Treatment Of Invasive Cervical Carcinoma:
Invas ive  cervica l  carc inom as are t rea ted  by surgery ,  rad io-or  
chemotherapy alone or by combinat ion .  The choice  of these 
d if fe ren t  t rea tm ent  methods is inf luenced by many fac tors  
including  w o m e n ’s age, heal th  and extent  of  the disease.  
Trea tm ent  is governed by the s tag ing  of the disease .  Pa t ien ts  with 
stage lb disease  are commonly t rea ted  with  w e r th e im ’s
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hysterec tom y or rad io therapy with a 5-year  surv iva l  in 70-90%. 
Radio therapy  gives s imilar  resul ts  to surgery but the rad ia t ion  
side e ffect  makes surgery the preferred  opt ion in the major i ty  of 
cases (Donato ,  1999). Stages I la  and l ib  d iseases  are t rea ted  with 
rad io therapy  with a 5-year  survival  rate in 70% of cases.  Pat ien ts  
with stages I l i a  and I l lb  disease  are t rea ted  with  rad io therapy  
with a 5-year  survival  rate  of 40%. Stages IVa and IVb disease 
are t rea ted  with rad io therapy  with 5-year  surv ival  rate  only 15%. 
Radio therapy  is given after  surgery when there  is lymph node 
spread or incom plete ly  excis ion  of the pr imary  tumour.  
Chemotherapy pr ior  to surg ical  t rea tment  is used to cause tumour 
shr inkage,  thus fac i l i t a t ing  the surgical  excis ion  of  the tumour.  
Chem o-rad io therapy  (c isp la t in -based )  has been used in t rea tment  
of large cerv ica l  les ions  where the dose of rad ia t ion  needed to 
achieve high rates of tumour control  exceeds the dose to le ra ted  
by normal  t issues  in the pelv is  (Green et al,  2001 ;Rose ,  2002).
1.8 Molecular Genetics
Despite  the im portan t  role of HPV associa ted  oncopro te in  in the 
genesis  of  cerv ica l  carc inom a,  there is strong ev idence  that  HPV 
infec t ion  alone is in su f f ic ien t  to cause m al ignant  t rans fo rm at ion  
(Southern  et al,  1998). Evidence  is now emerging  that  genet ic  
changes play a c r i t ica l  role in the t ransform at ion  of  HPV infec ted  
cells  and may account  for  the i r revers ib le  c l in ica l  behav iour  of
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CIN les ions .  These genet ic  changes include ac t iva t ion  of ce l lu la r  
oncogenes  and loss of tumour suppressor  genes.
1.8.1 Oncogenes
1.8.1.1  HPV Assoc iated  Oncogenes
All HPV types studied so far encode 8 Open Reading Frames 
(ORFs),  which are sequences  coding for p ro te ins  syn thes ized  
“ e a r ly ” (E) or “ l a t e ” (L) in vira l  rep l ica t ion  (early  and late refer  
to the t ime of v ira l  p ro te in  express ion  after  in fec t ion) .  The ORFs 
can be grouped according  to the ir  funct ion.
E l  gene encodes  a phosphopro te in  that  is the major  v iral  DNA 
rep l ica t ion  fac tor  and is necessary  for the in i t ia t io n  of v iral  DNA 
synthesis .  E l  has in t r ins ic  he l icase ,  ATPase  ac t iv i t ie s ,  and 
spec i f ic  DNA bind ing  abil i ty  (Lusky et al,  1991).  The E l  
pro te in ,  in assoc ia t ion  with E2, is essen t ia l  for v ira l  rep l ica t ion  
and the E1-E2 complex binds through E2 to spec i f ic  s i tes in the 
upstream regula tory  region im plica ted  in v iral  rep l ica t ion  and 
gene express ion .  E2 has the abil i ty  of t ransc r ip t ion  repress ion  of 
E6/E7, and its express ion  may resul t  in cell apoptos is  (D esa in tes  
et al,  1997).  In tegra t ion  of  the HPV genome into the host  
chromosome in the carc inom as  of ten  resul ts  in the d is rup t ion  of 
the viral  E l  or E2 genes (Southern  et al,  1998). The E2 gene is 
commonly d is rup ted  as a resu l t  of  v iral  in teg ra t ion ,  lead ing  to 
loss of its funct ion  (Choo et  al ,  1987; Corden et al ,  1999). Several
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s tudies  observed that  the loss of E2 express ion  in cerv ica l  
carc inoma cel ls  is importan t  in H PV -assoc ia ted  cerv ica l  
carc inogenes is .  A decrease  in HPV-18 E6/E7 t ranscr ip ts  has been 
detec ted  in Hela cel ls  after  the in troduc t ion  of E2 into the cel ls  
(Dowhanick  et al,  1995;Goodwin et al,  1998;Hwang et  al,  1993). 
The in troduc t ion  of E2 resul ts  in the growth arres t  of the HPV- 
posi t ive  carc inom a cell  l ines but  not the H PV-negat ive  carc inom a 
cell l ines (Dowhanick  et al, 1995;Goodwin et al,  1998;Hwang et  
al,  1993).
E3 and E4 encode pro te ins ,  which can d is rup t  the host  
cy top lasm ic  kera t in  ne twork,  p roducing  the c lass ica l  halo e ffec t  
in infected  kera t inocy tes .  The funct ion of E3 and E4 is not yet 
ful ly  unders tood  (Dowhanick  et al,  1995;Goodwin et al,  
1998;Hwang et al,  1993).
E5: It s t im ula tes  cell growth  by in te rac t ion  with the ep idermal  
growth fac tor  receptor  (Hwang et al,  1995;Zhang,B et al,  2002).  
E5 has been shown to have a t ransform ing  funct ion  in HPV types 
1, 6 and 16 (Chen, et al  1990;Crusius  et al,  1997). Moreover  E5 
has been shown to p revent  apoptos is  fo l lowing  DNA damage 
(Zhang,B et al,  2002). However ,  as H PV-infec ted  les ions  p rogress  
to cerv ica l  carcinoma,  the episomal viral  DNA f requen t ly  
becomes in tegra ted  into host  cell  DNA, and a subs tan t ia l  part  of  
genome, commonly inc luding  the E5 coding sequence  is de le ted  
(Schwarz  et al,  1985).
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E6 and E7 are the most important  HPV assoc ia ted  oncogenes .  E6 
and E7 can immortal ize  human cells ,  for example  t rans fec t ion  of 
human foresk in  kera t inocytes  with h igh-r isk  HPV DNA, bu t  not 
w i th  low-r isk  HPV DNA (Barbosa  et al ,  1991),  have been  
dem ons tra ted  to immortal ize  these cells  (Hawley-N elson  et al,  
1989;W oodworth  et al,  1989). Pers is ten t  express ion  of E6 and E7 
appears  necessary  to main ta in  the t ransform ed phenotype .  The 
app l ica t ion  of syn the t ic  anti E6 and E7 o l igonuc leo t ides  to 
cerv ica l  carc inoma cell l ines conta in ing  HPV-18 s ign i f ican t ly  
inh ib i ts  cell growth (Steele  et al,  1993). The E6 oncopro te in  
binds  to the p53 tumour suppressor  pro te in  and m edia tes  its 
degreda t ion  (Werness et al,  1990). The in te rac t ion  of h igh r isk  
HPV/E6 with p53 is not d i rec t  but  is mediated  by a ce l lu la r  
p ro te in  cal led  the E6-assoc ia ted  pro te in  (E6AP),  which is an 
ub iqu i t in  p ro te in  l igase  (Hubbert  et al,  1992;Scheffner  et  al ,  
1993;Talis  et al,  1998). In addit ion ,  E6 induces te lom erase  
ac t iv i ty  via  t ranscr ip t iona l  ac t iva t ion  of te lom erase  reverse  
t ransc r ip ta se  (hTERT) express ion  (K lingelhu tz  et al,  1996).
E7 binds the re t inob las tom a gene product  (Rb) and causes  its 
inac t iva t ion  which leads to cell p ro l i fe ra t ion  th rough  the 
ac t iva t ion  of genes under the control  of the E2F t r an sc r ip t io n  
fac to r  (S tanley ,  2001). When E2F prote in  complexes  with Rb, Rb 
acts  as a t ransc r ip t iona l  repressor  and suppresses  E2F 
t ran sc r ip t io n  act iv i ty  (Stanley ,  2001) . E7 binds to Rb, thus
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f ree ing  E2F and perm it t ing  its t r ansc r ip t iona l  act iv i ty .  In the 
normal li fe  cycle of HPV, the b inding of E7 to Rb is apparent ly  
essen t ia l  for the ac t iva t ion  of the cell cycle DNA rep l ica t ion  
machinery  in d i f fe ren t ia ted  kera t inocy tes  that  had otherwise  
exited  the cell  cycle.  HPV depends on the host  cell DNA 
polymerases  and rep l ica t ion  machinery  for the rep l ica t ion  of the 
vira l  genome. Because this machinery  is only expressed  in the S 
phase of the cell cycle, these viruses must  s t imula te  cel lu lar  
p ro l i fe ra t ion  and drive the cell  into S phase through  b inding  of 
E7 to Rb to free the E2F family  of t ransc r ip t ion  fac tors .
The in tegra t ion  of  v ira l  DNA into the host  genome does not occur 
at spec i f ic  chromosomal  si tes .  However, it has been found that  
HPV DNA may be in tegra ted  in the v ic in i ty  of known oncogene or 
tumour suppresser  gene (Sonnex,  1998). For example ,  in the HeLa 
cell l ine, in tegra t ion  of the HPV-18 genome is wi th in  
approx im ate ly  50 k i lobases  of  the c-myc oncogene  on human 
chromosome 8 (Durs t  et al,  1987), which may lead to increased  c- 
myc express ion  seen in a p ropor t ion  of cerv ica l  carc inoma. 
HPV16 in tegra t ions  in cerv ica l  carcinomas p re fe ren t ia l ly  target  
common fragi le  si tes inc lud ing  FRA3B (3 p l4 .2 )  where  the f ragi le  
h is t id ine  t r iad  (FHIT) gene,  a puta t ive  tumour suppresser  gene, is 
loca ted ,  and are accompanied  by de le t ion  of ce l lu la r  genes (Wilke 
et al,  1996;Thorland et al,  2003). Such an in teg ra t ion  event may 
lead to oncogene ac t iva t ion  or tumour suppresse r  gene
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inac t iva t ion ,  thus con tr ibu ting  to development  of cervical  
carcinoma.
1.8 .1 .2 Ras, c-myc
The Ras family  is a class of molecules  (G p ro te ins) ,  which are 
involved  in t ransm iss ion  of growth s t imula tory  s ignals  from the 
cell surface  membrane to the nucleus.  The gene conta ins  four 
exons,  which code for a 21-Kd protein  that  loca l izes  to the inner 
cell membrane  (McGrath  et al,  1984). Ras gene ac t iva t ion  is often 
caused by gene muta t ion  or gene am pl if ica t ion .  Several  studies 
have inves t iga ted  H-ras and K-ras gene m uta t ion  in cervical  
carcinoma since they are f requent ly  mutated in o ther  carcinomas.  
Col lec t ive ly ,  these studies  show that  14-35% of cervical  
carc inomas harbour  m uta t ion  in one of the H-ras hot-spots  
(codons 12,13 and 61) with the major i ty  occurr ing  at codon 12 
(Lee et al,  1996;Wong et al,  1995). Mutations in these hot-spots  
are known to cons t i tu t ive ly  act iva te  ras gene ac t iv i ty  (Barbacid, 
1987). Alonio  et al reported  Ha-ras mutat ion in 20% of CIN3 
les ions and 41% invas ive  carc inomas and showed that  the 
muta t ion  was assoc ia ted  with disease  p rogress ion  in 61% of cases 
(Alonio et a l , 2003) . In line with this f inding,  cerv ica l  carcinoma 
which over-express  ras p21 pro te in  has been shown to be 
assoc ia ted  with a poor p rognosis  (Sagae et a l , 1990). W hether  ras 
gene m uta t ion  is an ear ly event during cerv ica l  carcinoma 
developm ent  remains unclear  as confl ic t ing  data  on ras gene
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m uta t ion  in CINs have been reported  (Grendys et al,  1997;Lee et  
al,  1996). Several  s tudies  found no ras m uta t ions  or 
a m pl i f ica t ions  in CIN and invasive  carc inom a (Iwasaka et al,  
1992 ;Van Le et al,  1993;W il l is  et al,  1993).
The c-myc gene encodes a p ro te in  product  p redom inan t ly  located 
in  the cell nuc leus  and its const i tu t ive  express ion  genera l ly  
enforces  unscheduled  p ro l i fe ra t ion ,  p reven ts  d i f fe ren t ia t ion  or 
sens i t izes  cel ls  to apoptos is  (Donzel l i  et al,  1999;Facchin i  et al,  
1998;Galak t ionov  et  al,  1996;Koskinen  et  al,  1993). Several  
s tud ies  have shown that  c-myc gene ove r-express ion  is common 
and may corre la te  with the c l in ica l  behav iour  of  cerv ica l  
carc inom a.  Iwasaka  et al reported  an o ve r-express ion  of  c-myc 
gene as shown by im m unohis tochem is try  in 44% of invasive  
cerv ica l  carc inomas and an assoc ia t ion  of c-myc over-express ion  
with  poor p rognosis  ( Iwasaka  et al,  1992). Riou et al reported 
that  pa t ien ts  whose tumour showed c-myc ove r-express ion  had an 
e igh t - fo ld  g rea ter  inc idence  of early re lapse  than those w ithout  c- 
myc over express ion  (Riou et al,  1987). C-myc gene 
am pl i f ica t ion  has been found in 42% of h igh-grade  CIN les ions  
(Gol i jow  et al,  2001).  In some s tudies ,  the gene ampl i f ica t ion  
co rre la ted  with poor p rognosis  in early stage cases (Bourhis  et al,  
1990). As d iscussed  p rev ious ly ,  in tegra t ion  of the HPV genome 
f requen t ly  occurs  near the c-myc gene locus.  This  may deregula te  
c -myc t ranscr ip t iona l  regu la t ion  and account  for the cervica l
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carc inom as  that  show c-myc pro tein  ove r-express ion  but lack 
ev idence  of  the gene ampl i f ica t ion  (Coutur ie r  et  al,  1991).
1.8.2 Tumour Suppressor Genes
1.8 .2 .1  The Ret inoblastom a Gene
The re t inob las tom a gene is located on chromosome 1 3 q l4  and 
encodes  a nuc lear  phosphopro te in  (Rb). Rb is one of the major  
com ponents  that  regula te  the G l /S  t rans i t ion  and its checkpoin ts .  
It func t ions  by inh ib i t ing  the t ranscr ip t iona l  act iv i ty  of E2F, 
which  contro ls  the express ion  of genes necessary  for p rog res s ion  
into the S phase of the cell cycle.  The ac t iv i ty  of the Rb is 
m edia ted  by its phosphory la t ion  sta te. Rb is only able to complex 
with  E2F and blocks its t r anscr ip t iona l  ac t iv i ty  when it is in a 
hypophosphory la ted  state . When cel ls  are s t im ula ted  to 
p ro l i fe ra te ,  Rb becomes phosphory la ted  by the cycl in  D1/CDK4 
(cyc l in  dependent  k inase)  complex,  which contro ls  the t rans i t ion  
from G1 to S phase. This is normally  inh ib i ted  by cycl in-  
dependent  kinase  inh ib i to rs  (CDKI) such as p l 5  (WAF1), p l 6  
( INK4A),  p21 and p27 (KIP1) p ro te ins  (Arends et al,  1998;zur 
Hausen ,  2002;Baldwin  et al,  2003) . H yperphosphory la ted  Rb 
d is soc ia tes  from E2F, pe rm it t ing  its t r ansc r ip t iona l  ac t iv i ty .  
Re leased  E2F t ransac t iva te s  a set of  genes necessary  for  
p rog ress ion  into the S phase of the cell cycle.  These genes 
inc lude  cycl in  E, cycl in  A, Cdk2, and E2F-1 (one of the E2F
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fam ily )  (Arends et al,  1998;zur Hausen, 2002;Baldwin  et al, 
2003) .  In te res t ing ly ,  E2F-1 also induces the express ion  of 
p l9 A R F ,  which resul ts  in the s tab i l iza t ion  of  p53 (Hickman et al,  
2002) .  The t ranscr ip t iona l  ac t iva t ion  of E2F-1, as well  as cycl in  
E, cons t i tu tes  a feed-fo rward  mechanism: the addit ional
cyc l inE /C dk2  ac t iv i ty  ensures  the full phosphory la t ion  of Rb so 
tha t  more E2F molecules  are in the free act ive  form, which in 
turn resul ts  in an enhanced E2F1 and cycl in  E t ranscr ip t ion  (Sano 
et  al,  2002;zur  Hausen,  2002; Murphy et al,  2003).
1.8 .2 .2  p53 Gene
The p53 gene, located  on chromosome 1 7 p l3 .1 ,  encodes  for a 
t r an sc r ip t ion a l  fac tor  which p lays a c r i t ica l  role in m ain ta in ing  
the in tegr i ty  of genome, guarding  against  genome in s tab i l i ty  and 
oncogene  express ion ,  by inducing  both cell cycle arrest  and 
apop tos is  (Hickman et al,  2002).  A c t iva t ion  of p53 can be 
t r igge red  by both DNA damage agents  such as u l t rav io le t  or y 
rad ia t ion ,  carc inogens ,  chem othe rapeu t ic  drugs and non-DNA 
damaging  condit ions ,  inc lud ing  hypoxia  and d is rup t ion  of cell 
adhes ion  (Hickman et al,  2002). p53 ac t iva t ion  can also be 
t r igge red  by deregu la ted  express ion  of cer ta in  oncogenes  such as 
p l4 /1 9 A R F  (Hickman et al,  2002). These var ious  s ignals  act iva te  
p53 through  several  pa thways.  Once ac t iva ted ,  p53 t ransac t iva te s  
a set of  genes to induce cell  cycle  arrest  or apoptos is  (Hickman et  
al,  2002). The gene involved  in cell cycle a rres t  is mainly
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p 2 1 W A F l ,  which binds and inhibi ts  CDK p ar t icu la r ly  CDK2 
ac t iv i ty  (Harper  et al,  1993). The genes involved  in p53 mediated 
apoptos is  include BAX, NOXA, p53AIP, APF1, Puma and Fas 
(M iyash i ta  et al,  1994;Owen-Schaub et al,  1995;M iyash i ta  et al,  
1995;Moroni  et al,  2001 ;O daa et al,  2 0 0 0 ; 0 d a b et al,  
2000;Nakano et al,  2001).
In normal  cells ,  the level of p53 express ion is re la t ive ly  low and 
is regu la ted  by its regu la tor ,  MDM2. MDM2 binds to p53 and 
acts as an ub iqu it in  l igase ,  thus leads to p53 degradat ion  
(Skomedal  et al,  1999). D issocia t ion  of p53 from MDM2 can be 
induced  by phosphory la t ion  of  p53 and/or  MDM2 on severa l  key 
res idues  by s tress  or DNA damage ac t iva ted  k inases (Pr ives ,
1998).  In addit ion ,  MDM2 can be seques t ra ted  by p l4 A R F  
(Michael  et al,  2002) .
Inac t iva t ion  of p53 funct ion  could resul t  in inappropr ia te  
rep l ica t ion  of damaged DNA, inappropr ia te  cel l  surv iva l  after  
ce l lu la r  s t ress  or abnormal segrega t ion  of chromosomes during 
m itosis ,  thus con tr ibu t ing  to m al ignant  t rans fo rm at ion .  Loss of 
p53 funct ion  is the most common genet ic  de fec t  found in human 
carc inom a,  and is commonly caused by m uta t ion  in one a lle le  and 
loss  of the other ,  or increased  degradat ion  by both ce l lu la r  and 
v ira l  products .  However ,  P53 m uta t ions  are very rare in cerv ica l  
carc inom a (Scheffner  et al,  1993;Talis  et al,  1998).
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In cerv ica l  carcinoma, the E6 oncoprote in ,  as descr ibed  in sect ion  
1.8.1.1, binds to the p53 tumour suppressor  p ro te in  and media tes  
its degenera t ion  (Scheffner  et al,  1993;Talis  et al,  1998).
1.8.3 Chromosomal Loss In CIN And Cervical  Carcinoma
There  is no doubt that  HPV infec t ion  plays a c r i t ica l  role in the 
genesis  of cerv ica l  carcinoma. However,  HPV in fec t ion  alone is 
in su ff ic ien t  to cause m al ignan t  t ransform ation .  The evidence  in 
suppor t  of this not ion includes:  only a small  pe rcen tage  of HPV 
posi t ive  women develop cervica l  carcinoma (Rome et al,  
1987;Syr janen ,  1987); and a long la tency (up to 17 years)  
be tw een  HPV infec t ion  and emergence  of  CIN (Meijer  et al,
2 0 00 ).
Growing evidence  ind ica tes  that  genet ic  changes  play a c r i t ica l  
role  in the t rans fo rm at ion  of HPV infec ted  cells .  Larson et al 
have shown a s trong assoc ia t ion  be tween the number  of 
chrom osomal  regions showing loss of h e te rozygos i ty  (LOH) and 
the grade of  CIN les ions ,  which supports  the concept  of 
p rogress ive  accum ula t ion  of abnorm ali t ies  a f fec t ing  var ious  
tumour suppressor  genes (TSG) during deve lopm ent  of  cerv ica l  
carc inom a (L arson a et  al,  1997). A number of chrom osomal  
reg ions  have shown LOH in cerv ica l  carc inoma.  They inc lude  
3 p l4 .1 -p 2 2 ,  4 p l6 ,  4q21-35,  5 p l3 - 1 5 ,  6p21-22,  6q21-25,  l l p l 5 ,  
l l q 2 3 ,  1 3 q l 2 .3 - q l3 ,  1 7p l3 .3  and 1 8 q l2 .2 -2 2  (Mitra  et al,
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1994;M ul lokandov  et a l , 1996). Of these reg ions ,  3 p l4 .2 ,  3p22- 
21, 6p21 and l l q 2 3  have shown f requent  LOH in cervical  
ca rc inom a by a number of independent  s tud ies ,  suggest ing  that  
these  regions  may contain TSGs (Kersem aekers  et al,  1999; 
Chung et  al,  2000 ;G uoa et al  , 2000Chatter jee  et al,  2001; ;Har ima 
et al,  2001; et al; Acevedo et al,  2002) . Among them, a number 
of chrom osomal  regions at 3p (3 p l4 .1 ,  3p21-22)  are the most 
f requ en t ly  de le ted  in CIN and cervical  carc inom a although there 
are d isc repanc ies  in the frequency and minimum region of 
de le t ion  observed  (G uoa et al,  2000). The f requency  of LOH at 
3 p l 4 . 2  has been var ious ly  reported  in d i f fe ren t  grades of  CIN 
les ions  (30%-58%) and in cervica l  carc inom a (37-73%) (Kohno et  
al,  1993; Rader et al,  1998;Yoshino et al ,  1998;Butle r  et al,  
2 0 0 0 ;L in b et al,  2000;B ut le r  et  al,  2002).  LOH at 3 p l4 .2  occurs 
more f requent ly  in invasive  and h igh-grade  CIN les ions than 
CIN1 (But le r  et al,  2002).  Guo et al poin ted  out that  chromosome 
3p de le t ions  were observed  more f requen t ly  in CIN with 
coex is t ing  carc inoma than in CIN without  coex is t ing  carc inom a 
(G uo a et  al, 1998). A close assoc ia t ion  be tween  HPV infec t ion  
and LOH on chromosome 3p has been repor ted  (Muller  et al,  
1998;Yoshino  et al,  1998; But le r  et al,  2000). In vivo study 
shows that  HPV can insert  its genes into chrom osome 3 f ragi le  
si te  FRA3B located  at 3 p l4 .2 ,  de le t ing  a p iece of  DNA includ ing  
the Frag i le  H is t id ine  Triad gene (FHIT) (Thorland et al,  
2003 ;W ilke  et al,  1996).
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FHIT gene is a candidate  TS G (^)hta et al,  1996^. 
Im m unohis tochem is t ry  s tudies  have shown that  FHIT prote in  
express ion  is reduced or absent  in 50% of CIN3, and 78% of 
cerv ica l  carc inomas (Butler  et al,  2002). RT-PCR studies  have 
shown absent  FHIT t ranscr ip ts  in cerv ica l  carc inom a cell l ines 
(Greenspan  et al,  1997). Moreover,  LOH corre la ted  with reduced 
FHIT express ion  and both LOH and reduced FHIT express ion  
pos i t ive ly  corre la ted  with the h is to log ica l  grade of CIN (Birrer  et  
al,  1999;Connolly  et al,  2000;Butle r  et al,  2002). FHIT LOH has 
also been repor ted  to be s ign i f ican t ly  h igher  in recurren t  CIN 
les ions  (Wilke et al,  1996; Muller  et al,  1998; Yoshino et al,  
1998; L inb et al,  2000;Butle r  et al,  2000;Thor land  et al,  2003).
F requency  of LOH at 3p21-22 has been repor ted  to be between 
56%-75% in cerv ica l  carc inom a (Karlsen et al ,  1994;Huettner  et  
al,  1998). LOH at 3p21 pos i t ive ly  corre la tes  with m ito t ic  act iv i ty  
of tumour cel ls  (K e rsem aeke rsa et al,  1998). Pu ta t ive  TSG, p 
ca ten in  is mapped to 3p21 and The Transform ing  Growth Fac tor-p  
Receptor  (TpR) type II is mapped to 3p22. Both  have been 
inves t iga ted  and so far there is no convinc ing  data  to show that  
they are the de le t ion  targe ts  in these regions  (Lazo, 1999). 
However ,  increas ing  evidence  suggests  that  gene de le t ion  in these 
regions  is im portan t  in the genesis  and p rogress ion  of cerv ica l
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carc inom a (Wistuba  et al,  1997;Guoa et al,  2000 ;C hat te r jee  et al,
2 0 01 ).
A role of chromosome 4 in the development  of  cerv ica l  carcinoma 
has been suggested  through the abil i ty  of the whole  chromosome 
to rever t  immortal  HeLa cel ls to a senescent  phenotype  (Ning et  
al,  1991). Compara t ive  genomic  hybr id iza t ion  (CGH) and LOH 
studies  have revealed de le t ions  at spec i f ic  regions on 
chromosome 4. Four minimal regions of de le t ions  have been 
iden t i f ied  and they include 4q34-q35 (LOH f requencies  of 76%),  
4q25-q26 (48%),  4 p l 5 . 1 - p l 5 . 3  (36%) and 4 p l 6  (26%) (Sherwood 
et  al,  2000). D if fe ren t  pa t terns  of LOH have been  shown in 
d i f fe ren t  h is to log ica l  va r ian ts .  LOH at 4q34-q35 predom inan t ly  
occurred  in squamous cell carc inom a (83%), while  LOH at 4 p l5 .3  
f requen t ly  occurred  in adenocarc inom a (50%) of  the cervix 
(Sherwood et al,  2000).
High f requencies  of LOH have also been observed  in the short  
arm of chromosome 5. Mitra  et al showed frequen t  LOH at 
5 p l5 .1 - 1 5 .3  in both CIN (60%) and cerv ica l  carc inom a (50%) 
(Mitra  et al,  1995;Mitra ,  1999). Delet ion  at these  regions
appeared  to be independent  of high risk HPV in fec t ion  (Mitra,
1999).  Candidate  TSG programmed cell death  gene (PDCD6),  and 
thyroid  recep tor  in te rac t ing  pro te in  13 (TRIP13)  have been 
iden t i f ied  at 5 p l5 .3 .  However, s tudies  of the ir  express ion  did not
provide  evidence  of  dow n-regula t ion  in cerv ica l  carc inom a cell 
l ines (A rias -Pu l ido  et  al,  2002).
Several  regions of chromosome 6 have been shown LOH (Chuaqui  
et al,  2001). 6q21-q25 .1  have been shown LOH in 30% of CIN1, 
37% of CIN2, 40% of CIN3, and 55% of  cerv ica l  carcinoma 
(Chuaqui  et al,  2001).
On the short  arm of  chrom osome 6, 6p23-25 and 6p21.3 have been 
shown high f requenc ies  of LOH in cerv ica l  carc inom a and CIN 
les ions .
6p25 and 6p21.3  was found in 74% and 87% of cervica l
carc inomas respec t ive ly ,  91.7% of CIN2 and CIN3, and 50% of
CIN1 les ions (C ha t te r jee  et al,  2001).  Dele t ion  at 6p21 was 
s ign i f ican t ly  a ssoc ia ted  with poor overa l l  and d isease- f ree
survival  in pa t ien ts  w ith  cerv ica l  carcinoma (Harima et al ,  2001), 
and also a ssoc ia ted  with  disease  recurrence  after  rad io therapy  
(Harima et al,  2000).
The minimum reg ion  dele ted  at 6p25 conta ins  severa l  pu ta t ive  
TSGs including  TUBB, P16, ELANH2, FKHL6, and FKHL7
(Chat te r jee  et al,  2001) .  6p21.3 is also highly  gene rich and
harbors  at leas t  64 genes ,  including  a c lus te r  of 12 h is tone  family  
genes,  5 b u ty roph i l in  family  genes,  and HLA class I genes (HLA- 
A, HLA-C, HLA-E).  M uta t ion  analysis  of some of these  genes 
(IER3) did not  reveal  any pa thogenic  a l te ra t ions  (C ha t te r jee  et  al,
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2001). A l though the role of these genes in cerv ica l  
carc inogenes is  remains unknown, the HLA class I genes have 
been  proposed  as ta rge ts  of  6p21.3 de le t ions  in cerv ica l  
carc inom a.  Loss of HLA class I antigen express ion  is a common 
phenomenon in most cerv ica l  carcinomas (Keat ing  et al,  1995),  
and the loss of HLA-A2 and B7 express ion  is a ssoc ia ted  with 
poor  p rognosis  of cerv ica l  carcinoma (van Driel  et al,  1996).
On chromosome 9, LOH has been found at 9p ter-p22  in 14% of  
cerv ica l  carcinomas (Huettner  et al,  1998), and at 9 p te r -p l3  in 
67.5% of  cerv ica l  carc inom as (Manolaraki  et al,  2002).  Dellas  et 
al showed that  LOH at these regions was s ign i f ican t ly  more 
frequen t  in carc inom as with lymph node m etas tases  than in n o d e ­
negat ive  tumours (Dellas  et al,  1999).
Funct iona l  s tudies  have shown that  chromosome 11 carr ies  a gene 
or genes that  can suppress  the tum ourigen ic  p roper t ies  of human 
cerv ica l  carc inom a cel l  l ines (Sr iva tsan  et al,  2002;Saxon  et al,  
1986). LOH has been found at several  regions of  chromosome 11 
inc lud ing  l l p l 2 - 1 3 ,  l l p l 5 ,  l l q l 3 ,  and l l q 2 2 - 2 3 .  The observed  
f requencies  of LOH at these  regions varied  be tween s tud ies ,  
rang ing  from 14% to 33% at l l p l 5  and from 27% to 60% at 
1 Iq 2 3 .1 -q 2 3 .2  in cerv ica l  carcinoma (Pul ido  et al,  
2000 ;S teenbergen  et al,  1996).
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A candidate  TSG (PPP2R1B),  which maps to l l q 2 2 - 2 3 ,  has been 
found to be muta ted  in 15% of lung and colon carcinoma.  
However,  muta t iona l  analysis  of the PPP2R1B gene in cervica l  
carcinoma did not reveal  any evidence of  somatic  muta t ion  
(S teenbergen  et al,  1996; Pulido et al,  2000). Huet tner  et al have 
shown a corre la t ion  between LOH at l l q 2 3 . 3  and the extent  of 
lym phovascu la r  space invas ion  in radical  hys te rec tom y specimens 
(Huettner  et al,  1998). A s ign i f ican t  assoc ia t ion  between tumours 
with LOH at l l q 2 1 . 2 ,  and poor  survival  has also been reported 
(K ersem aeke rsa et al,  1998;Harima et al,  2001).
A lthough  a number  of s tudies  have inves t iga ted  LOH in cervical  
carc inom a and cerv ica l  in t raep i the l ia l  neop las ia ,  there are 
r e la t ive ly  few data re la t ing  LOH to c l in ica l  behav iour  or 
p rognosis  ( T a b l e l . l ) ,  pa r t icu la r ly  of the CIN les ions .
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Table 1.1: C o m m o n  LOH in CIN and c e r v i c a l  ca r c in o m a .
C h r o m o s o m a l
L o c a t i o n
LOH
F re q u en cy  
in CIN
LOH
Fre que nc y  
in c e rv ic a l  
c a r c i no m a
Co rr e l a t i on  
with p ro gn o s i s
Ref er enc e
3 p l 3 - 1 4 . 3 - 75% - J  o n e s & N  a k a m u r a ,  
1992
3 p l 3 - 2 1 . 3 - 45% - K o h n o  e t al ,  1993
3 p l 4 . 1 - 1 2 30% 37% - R a d e r  e t  al ,  19 9 8
3 p l 4 . 2 - 56% -
W is tu b a  e t  al ,  1 9 9 7
3 p l  4 .2 - 59% -
Y o s h i n o  e t  al ,  199 8
3 p l 4 . 2 52% 73% - B u t l e r  e t  al ,  2 0 0 2
3 p l 4 . 2 - 44% -
Y o s h i n o  e t  al ,  20 0 0
3 p l 4 . 2 58% - H i g h  ra te  in 
r e c u r r e n t  CIN
Li n ,  M .W ,  e t  al ,  
2 0 0 0
3p21 - 57% -
W is tu b a  e t  al ,  1 9 9 7
3 p 2 4 . 2 - 2 2 36% 80% - Guo e t  al ,  2 0 0 0
5 p l  5 .1  - 1 5 .2 60% 48% Associated with 
progression M i t r a , A . B . e t a l ,  199 5
6 p 2 1 . 2 - 4 6 . 8 0 %
A s s o c i a t e d
wi th
r e c u r r e n c e
a f t e r
r a d i o t h e r a p y
H a r i m a . A ,  e ta l ,  
2001
6p 2 3 21% 33% - R a d e r  e t  al ,  1 9 9 8
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1.8.4 Chromosomal gain in CIN and cervical carcinoma
The common chromosomal gains in CIN and cerv ica l  carcinoma 
are summarized in Table 1.2. CGH studies  have shown that  the 
most  f requent  and consis ten t  f inding in cerv ica l  carc inoma and 
CIN is 3q ampl i f ica t ion  (Heselmeyer  et al,  1996).  It is be l ieved  
that  3q ampl i f ica t ion  plays an important  ro le  in the t rans i t ion  
from severe dysp las ia  (CIN3) to invasive carc inom a (Hese lm eyer  
et  al,  1996). A m plif ica t ion  at 3q has also been observed  
f requent ly  in other  sol id tumours inc lud ing  carc inom a of the 
ovary,  lung, head and neck, suggest ing  the presence  of an 
oncogene importan t  for mult ip le  carcinoma types (Spe icher  et al,  
1995;Arnold  et al,  1996;Brass  et al,  1996; K i rchhoff  et al ,  1999). 
Using Southern  blot  and f luorescence  in si tu hybr id iza t ion  
(FISH),  the region targe ted  for am pl i f ica t ion  has been mapped 
w ith in  band 3q26.3  (Sugita  et al,  2000). P13 k inase /AKT
(PIK3CA) and hTR loca ted  in the centre  of the am pl i f ica t ion  
domain at 3q26.3  (Soder  et al,  1997).
PIK3CA encodes the p i  10a ca ta ly t ic  subuni t  o f  
p h ospha t idy l inos i to l  3 -k inase ,  which plays an importan t  role in 
regu la t ing  cell growth and apoptosis .  The gene is f requent ly  
am plif ied  in cerv ica l  carc inom a and this co rre la tes  pos i t ive ly  with 
3q26.3  ampl i f ica t ion  (Shayes teh  et al,  1999; Ma et al,  2000).  In 
cerv ica l  carc inoma cell  l ines ,  PIK3CA am pl i f ica t ion  is a ssoc ia ted  
with  increased  pro te in  express ion  and P13-k inase  ac t iv i ty  (Ma et
- 5 4 -
al,  2000). Furthermore ,  t rea tm ent  with a P13-k inase  inhib i tor  
s ign i f ican t ly  suppresses  cell p ro l i fe ra t ion  and promotes  apoptosis  
(Ma et al,  2000). These observat ions  suggest  that  PIK3CA 
am pl i f ica t ion  may be one of the genes targe ted  by 3q26.3 
am pl i f ica t ion .
Chromosomal  gain has also been detected  on l q  as 22% and 42% in 
CIN3 and cervica l  carc inoma respec t ive ly ,  where  is on l p  as 22% 
and 33% (Umayahara  et al,  2002).











3q 61% 67% -
Umayahara, 2002
3q 35% 72% -
Kirchhoff, 1999
3q - 77% Carcinoma progression
Heseimeyer, 1996
iq - 47% Carcinoma progression Heselmeyer,
1996)
iq - 45% -
Kirchhoff, 1999
tq 22% 42% - Umayahara, 2002
IP 22% 33% -
Umayahara, 2002
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1.8.5 Aneuploidy
A neuplo idy  is commonly assoc ia ted  with human m al ignanc ies  and 
cer ta in  p rem alignan t  condit ions .  It occurs  in most  if  not all 
invas ive  cerv ica l  carc inom as .  Aneuplo idy  also occurs  in CIN 
les ions  and its f requency corre la tes  with the CIN grade, be ing  
found in 14% of CIN1 but 55% and 94% of CIN2 and CIN3 
respec t ive ly  (Monsonego et al,  1997). Fur therm ore ,  aneuplo idy  
appears  to be assoc ia ted  with p rogress ion  and poor prognosis  of 
CIN les ions  (Fu et al,  1981;Dudzinski  et al,  1987). However ,  
s tud ies  by Hanse laar  et al and Atkin  et al showed that  d ip lo idy  in 
CIN les ion  did not necessa r i ly  indicate  good p rognosis  (H anse laar  
et  al ,  1988;Atkin  et al,  2004).  Thus, it remains to be inves t iga ted  
w he ther  DNA ploidy s ta tus  can be used for CIN prognosis .
1.8 .6  Telom erase
Telomere  is a specia l  DNA sequence e lement  at both ends of a 
l inear  chromosome, which is composed of severa l  hundred  repeats  
of  a s imple  hexanuc leo t ide  sequence  (TTAGGG) ex tending  up to 
30 kb. It p lays an im por tan t  role in the s t ruc tu ra l  in tegr i ty  and 
func t ion  of chromosomes by pro tec t ing  them from end-to -end  
fus ions ,  rea r rangem ents ,  degrada t ion ,  and chrom osomal  loss  
(Rhyu,  1995;Kyo et al,  1997; Wisman et al,  2001 ;R ees ink -Pe te rs  
et al,  2003). Telomere  also acts as a bu f fe r  zone,  which al lows 
loss  o f  te rm ina l  DNA sequence but not d is rup t ion  of vi ta l  p ro te in  
coding  sequence  during chromosome rep l ica t ion .  Repl ica t ion
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re la ted  shor ten ing  of te lomeric  DNA to a c r i t ica l  length  s ignals  
cel ls  to stop div is ion  and to enter a senescen t  sta te (Counter  et  
al,  1992;Gorham et al,  1997). As a resu l t  of this  “ end- 
r e p l i c a t io n ” problem, somatic  cel ls have a l im ited  p ro l i fe ra t ive  
capac i ty .  M aintenance  of te lomere length  is therefore  considered  
to be necessary  for continued cell d iv is ion  (Counter  et al,  
1992 ;Counte r  et al,  1994).
Te lom ere  length is m ain ta ined  by te lom erase ,  which is a 
sp ec ia l ized  RNA-pro te in  complex conta in ing  RNA tem pla te  (hTR) 
and p ro te in  components ,  the te lom erase  assoc ia ted  pro te in  (TP1) 
and the ca ta ly t ic  subunit  (hTERT) (Meyerson et al,  
1997 ;Nakam ura  et al,  1997). Telomerase  d irec ts  the synthesis  of 
te lo m er ic  repeats  at. chromosomal ends,  so its ac t iva t ion  is 
e ssen t ia l  for halt ing telomere shor tening  and a t ta in ing  ce l lu la r  
im m or ta l i ty  (Counter  et al,  1992;Counter  et  al,  1994). 
T e lom erase  express ion  is low or absent  in most  human somatic  
t is sues ,  with  its express ion  p r inc ipa l ly  res t r ic ted  in the adult  to 
ac t iva ted  lymphocytes ,  germ cel ls ,  and t issue  stem cel ls  (Broccol i  
et  al ,  1995;Hiyama et al,  1995).
S im i la r  to o ther  somatic  t issues ,  normal cervix  is negat ive  for 
te lom erase  act iv i ty  as shown by PCR-based  te lom erase  repeat  
am pl i f ica t ion  assay (TRAP) (Kawai et  al,  1998).  However ,  most  
cerv ica l  carc inomas are pos i t ive  for te lom erase  act iv i ty  
(A nderson ,  1997;Pao et al,  1997;Wisman et al,  1998).  In line
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with  this ,  am pli f ica t ion  or increased  copy number  of  the hTR and 
hTERT gene in a subpopula t ion  of tumour cells  has been detec ted  
in all cervica l  cancers (Soder et a l , 1997).  Moreover ,  hTERT 
gene ampl i f ica t ion  is a ssoc ia ted  with enhanced  hTERT prote in  
express ion  (Zhang,A et a l , 2002). A l though  the hTR and TPI 
( te lom erase  assoc ia ted  pro te in)  are commonly expressed  in the 
normal  cervix (71% to 100%) as well as in cerv ica l  carc inomas 
(43% to 100%) (Nakano et  al,  1998;Sni jders  et al,  1998;Takakura  
et al,  1998;Yashima et al,  1998), hTERT mRNA is expressed  in 
33% of normal cerv ices  but  in 80-100% cervica l  carc inomas 
(Nakano et al,  1998;Sni jders  et al,  1998;Takakura  et al,  1998). 
T e lomerase  act iv i ty  is de tec ted  in 6% of normal cases, 31% of 
CIN1, 80% of  CIN2, 71% of CIN3, and 88% of cerv ica l  carcinoma 
(Kawai et al,  1998).  Taken together ,  te lom erase  ac t iva t ion  may 
p lay  an importan t  role in the development  of cerv ica l  carcinoma.
A l though  some studies  suggested  that  te lom erase  assay or 
de tec t ion  of hTERT mRNA might  be a useful  sc reen ing  method 
for  de tec t ion  of neop las t ic  cells  in cervica l  les ions  (Kyo et al,  
1997;Takakura  et al,  1998),  others showed that  de tec t ion  of 
te lom erase  or its components  in CIN les ions  is ne i ther  of 
d iagnos t ic  nor p rognos t ic  value (Rhyu,  1995;Kyo et  al,  1997; 
Wisman et al,  2001 ;R ees ink -Pe te rs  et al,  2003).
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The aim of this thesis  is to isolate  and charac te r ize  p rognos t ic  
markers  that  d is t inguish  between CIN les ions  that  wil l p rogress  
to h igher  grade and those  that  are e rad ica ted  after  t rea tm ent .  
A dd i t iona l ly ,  the p rognos t ic  markers would then be c l in ica l ly  
evaluated  by corre la t ing  them to various c l in ica l  pa ram eters  such 
as fo l low up time, HPV sta tus  and trea tment .
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Chapter 2 
Materials And General Methods
2.1 Materials
2.1.1 Reagents
2.1 .1 .1  Chemicals
Sources of all reagents  and suppl iers  used in this  thes is  are l is ted  
below in Table 2.1.
Table  2.1 : S o u r c es  o f  the c h e m ic a l  reagents  used  in th is  t h e s i s .
C h e m i c a l s S o u r c e
A g a r o s e S ig m a
A m m o n iu m  persu lph ate S ig m a
B o r ic  acid S ig m a
B r o m o p h e n o l  b lu e S ig m a
C hlorofo rm Merck
d e o x y r i b o n u c l e o s i d e  5 - t r iph osp hate  
(dN T P )
Prom ega
E t h y le n e d i a m in e  t e t r a - a c e t i c  acid  
( E D T A )
S ig m a
Ethano l A na laR
Eth id ium brom ide S ig m a
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C h e m i c a l s S o u r c e
PCR primers G e n o s y s  or 
T he rm o H ybaid
Iso p ro p a no l Merck
F l u o r e s c e n t l y  l a b e l e d  PCR primers A p p l i e d
B i o s y s t e m s
M a g n es iu m  c h lo r id e L i fe
T e c h n o l o g i e s
Mineral  o i l S ig m a
PCR b uf fer L i fe
T e c h n o l o g i e s
P h en o l S ig m a
P h i X 1 7 4  D N A / H i n f  I markers P rom ega
P o l y a c r y la m id e P rom ega
P ro t e in a s e  k P rom ega
Rox s i z e  s tandard A p p l i e d
B i o s y s t e m s  Inc.
N , N , N ' , N ' - t e t r a m e t h y l -  
e t h y l e n e d i a m i n e  (T E M E D )
S ig m a
Tris  (T r izm a base ) S ig m a
Water (H PLC pure) S ig m a
X y l e n e Merck
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2.1 .1 .2  Enzymes And Assay Kits
Table  2.2: S o u r c e s  o f  b i o l o g i c a l  re agents  and a ssay  k i ts .
Chemicals S o u r c e
A m b io n  Kit AM S B i o t e c h n o l o g y
H p a l l  R e s t r i c t io n  e n d o n u c l e a s e Pr om ega
Protein  P re c ip i t a t io n  S o lu t i o n P rom ega
RN A  S to rage  S o lu t i o n A m b io n  Ltd
RT-PCR Kit Q IA G EN
S i l v e r  s ta in in g  kit P h a rm a c ia - A m e rsh a m
Taq p o ly m e r a s e L i fe  T e c h n o l o g i e s
2.1.2 Buffers And Solutions
Pro te inase  K d iges t ion  buffer :  10 mM Tris  (pH 9), 50 mM KC1, 
0.1% Triton  X, lOOpg/mL pro te inase  K.
E lec t ro ph o res is  loading  buffer :  0.25% brom ophenol  b lue,  0.25% 
xylene  cyanol, 6xTBE, 40% sucrose .
lOx TBE buffer  ( pH 8.0):  89mM Tris  base,  89mM boric  acid, 
2mM EDTA, d isso lved  in 1 l i t re  of  d is t i l led  water .  
lOx PCR buffer :  100 mM Tris HC1 (pH 9), 500 mM KCI, Tr i ton-X  
1 00 .
10% Ammonium Persu lpha te  (APS): O.lg of  APS powder
d isso lved  in 1ml d is t i l led  water .
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Blue Dye mix: 1 part  of (lOOmg/ml blue dextran ,  25mM EDTA)
d isso lved  in 12 parts  of de ionized  formamide.
2.1.3 Patient Materials
130 archival  cervical  Pap smears (18 CIN1, 56 CIN2, 56 CIN3), 
137 archival  fo rm al in - f ixed ,  para ff in -em bedded  cerv ica l  b iops ies  
(56 CIN1, 43 CIN2, 23 CIN3 and 15 cerv ica l  squamous cell 
ca rc inom a)  and 2 male tonsi l  b iopsies  were re t r ieved  from the 
su rg ica l  f i les  of the Depar tment  of H is topa tho logy ,  Univers i ty  
Col lege  London Hospita l  NHS Trust .  The morphology  of  the 
cerv ica l  smears was reviewed by Dr G abr i je la  Kocjan, 
D epar tm en t  of H is topa tho logy ,  Univers i ty  College London. The 
use of these  archival  specimens for research was approved by the 
j o in t  UCL/UCLH committees  on the ethics of the human research .
2.2 Methods
The methods that  were commonly used for inv es t ig a t io n s  in 
d i f fe ren t  resu l t  chapters  were descr ibed  below, while  those only 
used for  a spec i f ic  resu l t  chapter  were descr ibed  in appropr ia te  
chap ters  respec t ive ly .
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2.2.1 Preparation Of Archival Specimens For 
Microdissection
For Pap smears,  the dyskaryo t ic  cells  were iden t i f ied  and marked 
w ith  a diamond pen on the reverse  side of the s l ides .  The s l ides 
were  then incubated  in xylene for 2-5 days to remove the 
covers l ips  and then washed in 100% and 70% ethanol.
For  formal in  f ixed and para ff in  embedded t issue  specimens ,  3-5pm 
sect ions  were cut using a microtome and dried in an oven o v e r ­
n ight.  Sections were deparaf f in ized  in xylene for 5 minutes  twice 
and processed through 100%, 90% and 70% ethanol  so lu t ion .  The 
sec t ions  were then r insed in running water  for 1 min, and br ief ly  
s ta ined  with haem atoxyl in ,  washed with running water  for 2-3 min 
and processed  in 70%, 90% and 100% ethanol  so lu t ion .
2.2.2 Microdissection
Normal and dyskaryo t ic  cel ls  were m icrod issec ted  separa te ly  
using  a glass  t ransfe r  p ipe t te  as descr ibed  p rev ious ly  by Pan et al 
(Pan et al,  1994).  Br ief ly ,  the respec t ive  cells  were iden t i f ied  
under  a microscope  and a drop of 50% ethanol was laid on top of 
them (Figure  2.1).  The cells  were then scraped off  the sl ide,  
a sp i ra ted  into a g lass  t ransfe r  p ipet te ,  and then t rans fe r red  into a 
c lean  micro tube.  In some cases,  where the neop las t ic  cel ls  were 
surrounded  by normal  cel ls ,  the sur rounding  normal  cel ls  were 
scraped  off  the s l ides  f irst .
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AB
F i g u r e  2.1: M i c r o d i s s e c t i o n  o f  d y s k a r y o t i c  c e l l s  f r o m  a r c h i v a l  s m e a r s .
A)  R o u t i n e l y  s t a i n e d  and p r e p a r e d  c e r v i c a l  s m e a r  g l a s s  
s l i d e  wi t h  m a n u a l l y  d r a wn  c i r c l e s  s u r r o u n d i n g  t he  a r e a s  
c o n t a i n i n g  d y s k a r y o t i c  c e l l s .  B)  W i t h i n  t he  c i r c l e ,  a c l u s t e r  
o f  s e v e r e l y  d y s k a r y o t i c  c e l l s  i n d i c a t i n g  a C I N 3 l e s i o n ,  
w h i c h  w a s  s e l e c t i v e l y  r e m o v e d  f r o m t he  g l a s s .
By s u c h  a p p r o a c h ,  h i g h l y  e n r i c h e d  t u m o u r  c e l l s  p o p u l a t i o n  and  
n o r m a l  c e l l s  w e r e  o b t a i n e d  in e a c h  c a s e .  T h e  m i c r o d i s s e c t e d  c e l l s  
w e r e  p e l l e t e d  d o w n  by c e n t r i f u g a t i o n ,  t he  t u b e  w a s  l e f t  o p e n  at 
r o o m  t e m p e r a t u r e  to a l l o w  the  e t h a n o l  to d ry ,  b e f o r e  p r o c e e d i n g  
to  D N A  e x t r a c t i o n .
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A number  of p recau t ions  were taken during  m ic rod issec t ion  in 
o rder  to avoid po ten t ia l  contamination:
1- Sec t ion  cutt ing and m icrod issec t ion  were always carr ied  out in 
a labora to ry  free of PCR and cloning products ;
2- New pipe t tes  were used for m ic rod issec t ing  d i f fe ren t  cell 
popu la t ions  in each case.
3- Fresh  50% of ethanol  was prepared and a l iquoted  into clean 
m ic ro tubes  pr ior  to m ic rod issec t ion .  An a l iquote  was used for 
m ic rod is sec t ion  of each sample .
4- Normal and tumour cells  were a lways m ic rod issec ted  
separa te ly  and t rans fe r red  to separa te  clean m icro tubes .
2.2.3 DNA Preparations
2.2 .3 .1  Crude DNA Preparat ions
Cells  m ic rod issec ted  from Pap smears were washed  in 1ml of 
lOmM Tris  (pH 8.0) and 1 mM of EDTA at 4°C for 1 hour to 
remove the sta in  and then cen tr i fuged  at 13,000g for  5 minutes .  
The cel l  pe l le ts  were then d iges ted  with p ro te inase  K (100pg /m L) 
in 50-150p,L PCR buffer  con ta in ing  10 mM T ris -HCl (pH 9.0),  50 
mM KC1 and 1.0% Triton  X-100) .  The volume of  PCR buffer  used 
for d iges t ion  depended on the to ta l  number  of the  m ic rod issec ted  
cells .  The d iges t ion  was carr ied  out for 16-20 hours  at 56°C. The 
d iges ts  were then heated  at 95°C for  lOmin to inac t iva te  
p ro te inase  K and cen tr i fuged  to remove cell  debris .  The resu l t ing
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superna t ant s  were stored at -20°C and used for PCR. Similar  
crude  DNA prepara t ions  were carr ied out  on cel ls  mic rod issec t ed  
f rom archival  cervical  t issue biopsies .
2.2 .3 .2  DNA Purif icat ion
To puri fy the crude DNA preparat ion,  protein was pr ec ip i t a ted  
and removed.  Di f ferent  protein prec ip i t a t ion  methods  including 
p rec ipi t a t i on  wi th sa turated NaCl and Prote in  Prec ipi ta t ion  
Solut ion (Promega,  Southampton,  U.K.)  were tes ted.  For  DNA 
pur i f ic a t ion  wi th sa turated NaCl ,  50pL NaCl (6M) was added to 
the DNA pal let  fol lowed by cent r i fugat ion at 2 ,000g for  10 
minutes  to remove the pel le ted protein.  The DNA samples  
pur i f i ed  fai led to show complete  d iges t ion wi th r es t r i c t ion  
endonucl ease ,  thus cannot  be used for endonuclease  diges t ion 
based  study.
For  DNA pur i f i ca t ion  with Prote in  Prec ipi ta t ion  Solut ion 
(Promega,  Southampton,  U.K.) ,  70pL Prote in  Prec ipi ta t ion  
Solu t ion  was added to each 200pL DNA crude prepara t ion .  
Prec ipi ta t ed  pro te in  was then removed by cen t r i fuga t i on  at 
25 ,000g for 20 minutes  at 4°C. DNA in the superna t an t  was then 
pr ec ip i t a ted  wi th i sopropanol ,  washed in 70% e thanol ,  air  dried 
and f inal ly d i ssolved in 20pL di s t i l l ed  water .  DNA samples  were 
s imi la r ly  pur i f ied  f rom formal in- f i xed  and par af f i n- embedded  
t i ssues .
- 6 7 -
2.2.4 Polymerase Chain Reaction (PCR)
2.2 .4 .1  Primers Design
All  PCR pr imers  (Table 2.3) used in this s tudy except  for the 
androgen receptor  and HPV pr imers ,  were des igned with the help 
of  a computer  pr imer  design programme (GCG Wiscons in  Package 
Pr imer  Design) .




Forward Primer Reverse Primers
Estimated 
size (bp)
D3S1566 3pl3 5 ' TAATTGAGAAGTCATGCCCTG3 ' 5'GCTCAAAGAAATGTCCTGGA3' 170
D3S1285 3pl4.1 5'CACCCTACTGTGCTATCAAACA3' 5'AGTATCCAGAGGCTGGGAAG3' 153
D3S1300 3pl4.2 5' GCTCACATTCTAGTCAGCCTG3' 5'TGTCACAGAATAGTCTTTCCCA3' 165
D3S1289 3p21.1 5'GCAACTTGTAAGAGAGCATTCA3' 5'ACATTACAGAAATGTGATGCA3' 259
D3S1260 3p22.2 5'GCTACCAGGGAAGCACTGTA3' 5'GCTAAACTGAAGACCCTGCA3 ' 126
D3S1611 3p22.3 5'TAATCCCAGCACTTCGAGAG3' 5'AGACTACAGGCATTTGCCAC3' 117
D5S406 5pl5.32 5'TGCCAATACTTCAAGAAAAACA3' 5'ACTTGGGATGCTAACTGCTG3' 188
D6S105 6p21.1 5'CCAAAGTGCTGGGATTACAG3' 5'TCAAGGAAGAGAGACCATGC3' 145
D6S265 6p21.1 5'ATCACCCCCCTCACACAC3' 5'TCTAATCGAGGTAAACAGCAGA3' 100
D6S277 6p24.3 5'AGCTGAATAACACGAGGTG3' 5 ' TACATTTTTGATGACAATGGAA3 ’ 101
D11S35 llq22.1 5'GAGGAAAGTCATGAACGCAG3' 5'ATCGATTAACCAACTTCACACA3' 100
D11S528 llq23.3 5'GCCTAACTAATGGTGTCCCC3 ' 5'GACCCCAGTGTGAGATGAAT3' 150
HPV16 NA 5'CAGGACCCACAGGAGCGACC3' 5'CGACCGGTCCACCGACCCCT3' 398
HPV18 NA 5'CCGAGCACGACAGGAACGACT3' 5f TCGTTTTCTTCCTCTGAGTCGCTT3' 174
HPV33 NA 5'AACGCCATGAGAGGACACAAG3' 5'ACACATAAACGAACTGTGGTG3' 212
HPV45 NA 5f TTGGAATTTTGGTGTCCCTC3' 5'TCCTGCTTTTCTGGAGGTGT3' 114
HPV56 NA 5'TGATGCACGAAAAATTAATC3' 5'CGGGGATAACCCAATATTCC3' 160
P53 EXON 5 5'TTCCTCTTCCTGCAGTACTC3' 5'ACCCTGGGCAACCAGCCCTGT3' 245
EXON 8 5'CCTATCCTGAGTAGTGGTAA3' 5'GTCCTGCTTGCTTACCTCGC3 ' 185




Forward Primer Reverse Primers
Estimated 
size (bp)
BCL 10 | EXON 3 5 ' TTAACAAGTCACAAGATGGACAGTG3' 5'CATTAAAAATTAAAAGGCAATAAAGTG3' 460
| I
AR ; NA 5'TCCAGAATCTGTTCCAGAGCGTGC3f 5'GCTTGGGGAGAACCATCCTCAC3' 220
G6PD | NA 5'GGCAACAGATACAAGAACGTGAA3' 5'CGCAGAAGACGTCCAGGAT 3' 67
5'CCAGCTCAATCTGGTGCAG3' 151
5'CCCTCATACTGGAAACCCACT3' 242
2.2 .4 .2  P C R  M e th od
For each pr imer  pair ,  PCR condi t ions  including anneal ing 
tempera ture ,  cycl ing parameters  and MgC12 concent r a t i on  were all 
sys temat ica l ly  opt imised  using posi t ive  and negat ive  controls  
before  appl ica t ion to test  samples  as summar ized  in Table 2.4. 
T a b l e  2.4:  PCR condi t ions  used in this thes is
Gene tain ted PCR programme PCR condition MgC12 concentration
p53 and BCL1D Hot-start touch down 
pio gramme
38 cycles o f de natural ion at 
94*C far 50 seconds, 
annealing temperature 
starting at 60X3 reducing 2X3 
e very cycle until 55X3, and 
extension at 72X1 far 3D 
seconds, tallowed by a final 
extension at 72X3 far 5 
minutes.
15 mM
AR Hot-start touch down 
programme
35 cycles afdenaturationat 
94X3 far 50 seconds, 
annealing temperature 
starting at 60X3 reducing 1X3 
every cycle until 57X3, and 
extension at 72X3 far 50 
seconds, followed by a final 
extension at 72X3 far 5 
minutes.
15 mM
- 6 9 -
Gene targeted PCR programme PCR condition MgC12 concentration
Microsatellite markers Hot-start touch down 
programme
38 cycles of denaturation at 
94°C for 50 seconds, 
annealing temperature 
starting at 60°C reducing 2°C 
eveiy cycle until 55°C, and 
extension at 72°C for 50 
seconds, followed by a final 
extension at 72°C for 5 
minutes.
1.5 mM
HPV Hot-start touch down 
Programme
35 cycles of denaturation at 
94°C for 50 seconds, 
annealing temperature 
starting at 60°C reducing 1°C 
every cycle until 57°C, and 
extension at 72°C for 50 
seconds, followed by a final 
extension at 72°C for 5 
minutes.
1.5 mM
For  each exper iment ,  a master  mixture  including all the necessary  
PCR reagents  except  the t emplate  DNA was f i rs t  prepared  and 
a l i quot ed  into PCR microtubes  or micro t i t e r  plate wel ls ,  and DNA 
samples  were subsequent ly  added,  fol lowed by a drop of  mineral  
oi l .  Appropr i a t e  pos i t ive  and negat ive  (wi thout  t empla te  DNA) 
cont ro l s  were included in each exper iment .  A typical  PCR react ion 
was per formed in a 25 pL react ion mixture  conta in ing  2 .5pL  10 x 
PCR buffer ,  0 . 2pL  dNTP (f inal  concent ra t ion  200pM of  each 
dNTP) ,  4pmol  of  each pr imer ,  1.5 mM of  M g C h ,  0 . 38-1.0  uni t  Tag 
Polymerase ,  dH20 to 22pL and 3pL DNA sample.
PCR was carr ied out  in a thermal  cycler  (Hybaid ,UK)  using 
appropr i a te  PCR programme as speci f ied for each pr imer  set  in 
Table  2.4.
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All  PCR se t -ups  were  performed in a room separa te  from product  
ana lyses  and DNA ext rac t ion  to avoid the r isk of  contamina t ion .  
Other  p r ecau t ions  taken to avoid cross contamina t i on  dur ing PCR 
set  up i nc lud ing  separa te  s torage for PCR reagents  and DNA 
samples ,  use of  f i l t e red  t ips and use of  separa te  p ipet tes  for 
measur ing  PCR r eagent s  and DNA samples.
2.2.5 Electrophoresis of PCR Products
The method  used for  PCR product  analysi s  depended on the 
p roduc t  size and the resolut i on  requi red.  Po lyacryl amide  gels were 
used for  ana lys i s  of  PCR products  less than 250bp or in 
exper iment s  where  a high resolu t ion  separa t ion was des i red,  e.g.  
c lona l i ty  analys i s .
Aga rose  gels  were  used for analysis  of product  over  250bp or in 
exper iment s  that  did not  requi re  a high resolut ion,  e.g.  to check 
whe ther  PCR was success fu l .
2.2 .5 .1  E lec tro p h o r es is  On Agarose  Gels
1.5% agarose  ge ls  were  used.  1.5 gram of agarose  was d i ssolved 
in 100 mL of  l x T B E  buffer  by boi l ing in a microwave.  Af ter  
cool i ng  to ~50°C,  5p L  ethidium bromide (O. lpg /ml )  was  added to 
the mix tur e .  50 mL of  Agarose  were poured into an appropr ia te  
gel  t ray and a comb inser ted .  When the gel was set,  the comb was 
ca re fu l l y  r emoved .  lOpL of  PCR product  was mixed wi th 2pL of 
load ing  buf fe r  (Bromophenol  Blue and sucrose so lu t ion)  before
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loading  into the wel ls .  Gels were run at 80 vol tages  for 30 min,  
then r emoved f rom the apparatus  and viewed under  an u l t rav io le t  
l ight  i l l umina tor .  Digi tal  images were taken using the Kodak 
EDAS 290 documenta t ion  system (Anachem,  Luton) .
2.2 .5 .2  E lec trop hores is  On Polyacrylam ide  Gels
7% polyacry l amide  gels  were used for analysi s  of  PCR products .  
To prepare  the polyac ry lamide  gel,  1.75 mL acrylamide  (40% of 
29:1 acrylamide:  b i s-acry l amide) ,  2mL 5xTBE,  6.25 mL H2O and 
100pL TEMED were mixed.  The gel mix was poured  be tween  the 
glass  p la tes  and comb inser ted  according to the m an u fa c t u r e r ’s 
ins t ruc t ions .  The gel was lef t  for 30 minutes  to set ,  the wel l s  were 
c leaned,  4-10 pL of  PCR products  were mixed wi th 2pL  loading  
buf fer  and l oaded into wel ls .  The gels were run at 150 vo l tages ,  
for  90 min.  Gels  were  s ta ined wi th ethidium bromide  for  2 minutes  
and viewed under  an ul t rav io le t  l ight  i l lumina tor .  For c lona l i ty  
analys i s ,  gels  were  v i su l i sed  by s i lver  s ta ining.
2 .2 .5 .3  S i lver  Sta in ing
7% polyacry lamide  gels  were stained using PlusOne Si lver  
S ta ining Kit  in a GeneSta in  Automated  Gel Sta iner  (Pharmac ia -  
Amersham,  Li t t le  Chal font ,  Buckinghamshi re ,  UK).
Gels  were f ixed in a f ixing solut ion stained in a s t a in ing so lut ion 
and then deve loped  in a solut ion conta in ing  25ml Sodium 
carbonate  (5x) ,  125pL Sodium th iosulpha te  and 125pL
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Formaldehyde  in 100 ml water .  The gels were then soaked in 
s topping and preserv ing  solut ion.
2.3 Analysis Of PCR Products Using An ABI 377 DNA 
Sequencer
Dyskaryo t i c / neop l as t i c  and normal  cel ls f rom each case were 
analyzed in para l le l .  The PCR products  were analysed  on 4.5% 
polyacrylamide  denatur ing gels  (Acrylamide  : N-N v-Methylene-  
b i s - ac ry l am ide= 29 : l )  (Nat ional  Diagnos t ics ,  Hul l )  in l x T B E  
buf fer  (Nat ional  Diagnost ics ,  Hul l )  using an ABI 377 automated 
f l uorescen t  DNA sequencer  (Appl ied Biosys tems ,  Fos ter  Ci ty,  
Cal i fornia ,  USA),  which has a four -color  de tec t ion  sys tem.  One 
pi of  each PCR react ion was mixed wi th 1 .5pL blue dye and l p l
of  a ROX (for f i l ter  set  D) f luorescent  size marker  (Appl ied
Biosys tems ,  Fos ter  Ci ty,  Cal i fornia ,  USA).  This  mix was 
denatured  for 2 minutes  at 94°C and l p l  was loaded into each 
wel l  on a p rewarmed gel using membrane comb method according  
to (Hamoudi  et al,  2002) .  The gel was run for 4 hours  at 150
wat ts  power ,  50 mil l i  amps current ,  1650 vol ts  vol tage ,  scan rate
of  1200 scans per  hour  and 50°C tempera ture .  Whi l s t  the PCR 
product s  were separa ted  dur ing e lec t rophores i s ,  the f luorescence  
was  detected  in the laser  scanning region using f i l t er  set  D. The 
data  was col lec ted and stored using the GeneScan Col lec t ion  
Sof tware  2.0 (Appl ied  Biosys tems ,  Fos ter  Ci ty,  Ca l i fo rn ia ,  USA).  
The f luorescent  gel data  col lec ted dur ing the run was
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automat ica l l y  analysed by the GeneScan Analys i s  Sof tware  3.1 
(Appl ied Biosys tems ,  Fos ter  City,  Cal i fornia ,  USA).  Sample 
sheets  were prepared using in house SampConver tor  sof tware.  The 
size s tandard cal l ing for  each lane and the qual i ty  of  data were 
checked au tomat ica l ly  us ing in house GSQC vers ion 1.1 sof tware.  
Each f l uorescent  peak was quant i f ied  in terms of size (in base 
pai rs ) ,  peak height  and peak area according to (Lakhani  et al,  
1996).  The resul ts  were then imported into Genotyper  (vers ion 
2.1) (Appl ied Biosys tems ,  Fos ter  City,  Cal i fornia ,  USA) for 
fur ther  analysi s  and pr in t ing.
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CHAPTER 3
Archival Cervical Smears: A Versatile Resource For 
Molecular Investigations
3.1 Introduction
As de ta i l ed  in the General  In t roduct ion,  most  cervica l  carc inomas  
are be l i eved  to derive from preneopl as t i c  epi thel i a l  l es ions 
known as Cervical  In t raepi t he l ia l  Neoplas ia  (CIN).  Cervical  
smear  test  was  i nt roduced in 1943 and has been subsequent ly  used 
as a sc reening  method for these les ions .  Na t ionwide  screening 
p rogrammes  were  set  up in many developed count r ies  in 1980s 
and have resul ted in a dramat ic  reduct ion in the cervical  
ca rc inoma  mor ta l i ty  rate (Schoel l  et al,  1999).  Archiva l  cervical  
smears  r epr esent  one of  the largest  resources  of pa thologica l  
spec imens .  With the appropr ia te  long- term c l inica l  fol low-up,  
they could r epresent  the most  impor tant  source for research  into 
cervica l  ca r c inoma  including molecular  i nves t iga t ions .  Despi te  
this huge po t en t ia l ,  only a few molecular  inves t i ga t ions  based on 
archival  cerv i ca l  smears  have been repor ted in the l i t e ra ture .
Several  s tudies  have shown that  archival  cervica l  smears  can be 
used for  PCR ampl i f i ca t ion  of  genomic  sequences  ( Jackson et al,  
1990; Roda Husman et  al ,  1995;Chen et al,  1996;  Puranen  et  al,  
1996 ;McGoogan  et al,  1998).  These s tudies  were based on a
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re la t ive ly  large number  of  mixed normal  and dyskaryot ic  cel ls 
co l lec ted  from cervical  smears .  The la t t er  cel ls  are of  main 
research interes t .  It is not  known whether  PCR could be appl ied 
to a small  number  of dyskaryot ic  cel ls ,  mic rodissec t ed  from 
archival  smears .  In addi t ion,  it remains  to be tes ted whether  
archival  cervical  smears  are sui table  for  PCR-based  RNA 
analysis .  To address  these issues,  we p repared  DNA and RNA 
samples  from dyskaryot ic  cel ls ,  microdis sec t ed  from archival  
cervica l  smears  and sys temat ica l ly  tes ted to what  extent  such 
archival  mater ia l  can be used for PCR-based  molecular  
inves t iga t ions .
3.2 Materials And Methods
3.2.1 Materials
Cervical  smears  wi th a s torage t ime be tween 10 to 11 years  from 
30 pat ients  (7 CIN1,  11 CIN2 and 12 CIN3),  i nc luding  6 cases 
(CIN3)  wi th matched par af f in - embedded t is sues ,  were re t r ieved 
from the pa thologi ca l  f i les  of  the Depar tment  of  His topa thology,  
Univers i ty  Col lege London.  Formal in- f ixed ,  pa ra f f in - embedded 
t i ssue from fur ther  15 pa t ient s  d iagnosed  as having cervical  
squamous cel l  carc inoma were also re t r i eved.  The morphology  of 
these cervical  smears  and biops ies  was reviewed.  Fo rma l in- f ixed
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and para f f in - embedded t i ssues  tonsi ls  from 2 male pat ient s  were 
used as controls .
3.2.2 Methods
3 .2 .2 .1  M icrod issect ion
Dyskaryo t ic  cel ls  ( 105-107) as well  as normal  cel ls  were 
mic rod is sec t ed  using glass t ransfer  p ipet tes  as descr ibed in 
sect ion 2 .2 .2  of Chapter  2 (Figure  2.1).
3.2 .2 .2  Crude DNA Preparat ion And PCR Of Genomic  
Sequences
Crude DNA preparat ion:  This  was carr ied out as descr ibed  in 
sect ion 2 .2.3.1 of Chapter  2.
3 .2 .2 .2 .1  PCR Of The P53 And BCL10 Gene
3pl  of crude DNA preparat ions  was used for  PCR ampl i f i ca t ion  of 
three  genomic  segments  of  var iab le  sizes:  p53 exon 8 (185bp) ,  
p53 exon 5 (245bp)  and BCL10 coding exon 3 (460bp) .The  
p r i m e r s  u se d  for  PCR of  the p53 and BCL10 gene are  shown  in 
Table  2.3 o f  C h a p t e r  2. PCR was per formed in a thermal  cycler  
(Hybaid,  U.K. )  using a “hot - s tar t  t ouch-down” programme with 
anneal ing t empera ture  s tar t ing at 60°C,  reducing 2°C every cycle 
unt i l  55°C for  38 cycles  as descr ibed in Table 2.4 of  Chapter  2. 
PCR products  were analysed by e lec t rophores i s  on 1.5% agarose 
gels .
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3 .2 .2 .2 .2  Loss Of H eterozygosi ty  (LOH) Analys is
Four  microsa te l l i t e  loci  of  var ious  chromosomes ,  namely 
D3S1289,  D5S406,  D6S265 and D11S528,  were se lec ted  and 
subjec ted  to PCR wi th f luorescent ly  l abe l led  pr imers  (Table  2.3 
of C h a p t e r  2) .  PCR was carr ied out  in a thermal  cycler  using a 
“hot -s t ar t  t ouch -down” programme as above.  PCR product s  were 
f i rs t  conf i rmed on agarose gels and then analysed on an ABI 
Pr i sm 377 DNA sequencer  wi th GeneScan sof tware  (vers ion 3.0).  
Dyskaryo t ic  and normal  cel ls  from the same case were analysed 
in para l le l .
3.2 .2 .3  DNA P ur if ica t ion ,  Restr ic t ion  Enzyme D igest ion  And  
PCR Based Clonal i ty  Analys is
3 .2 .2 .3 .1  DNA Purif ica t ion
The crude DNA preparat ions  were adequate  for  PCR ampl i f i ca t ion  
of  genomic  sequences  but  not  for r es t r i c t ion  enzyme diges t ion ,  
which  is requi red for  many molecular  i nves t i ga t ions ,  inc luding  
PCR based c lonal i ty  analys is  of  the X-chromosome inac t i va t i on  
pa t tern .  For  such i nves t i ga t ions ,  highly pur i f ied  DNA samples  
are necessary.  The crude DNA prepa ra t ions  f rom the 
microd is sec t ed  cel ls were fur ther  pur i f ied  as de ta i l ed  in sect ion
2.2 .3.2 of Chapter  2.
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3 .2 .2 .3 .2  Restr ic t ion  Enzyme Digest ion
4pl  of pur i f ied DNA was diges ted with and wi thout  12 uni ts 
Hpa l l  in a total  of  lOpl  react ion mixture  at 37°C for 16-20 hours.  
For  each exper iment ,  one male DNA sample  was s imi lar ly  
d iges ted  as a control .
3 .2 .2 .3 .3  PCR Of The A ndrogen  Receptor  (AR) Gene
For c lonal i ty  analysi s ,  5pl  of Hpa l l  d iges ted and mock-d iges ted  
DNA samples  were used for  PCR of  the highly polymorphi c  CAG 
repeat  (Figure  3.1) of  the AR gene.  The p r i m e r s  u sed  fo r  PCR 
o f  the AR gene are sh o w n  in Table 2.3 of  C h a p t e r  2. The 
ampl i f i ca t ion  was car r ied  out  in a thermal  cycler  using a “hot- 
s tar t  t ouch-down” programme as descr ibed in Table 2.4 of 
Chapter  2. PCR product s  were separated on 7% polyac ry lamide  
gels  by e lec t rophores is  and vi sua l ized  by s l iver  s ta ining 
(Pharmac ia -Amer sham,  Amersham Biosc iences  UK Ltd. ,  Li t t le  
Chalfont ,  Buck inghamshi re ,  UK) as descr ibed in Sect ion 2.2.4.3 
of  Chapter  2. The sample  was considered monoclonal  i f  only one 
a l lele  is ampl i f ied af ter  Hpa l l  d iges t ion,  whereas  the sample  was 
considered  as po lyc lona l  if both al le les  d i sp l ayed  s imi lar  
intensi ty.




Inactive allele > I (CAGCAGCAGCAG) _  ■i *
Hpall
AR1 1
Active allele — = --------u — (CAGCAGCAG) — —
AR2
Figure  3.1: S c h e m a t i c  i l lu s t r a t io n  o f  PCR b ased  c l o n a l i t y  a n a ly s i s  o f  the  
AR g e n e .  B e c a u s e  the i n a c t iv a ted  a l l e l e  i s  h e a v i l y  m e th y la t ed  
( C H 3 ) ,  it w i l l  not be d ig e s t e d .  The re s t r i c t io n  e n z y m e  H p a l l  
w i l l  cut o n ly  the a c t iv e  a l l e l e .  And o n ly  the i n a c t i v a t e d  a l l e l e  
w i l l  s er ve  as a t e m p la t e  for the PCR.
3.2.2.4 Reverse Transcription PCR Of The Glucose-6-Phosphate 
Dehydrogenase Gene
3 .2 .2 .4 .1  RNA Extract ion
Total  RNA ext rac t ion  from microdis sected  dyskaryo t ic  cel ls  was 
car r ied  out  using an Ambion Kit (AMS Bio t echnology ,  Oxon,  
UK).  Cel ls  were  d iges ted in 100 pL of diges t ion buf fer  conta in ing  
100 jig of  pro t e inase  K at 45°C for 2 hours.  The diges ts  were 
added wi th 600 pL of  RNA ext rac t ion  buffer  and i ncubated  at 
room t empera ture  for 5 min fo l lowed by ext rac t ion  wi th 700 pL 
of  acid phenol :  chloroform.  The aqueous layer  of  the ext rac t s  was 
recovered  into a f resh tube and 1 pL of l inear  acry l amide  (5 pg/  
pL) was added as a carr ier .  The RNA was p r ec ip i t a ted  wi th an
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equal  volume of i sopropanol  at -20°C for 2 hours  and pe l le ted in 
a microcent r i fuge  at 4°C for 15 min.  The RNA pel le t  was then 
washed wi th 70% alcohol ,  a i r -dr ied and di ssolved in 20 pL of 
RNA Storage Solution™ (Ambion (Europe)  Ltd. ,  Hunt ingdon,  
Cambr idgeshi re ,  UK).
3.2 .2 .4 .2  Reverse Transcr ip t ion  PCR
The ext racted RNA was used for reverse  t r anscr ip t i on  and 
subsequent  cDNA ampl i f i ca t ion  of the g lucose-6-phospha te  
dehydrogenase  (G6PD) gene.  To e l iminate  ampl i f i ca t ion  from 
contamina t i ng  genomic  DNA, the sense pr imer  was des igned to 
span an exon-exon boundary .  The sense pr imer  was combined 
wi th three ant i sense  pr imers ,  in order  to obtain a PCR product  of 
67 bp,  151 bp and 242 bp,  r espec t ive ly  (Table 2.3 of C h a p t e r  2) .
One-s tep  reverse  t ranscr i p t i on  PCR (RT-PCR) was per formed 
using a Qiagen OneStep RT-PCR Kit  (Qiagen,  West  Sussex,  UK).  
G6PD pr imers  were added to the RT-PCR mixture  at a f inal  
concen t r a t i on  of  0.6 pM for the sense pr imer  and 0.15 pM for 
each of the three ant i sense  pr imers ,  and 5 pL of  the above-  
ext rac ted  total  RNA was used as a template  for a 25 -pL  RT-PCR 
react ion.  The thermal  cycler  was programmed to star t  wi th 
reverse  t r anscr i p t i on  at 50°C.  A final  extens ion step at 72°C for 
10 min conc luded the react ion.  PCR products  were analysed on
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10% polyacry lamide  gels and vi sual ized by e thidium bromide  
s ta ining.
3.3 Results
3.3 .1  Crude DNA Preparat ions  Are Suitable  For PCR  
Am plif icat ion  Of Genomic Sequences
To test  the sui tabi l i ty  of  crude DNA preparat ions  from archival
cervica l  smears  for PCR-based  molecular  inves t i ga t ions ,  we f i rst
pe r formed PCR ampl i f i ca t ion  of  three gene segments  of  var ious
sizes.  When gene f ragments  less than 250 bp were examined,  each
of  the 21 cervical  smears  examined showed a product  of  expec ted
size for both p53 exon 8 (185 bp) and exon 5 (245 bp) PCRs.
When a s igni f icant ly  longer  f ragment ,  BCL10 coding exon 3 (460
bp) ,  was tes ted,  17 of  the 21 (81%) samples  yie lded a p roduct  of
expec ted  size (Figure  3.2A).
Simi la r ly ,  PCR ampl i f i ca t ion  of  4 mic rosa te l l i t es  ranging from 
100 to 260bp was success ful  in all 20 cases examined.  LOH was 
de tec ted  by para l le l  analysis  of  dyskaryot ic  and normal  ep i the l i a l  
cel l s  of  the same case (Figure  3.2B).  Table 3.1 summar i ses  the 
he te rozygous  rate and f requenc i es  of  LOH of  these loci .
- 8 2 -
Table 3.1: summary  o f  the h e t e r o z y g o u s  rate and f r e q u e n c i e s  o f  LOH o f  the 
l o c i  s tu d ie d .
Locus
CIN1 CIN2 CIN3
Heterozygosity LOH Heterozygosity LOH Heterozygosity LOH
D3S1289 4/4 1/4 8/8 6/8 8/8 5/8
D5S406 3/4 0/3 7/8 3/7 6/8 2/6
D6S265 3/4 0/3 6/8 0/6 7/8 0/7
D11S528 3/4 3/3 8/8 3/8 8/8 2/8
- 8 3 -
B A N
___________ A__________ D 1H-VOQO D3S1289









. j JL D -6000—4000-2000 D11S528
Figure  3.2 : A: E x a m p l e s  o f  PC R a m p l i f i c a t i o n  o f  B C L 1 0  c o d i n g  e x o n  3 
( 4 6 0 b p )  f r o m c r u d e  D N A  p r e p a r a t i o n s  o f  m i c r o d i s s e c t e d  
d y s k a r y o t i c  c e l l s .  M: D N A  ma r k e r ;  1- 9:  d i f f e r e n t  c a s e s .
B: E x a m p l e s  o f  L O H  a n a l y s i s  o f  f o u r  m i c r o s a t e l l i t e  l o c i
f r o m  c r u d e  D N A  p r e p a r a t i o n s  o f  m i c r o d i s s e c t e d  c e l l s .  
D y s k a r y o t i c  c e l l s  s h o w  an a l l e l i c  d e l e t i o n  in c o m p a r i s o n  
w i t h  n o r m a l  c e l l s .
N: n o r ma l  c e l l s ,  D: d y s k a r y o t i c  c e l l s .
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3.3 .2  Purif ied  DNA Sample Is Necessary For PCR-Based  
Clonal i ty  Analys is  And Can Be Applied  To Cervical  
Smears
Good qual i ty  of pur i f ied DNA was essent ia l  for complete  Hpa l l  
d iges t i on  and hence c lonal i ty  analysis .  Of  several  DNA 
ext rac t ion  protocols  tes ted,  the one deta i l ed  in the sect ion 2.2.3.2 
of  Chapter  2 gave cons i s tent  resul ts  and was used for all c lonal i ty  
assays.  To apply c lonal i ty  analysis  to cervica l  smears ,  we f i rst  
used the fo rmal in - f i xed ,  pa ra f f in - embedded  cervica l  t i ssues  to 
es tabl i sh  the methodology.  In each exper iment ,  Hpa l l -d ige s ted  
male  DNA samples  showed no PCR ampl i f i ca t ion  of the AR gene,  
i nd icat ing  complete  d iges t ion (Figure3.3) .  Normal  epi thel ia l  
cel l s  d is tant  from tumour  les ions  showed polyc lona l  pa t terns  wi th 
no apparent  skewing in all 12 cases examined (Figure4.1) .  
Ne opl as t ic  cel ls microd is sec t ed  from cervica l  b iops i es  of  CIN3 
and squamous  cell  carc inoma,  d i splayed a monoclona l  pa t t ern  in 
18 of  19 he te rozygous  cases (Figure4.1) .  The remaining 
he te rozygous  case was CIN3 and exhibi ted a polyc lona l  pat tern.  
A review of the or iginal  hi s to logy s l ides showed two separa te  
foci  of  CIN3 les ions .  Clonal i ty  analysis  of  these separa te  les ions  
was not  pe rformed because  of the insuf f ic ient  mater ia l .  In each 
of  the 6 cases of CIN3,  in which both cervical  smear  and t issue 
b iopsy  were avai lable ,  both specimens d i sp l ayed  the same 
monoclonal  pa t tern  (Figure4 .1) ,  conf i rming that  a rchival  cervical  
smears  are sui table  for  PCR-based  clonal i ty  analysi s .
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Male C1 C2 C3 C4 C5
Figure 3.3: Clonality analysis o f dyskaryotic cells from archival cervical smears. Purified DNA
samples were prepared from microdissected dyskaryotic cells. Male DNA shows lack 
of amplification after HapII digestion as expected, indicating complete digestion with 
HapII restriction enzyme. C 1 is a CIN1 and shows a polyclonal pattern. C2 and C3 are 
CIN2, and C4 and C5 are CIN3. They show a monoclonal pattern. M: DNA marker; 
without Hpall digestion; +: with Hpall digestion; Male: male DNA;
3 . 3 . 3  Re ve r s e  T r a n s c r i p t i o n - P C R  Of  The  G6 PD Gene
To e x a m i n e  w h e t h e r  a r c h i v a l  c e r v i c a l  s m e a r s  a re  s u i t a b l e  fo r  
P C R - b a s e d  R N A  d e t e c t i o n ,  we  p e r f o r m e d  R T - P C R  o f  t he  G 6 P D  
g e n e  in 10 c a s e s  o f  C I N 3 .  T h r e e  s e g m e n t s  o f  t he  g e n e  r a n g i n g  
f r o m  67 bp to 242  bp  w e r e  a m p l i f i e d  in a s i n g l e  t ub e  in e a c h  
c a s e .  Al l  c a s e s  s h o w e d  a m p l i f i c a t i o n  o f  an e x p e c t e d  6 7 - b p  
p r o d u c t ,  a nd  e i g h t  o f  t he  10 c a s e s  y i e l d e d  an e x p e c t e d  1 5 1 - b p  
p r o d u c t .  H o w e v e r ,  t h e  24 2  bp  f r a g m e n t  was  no t  a m p l i f i e d  in any  
o f  t he  c a s e s  e x a m i n e d  ( F i g u r e 3 . 4 ) .  To  a s c e r t a i n  f u r t h e r  t h a t  t he  
f a i l u r e  o f  t he  a m p l i f i c a t i o n  o f  t he  2 4 2 - b p  p r o d u c t  r e s u l t e d  f r o m  
R N A  d e g r a d a t i o n  r a t h e r  t h a n  f a i l e d  a m p l i f i c a t i o n  in a m u l t i p l e x  
P C R  r e a c t i o n ,  a s e p a r a t e  R T - P C R  w i t h  a s i n g l e  p a i r  o f  p r i m e r s  
f o r  2 4 2  bp  f r a g m e n t  wa s  p e r f o r m e d .  T h e  s i n g l e  se t  P C R  
c o n s i s t e n t l y  s h o w e d  a n e g a t i v e  r e s u l t  d e s p i t e  a m p l i f i c a t i o n  o f  an 
e x p e c t e d  p r o d u c t  f r o m  p o s i t i v e  c o n t r o l s .
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M + - 1  2 3 4 5 6 7 8 9  10
150bp 
75bp
Figure 3.4: RT-PCR of the G6PD gene of dyskaryotic cells microdissected from archival smears.
All cases show amplification of a 67bp product, and 8 o f 10 cases display amplification 
of 151bp products. +: positive control, negative control.
3 .4  D i s c u s s i o n
P r e v i o u s  s t u d i e s  h a v e  s h o w n  t ha t  P C R  a m p l i f i c a t i o n  o f  g e n o m i c  
D N A  s e q u e n c e s  c o u l d  be  a c h i e v e d  w i t h  D N A  s a m p l e s  p r e p a r e d  
f r o m  a r e l a t i v e l y  l a r g e  p o p u l a t i o n  o f  m i x e d  n o r m a l  and  
d y s k a r y o t i c  c e l l s  c o l l e c t e d  f r o m  a r c h i v a l  c e r v i c a l  s m e a r s  
( J a c k s o n  e t  a l , 1 9 9 0 ; R o d a  H u s m a n  et  al ,  1 9 9 5 ; P u r a n e n  e t  al ,  
1 9 9 6 ; C h e n  et  al ,  1 9 9 6 ;  M c G o o g a n  et  al ,  1 9 9 8 ) .  O u r  p r e s e n t  s t u d y  
f u r t h e r  d e m o n s t r a t e s  t h a t  P C R  a m p l i f i c a t i o n  o f  g e n o m i c  D N A  
s e q u e n c e s  can  be  a p p l i e d  to c r u d e  D N A  p r e p a r a t i o n  f r o m  s m a l l  
n u m b e r  o f  c e l l s  m i c r o d i s s e c t e d  f r o m  a r c h i v a l  s m e a r s .  W h e n  the  
D N A  s e g m e n t  to be a m p l i f i e d  is r e s t r i c t e d  to 2 5 0  bp  or  l e s s ,  m o s t  
i f  n o t  al l  a r c h i v a l  s m e a r s ,  c a n  be u s ed .  T h i s  m e a n s  t h a t  the  
m o l e c u l a r  a n a l y s e s  b a s e d  on  P C R ,  s u c h  as s c r e e n i n g  f o r  g e n e  
m u t a t i o n  and  L O H ,  a n d  H P V  t y p i n g ,  c a n  be  p e r f o r m e d .  I f  i t  is 
n e c e s s a r y  to t a r g e t  a s l i g h t l y  l a r g e r  f r a g m e n t ,  a r c h i v a l  c e r v i c a l  
s m e a r s  c o u l d  s t i l l  be  a v a l u a b l e  r e s o u r c e  f o r  P C R  up to 4 6 0  bp.  
O v e r a l l ,  t he  q u a l i t y  o f  D N A  s a m p l e s  p r e p a r e d  f r o m  a r c h i v a l
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cervica l  smears  is bet ter  than those pr epared  from archival  
fo rmal in- f i xed  and para f f in -embedded  t i ssue,  from which it is 
of ten di f f icul t  to ampl i fy f ragments  l arger  than 300 bp (Jackson 
et al,  1990; Coates  et al,  1991).
Af t er  pur i f ica t ion ,  DNA samples  prepared from microdissected  
dyskaryot ic  cel ls  can be readi ly diges ted wi th res t r i c t ion 
enzymes ,  such as HapII .  They are t herefore  sui table  for  PCR- 
based c lonal i ty  analysi s  of  the X-chromosome inac t iva t ion 
pa t tern .  By para l le l  analysis  of cervical  smears  and matched 
cervica l  t i ssue biops ies ,  we demons t ra ted  that  PCR-based  
c lona l i ty  analysi s  could be readi ly  appl ied to archival  smears  
wi th more than 10 years  of  s torage t ime.  In addi t ion to c lonal i ty  
analys i s ,  such pur i f ied  DNA samples prepared  from archival  
smears  should be adequate  for methyla t ion  speci f ic  PCR to study 
t ranscr i pt i ona l  suppress ion  of  TSGs such as p l 6 ,  which is 
impl ica ted  in the pa thogenes i s  of  cervical  carc inoma (Dong et al,  
2001;Vi rmani  et al,  2001) .
Based on microdissec t ed  dyskaryo t ic  cel ls ,  we also demons t ra ted  
that  archival  cervica l  smears  are sui table  for RT-PCR.  For a 
success ful  RT-PCR,  a gene- spec i f i c  pr imer ,  the ant i sense  G6PD 
pr imer ,  rather  than an ol igo (dT) pr imer  or random hexomers ,  
should  be used for cDNA synthes is .  The ol igo (dT) pr imer  targets  
the 3 ’ end of  RNA molecules  and is not  adequate  for synthes i s  of
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cDNA from degradated  RNA samples ,  such as those prepared  from 
archival  f ixed t i s sue /ce l l s .  The gene-spec i f i c  pr imer  t argets  the 
f ragment  to be ampl i f i ed  by RT-PCR should be res t r i c ted  to less 
than 150 bp. With increas ing data on t ranscr i pt i ona l  prof i les  from 
microarray,  quant i t a t ive  PCR to evaluate  gene express ion  in a 
large ser ies  of cases  is necessary.  The RT-PCR protocol  repor ted 
in the present  s tudy provides  the basis  to ut i l i ze  such valuable  
archival  mater ia ls .
In summary,  archival  cervical  smears  can be used for a var ie ty  of 
PCR-based  molecul ar  analyses  at both DNA and RNA levels .  In 
view of the huge resources  of archival  cervical  smears  and thei r  
long cl inical  fo l low-up,  the potent ial  to gain knowledge  on 
cervica l  carc inoma by the molecular  study of  these archival  
mater ia l s  is immense.
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Chapter 4 
Clonality Analysis Of Archival Cervical Smears: 
Monoclonality Correlates With Grade And Clinical 
Behaviour Of Cervical Intraepithelial Neoplasia
4.1 Introduction
C e r v i c a l  sme a r  has  been  u sed  as a s c r e e n i n g  m e t h o d  to 
i d e n t i f y  the  p r e i n v a s i v e  l e s i o n s  of  t he  c e r v ix  and  has  
p e r m i t t e d  a d r a m a t i c  r e d u c t i o n  in c e r v i c a l  c a r c i n o m a  
m o r t a l i t y  ( S c h o e l l  et al,  1999) .  H o w e v e r ,  m o r p h o l o g i c a l  
i n t e r p r e t a t i o n  of  some ce l l  c h a n g e s ,  p a r t i c u l a r l y  in the  ea r l y  
CIN l e s i o n s ,  as we l l  as p r e d i c t i o n  of  t h e i r  c l i n i c a l  b e h a v i o u r  
by m ean s  of  c y t o l o g i c a l  e x a m i n a t i o n  a lone  may  be d i f f i c u l t .  
D e s p i t e  the  a p p a r e n t  m o r p h o l o g i c a l  h o m o g e n e i t y  w i t h i n  the 
same  s u b g r o u p ,  CIN l e s i o n s  may have  v a r i a b l e  c l i n i c a l  
b e h a v i o u r .  It  is e s t i m a t e d  t ha t ,  in t he  a b s e n c e  o f  any 
t r e a t m e n t  a p p r o x i m a t e l y  60% of  CIN1 l e s i o n s  r e g r e s s  ( 
Os to r ,  1 9 9 3 ; D u g g a n  et  al,  1998 ) ,  30% p e r s i s t  and  10% 
p r o g r e s s  to a h i g h e r - g r a d e  l e s i o n .  For  C IN2  l e s i o n s ,  a r o un d  
40% r e g r e s s  w h i l e  40% and 20% p e r s i s t  or  p r o g r e s s  
r e s p e c t i v e l y  ( Os to r ,  1 9 9 3 ; D u g g a n  et al,  1998 ) .  S i m i l a r l y ,  
33% of  CIN3 r e g r e s s ,  56% and 12% p e r s i s t  or  p r o g r e s s  
r e s p e c t i v e l y  ( Os to r ,  1 9 9 3 ; D u g g a n  et al,  1998 ) .  In a d d i t i o n ,
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d e s p i t e  the  t r e a t m e n t ,  a p p r o x i m a t e l y  5% o f  CIN l e s i o n s  show 
d i s e a s e  relapse or progress ion  ( T s u k a m o t o ;  1 9 8 5 ; G u n a s e k e r a  
et al,  1990 ) .  C u r r e n t l y ,  t he r e  are no b i o m e d i c a l  or m o l e c u l a r  
m a r k e r s  t ha t  can  d i s t i n g u i s h  the  l e s i o n s  w i t h  p o t e n t i a l l y  
d i f f e r e n t  c l i n i c a l  b e h a v i o u r .  A l t h o u g h  s e v e r a l  m a r k e r s ,  
i n c l u d i n g  d e l e t i o n  of  the p l 6  gene  and e x p r e s s i o n  of  the  
i n t e g r a t e d  HPV o n c o g e n e s ,  have  be en  a s s o c i a t e d  w i t h  
a d v a n c e d  CIN l e s i o n s  ( K lae s  et al,  1 9 9 9 ; K l a e s  et al,  200 1 ) .
M o n o c l o n a l i t y  (clonal  expans ion from a s ingle  t rans formed cel l)  
is the ha l lmark  of neoplas t ic  growth.  C l o n a l i t y  a n a l y s i s  is 
v a l u a b l e  in d i a g n o s i s  o f  n e o p l a s t i c  l e s i o n s ,  p a r t i c u l a r l y  at  
e a r l y  s t a g e s ,  and in a s s e s s m e n t  of  c l o na l  r e l a t i o n s h i p  o f  
d i f f e r e n t  l e s i o n s  in the same pa t ient s  ( A l l e n  et  a / , 1 9 9 2 ; G a l e  et  
a / , 1994 ). It  has  be en  show n  tha t  mos t  o f  CIN3 and i n v a s i v e  
c a r c i n o m a s  as we l l  as the  m a j o r i t y  o f  C IN2  l e s i o n s  are  
m o n o c l o n a l ,  w h e r e a s  CIN1 l e s i o n s  are p o l y c l o n a l  ( E n o m o t o  
et  a / , 1 9 9 4 ;  Pa rk  et al,  1996;  Ko et  a / , 1 9 9 7 ; G u o a et  al ,  1998 ) .  
D e s p i t e  such  s i g n i f i c a n t  c o r r e l a t i o n  b e t w e e n  c l o n a l i t y  and 
CIN g rad e ,  it  has  no t  been  e x p l o r e d  w h e t h e r  c l o n a l i t y  can  be 
u sed  to p r e d i c t  the  c l i n i c a l  b e h a v i o r  of  CIN l e s i o n s .
For  n o n - l y m p h o i d  m a l i g n a n c i e s  in wo m en  i n c l u d i n g  c e r v i c a l  
c a r c i n o m a ,  c lonal i ty  is commonly de termined  by PCR-based  
a n a l y s i s  of  the  i n a c t i v a t i o n  p a t t e r n  of  X - c h r o m o s o m e  ge ne s .
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The p r i n c i p l e  o f  the  a ss ay  r e l i e s  on the  f ac t  t ha t  in e ach  cel l  
du r i n g  the  p r o c e s s  of  e m b r y o g e n e s i s  in f e m a l e s ,  e i t h e r  the  
m a t e r n a l l y  d e r i v e d  or p a t e r n a l l y  d e r i v e d  X c h ro m o s o m e  is 
r a n d o m l y  and  p e r m a n e n t l y  i n a c t i v a t e d  (Ga l e  et  
al,  1 9 9 3 ; E n o m o t o  et  al,  1994) .  Th is  i n a c t i v a t i o n  p a t t e r n  is 
s t a b l e  and is i n h e r i t e d  by i t s  p r o g e n y  c e l l s .  Th us ,  n o r m a l  
t i s s u e s  in f e m a l e s  are c o m p o s e d  of  c e l l u l a r  m o s a i c s  d i f f e r i n g  
in w h i c h  one  o f  the  two X c h ro m o s o m e s  is i n a c t i v a t e d .  By 
c o n t r a s t ,  n e o p l a s m s  of  f e m a le s  or ig ina t ing  from a s ingle 
t r an sfo rmed cel l  sho w an u n i f o r m  i n a c t i v a t i o n  p a t t e r n  ( A l l e n  
et al,  1 9 9 2 ; G a l e  et  al,  1994 ) .
Se v e ra l  p o l y m o r p h i c  ge nes  on X - c h r o m o s o m e  i n c l u d i n g  
G6PD,  ha ve  b e e n  e x p l o r e d  fo r  c l o n a l i t y  a n a l y s i s .  A m o n g  
t h e s e  g e n e s ,  androgen receptor  (AR) is the  mo s t  c o m m o n l y  
u sed  b e c a u s e  i t  c o n t a i n s  a h i g h ly  p o l y m o r p h i c  sh o r t  t a n d e m  
r e p e a t ,  w h i c h  is a d j a c e n t  to a c l u s t e r  of  CpGs ,  the  s i t e  o f  
m e t h y l a t i o n  ( G u o a et al,  1998 ) .  The  region s p a n n i n g  t he  
r e p e a t  and  m e t h y l a t i o n  s i t e s  can be a m p l i f i e d  by PCR s in ce  
t hey  are  c l o s e  to each  o t h e r .  Wi th  the he lp  of  m e t h y l a t i o n  
s e n s i t i v e  e n z y m e ,  such  as H p a l l ,  the  two a l l e l e s  c an  be 
e a s i l y  d i f f e r e n t i a t e d  ( F i g u r e  3 .1 ,  c h a p t e r  3) .  Th i s  PCR b a s e d  
c l o n a l i t y  a n a l y s i s  was  f i r s t  a p p l i e d  to f r e s h  f r o z e n  t i s s u e s  
and s u b s e q u e n t l y  f o r m a l i n  f i x ed  and p a r a f f i n  e m b e d d e d  
t i s s u e s  o f  m an y  c a r c i n o m a  types  i n c l u d i n g  c e r v i c a l  
c a r c i n o m a  ( E n o m o t o  et al,  1997) .
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In t he  p r e s e n t  s t udy ,  we a pp l i e d  t h i s  P C R - b a s e d  c l o n a l i t y  
a s s a y  to a r c h i v a l  c e r v i c a l  sm ea r s  and e x p l o r e d  the  v a lu e  of  
c l o n a l i t y  a n a l y s i s  in the  p r e d i c t i o n  of  CIN l e s i o n s  c l i n i c a l  
b e h a v i o u r .  We also  c o r r e l a t e d  c lo n a l i t y  w i t h  h igh  r i s k  HPV 
s u b t y p e s .
4.2 Materials And Methods
4.2.1 M aterials
Archiva l  cervical  smears  wi th an avarage s torage  t ime of  10 years 
from 33 pat ient s  (9 CIN3,  21 CIN2 and 3 CIN1)  were examined.  
These cervical  smears  were se lected because  they conta ined 
abundant  dyskaryo t ic  cel ls .  In each case,  the cytologica l  
d iagnos is  was conf i rmed by h i s to logica l  examina t ion  of the 
cervical  biopsy.  The morphology of the cervica l  smears  was 
reviewed by Dr G. Kocjan.  Formal in- f ixed ,  pa ra f f in - embedded 
tons i l s  from 2 male pa t ient s  were used as controls .
4.2.2 Methods
4 .2 . 2 . 1  M i c r o d i s s e c t i o n  And DNA E x t r a c t i o n
N o r m a l  and d y s k a r y o t i c  c e l l s  f rom cervica l  sm e a r s  we re  
m i c r o d i s s e c t e d  as d e s c r i b e d  in Se c t i o n  2 .2 .2  o f  C h a p t e r  2. 
H i g h l y  p u r i f i e d  DNA s a m p le s  we re  p r e p a r e d  f r om  the 
m i c r o d i s s e c t e d  c e l l s  as d e t a i l e d  in S e c t i o n  2 . 2 . 3 . 2  of
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C h a p t e r  2. H i gh ly  p u r i f i e d  DNA sa m p le s  we re  a l so  
p r e p a r e d  f r om  two t o n s i l s  of  mal e  p a t i e n t s .
4 . 2 . 2 . 2  R e s t r i c t i o n  E n zy m e  D ig e s t io n
P u r i f i e d  DN A (4p,L) was  d i g e s t e d  wi th  and w i t h o u t  12 un i t s  
H p a l l  as d e t a i l e d  in S ec t i o n  3.2.2.3.2 of  C h a p t e r  3. Fo r  each  
e x p e r i m e n t ,  a mal e  DNA sam p le  was  s i m i l a r l y  d i g e s t e d  as a 
c o n t r o l .
4 .2 . 2 . 3  P o ly m e r a s e  C h a in  R e a c t io n
H p a l l - d i g e s t e d  and m o c k - d i g e s t e d  DNA s a m p le s  we re  used  
fo r  PCR o f  t he  h i g h ly  p o l y m o r p h i c  CAG r e p e a t  of  AR gene  
as d e s c r i b e d  in S e c t i o n  2 .2 .4 .2  of  C h a p t e r  2 (The  p r i m e r s  
u se d  fo r  PCR of  the  AR gene  and h igh  r i sk  HPV s u b t y p e s  are 
sh o w n  in Table  2.3 of C h a p t e r  2) .  The  PCR p r o d u c t s  we re  
s e p a r a t e d  on 1% p o l y a c r y l a m i d e  ge ls  by e l e c t r o p h o r e s i s  and 
v i s u a l i z e d  by  s i l v e r  s t a i n i n g  as d e t a i l e d  in S e c t i o n  2 .2 . 5 .3  of  
C h a p t e r  2.
4 . 2 . 2 . 4  I n t e r p r e t a t i o n  O f  C l o n a l i t y  Data
C a s e s  we re  c o n s i d e r e d  as h e t e r o z y g o u s  ( i n f o r m a t i v e )  i f  the 
PCR p r o d u c t s  f r om the  u n d i g e s t e d  DNA f rom s a m p le s  of  
n o r m a l  c e l l s  sh ow ed  two ba nd s  o f  s i m i l a r  i n t e n s i t y .  Case s  
w i t h  on l y  one  m a j o r  ban d  we r e  h o m o z y g o u s  for  the  AR gene
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and  t hus  u n i n f o r m a t i v e .  In i n f o r m a t i v e  ca se s ,  c l o n a l i t y  was 
j u d g e d  by v i su a l  c o m p a r i s o n  of  the  r e l a t i v e  i n t e n s i t y  of  two 
a l l e l e s  in p r e s e n c e  and ab se n c e  of  r e s t r i c t i o n  enzy me  
d i g e s t i o n .  The sample was considered monoclonal  i f  only one 
a l le le  is ampl i f ied af ter  Hpa l l  diges t ion,  whereas  the sample  was 
cons ider ed  as polyclonal  i f  both al leles d i sp layed  s imi lar  
intens i ty .
4 . 2 . 2 . 5  HPV PCR
H i g h - r i s k  HPV s u b t y p e s  16 and 18 and 33 we r e  d e t e c t e d  by 
PCR us i n g  p r i m e r s  e s t a b l i s h e d  in p r e v i o u s  s t u d i e s  as 
d e s c r i b e d  in Table  2.3 of  C h a p t e r  2 ( M i l l e r  et  f l / , 1 99 4 ;O s t w a l d  
et  a / , 1 9 9 4 ; K a r l s e n  et al,  1996 ) .  PCR p r o d u c t s  we r e  analyzed 
on 7% of  p o l y a c r y l a m i d e  ge l s .
4.3 Results
4.3.1 Correlation Of Clonality With Grade And Clinical 
Behavior Of CIN
D y s k a r y o t i c  c e l l s  f r o m c e r v i c a l  sm ea r s  sh o w ed  m o n o c l o n a l  
p a t t e r n s  in 9 /9 CIN3 and  15/21 CIN2 .  The r e m a i n i n g  6 CIN2  
and  3 CIN1 s h o w e d  p o l y c l o n a l  p a t t e r n s  ( F i g u r e  4 .1 ) .  Al l  
p a t i e n t s  w i t h  m o n o c l o n a l  CIN l e s io n s ,  i n c l u d i n g  9 CIN3 and 
15 CIN2,  we re  show n  to have  had e i ther  pers i s t ence  or 
progres s ion  of  t he  d i s e a s e  du r i ng  f o l l o w - u p ,  d e s p i t e  
t r e a t m e n t .  In 6 C IN2  c a s e s  ( n o s . 4 , 9 , 1 0 , 1 3 - 1 5 )  in wh ic h
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s u f f i c i e n t  d y s k a r y o t i c  c e l l s  w e r e  a v a i l a b l e  f o r  a n a l y s i s  f r o m
s u b s e q u e n t  C I N  l e s i o n s ,  b o t h  t h e  o r i g i n a l  C I N 2  a n d
s u b s e q u e n t  l e s i o n s  ( C I N 3  in 3 c a s e s  a n d  C I N 2  in 3)  s h o w e d  
an  i d e n t i c a l  m o n o c l o n a l  p a t t e r n  ( F i g u r e  4 . 1 ) ,  s u g g e s t i n g  a 
c l o n a l  l i n k .  I n  c o n t r a s t ,  p a t i e n t s  w i t h  p o l y c l o n a l  C I N
l e s i o n s ,  i n c l u d i n g  3 C I N 1  a n d  6 C I N 2 ,  b e c a m e  n e g a t i v e  a f t e r  
t r e a t m e n t  a n d  r e m a i n e d  d i s e a s e  f r e e  d u r i n g  f o l l o w - u p .  
C l o n a l i t y  t h e r e f o r e  a p p e a r s  t o  h a v e  h a d  a s t r o n g  c l i n i c a l  
p r e d i c t i v e  v a l u e ,  p a r t i c u l a r l y  i n  t h e  c a s e  o f  C I N 2  l e s i o n s .  
T h e r e  w a s  no  a p p a r e n t  d i f f e r e n c e  i n t r e a t m e n t  m o d a l i t y  o r  
s u b t y p e s  o f  H P V  i n f e c t i o n  b e t w e e n  m o n o c l o n a l  a n d
p o l y c l o n a l  C I N 2  l e s i o n s  ( T a b l e  4 . 1 ) .
Biopsy Smear C4 smear
C26 C28 Original Relapse




Figure 4.1: Clonality analysis of microdissected dyskaryotic cells from cervical smears and cervical 
biopsies. M: DNA marker; without Hpall digestion; +: with Hpall digestion; Male: 
male DNA; N: normal cervical epithelial cells; Dyskaryotic cells from cervical smears 
(CIN3) in cases 26 and 28 show identical monoclonal patterns to their corresponding 
tumour cells from cervical biopsies. The original CIN2 and subsequent CIN3 lesion in 
case 4 showed an identical monoclonal pattern, suggesting a clonal link.
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T a b le  4 .1: Summary of clinical and laboratory studies.
Case No.





1 CIN1 P - ve No DF 36
2 CIN1 P - ve No DF 60
3 CIN1 P - ve No DF 120
4 CIN2 M HPV16 CB CIN3 (8) 48
5 CIN2 M HPV16 NA CIN3 (9) 72
6 CIN2 M HPV33+16 CB CIN3 (13) 12
7 CIN2 M HPV18 NA CIN3 (21) 120
8 CIN2 M HVP33+16 CB CIN3 (68) 132
9 CIN2 M HPV16 CB & LE CIN3 (23) 60
10 CIN2 M HPV16 CB CIN3 (13) 13
11 CIN2 M HPV16 CB & LE CIN2 (5) 36
12 CIN2 M HPV16 CB CIN2 (6) 36
13 CIN2 M HPV16 NA CIN2 (21) 84
14 CIN2 M HPV33+16 CB CIN2 (10) 24
15 CIN2 M HPV33 NA CIN2 (14) 24
16 CIN2 M HPV18 NA CIN1 (26) 72
17 CIN2 M HPV16 NA CIN1 (1) 24
18 CIN2 M HPV16 NA NA
19 CIN2 P HPV33 CB DF 60
20 CIN2 P HPV16 LE DF 12
21 CIN2 P HPV16 LE DF 36
22 CIN2 P HPV33 CB & LE DF 108
23 CIN2 P - ve CB DF 72
24 CIN2 P - ve NA DF 108
25 CIN3 M HPV16 CB & LE CIN3 (9) 60
26 CIN3 M HPV18 CB CIN3 (39) 120
27 CIN3 M HPV18 CB CIN3 (23) 120
28 CIN3 M HPV16 NA CIN3 (6) 84
29 CIN3 M HPV33 CB CIN2 (8) 84
30 CIN3 M HPV33 CB & LE CIN1 (11) 24
31 CIN3 M HPV16 CB CIN1 (17) 48
32 CIN3 M HPV33 CB CIN1 (67) 120
33 CIN3 M HPV16 CB NA
CB: cone  b io p s y ;  LE: lo o p  e x c i s i o n ;  DF: d i s e a s e  free; NA: not a v a i l a b l e .  
*number in b rack et s  in d i c a t e s  the t ime (m o n th s )  o f  the recurrent  d i s e a s e .
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4.3.2 Correlation Between Clonality And HPV Subtypes
H i g h - r i s k  HPV s u b t y p e s ( 1 6 , 1 8  and 33)  we r e  d e t e c t e d  in  all  
m o n o c l o n a l  CIN l e s i o n s ,  i n c l u d i n g  9 CIN3  and 15 CIN2  and 
4 o f  the  6 p o l y c l o n a l  C I N2  (T ab l e  4 . 1 ) .  HPV 16 a c c o u n t e d  
for  62% o f  the  p o s i t i v e  ca se s .  In 3 C I N2 ,  bo t h  HPV 16 and 
33 we re  p r e s e n t .  H i g h - r i s k  HPV s u b t y p e s  we re  not  d e t e c t e d  
in CIN1 l e s io n s .
4.4 Discussion
CIN l e s io n s  show v a r i a b l e  c l i n i c a l  b e h a v i o u r ,  w i th  
a p p r o x i m a t e l y  5% of  C I N2  l e s i o n s  p r o g r e s s i n g  to C IN3  or 
i n v a s i v e  l e s i o n s  d e s p i t e  t r e a t m e n t  (Tsukamoto ,  
1985;Gunasekera  et al ,  1990).  One  of  the  m a j o r  d i f f i c u l t i e s  in 
the  c l i n i c a l  m a n a g e m e n t  o f  p a t i e n t s  w i t h  CIN l e s i o n s  is to 
i d e n t i f y  t h ose  t ha t  w i l l  p r o g r e s s  or p e r s i s t .  To da t e ,  t he r e  
are  no r e l i a b l e  c l i n i c a l  or  m o l e c u l a r  m a r k e r s  f or  CIN 
p r o g r e s s i o n .  We i n v e s t i g a t e d  t he  v a lu e  of  c l o n a l i t y  as a 
p r o g n o s t i c  m a r ke r  r e t r o s p e c t i v e l y  u s i ng  a r c h i v a l  c e r v i c a l  
s m e a r s ,  o f  w h i c h  t he  c l i n i c a l  f o l l o w - u p  was  we l l  
d o c u m e n t e d .
By p a r a l l e l  a n a l y s i s  o f  c e r v i c a l  s m e a r s  and m a t c h e d  c e r v i c a l  
b i o p s i e s ,  we d e m o n s t r a t e d  in Chapter  2 t h a t  P C R - b a s e d  
c l o n a l i t y  a n a l y s i s  c o u l d  be r e a d i l y  a p p l i e d  to a r c h i v a l  
s m e a r s  w i th  >10 y e a r s  o f  s t o r a g e  t ime .  Our  r e s u l t s  f r om
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c e r v i c a l  sm ea r s  are in l ine  w i th  p r e v i o u s  f i n d i n g s  f rom 
s t u d i e s  ba sed  on b i o p s i e s  o f  c e r v i ca l  c a r c i n o m a :
CI N3 and the  m a j o r i t y  of  CIN2 l e s i o n s  are  m o n o c l o n a l ,  
w h e r e a s  CIN1 l e s i o n s  are  p o l y c l o n a l  ( E n o m o t o  et  
al,  1 9 9 4 ; P a r k  et al,  1996;  Ko et  a / , 1 9 9 7 ; E n o m o t o  et al,  1997 
; G u o a et al,  1998 ) .
We f o c u s e d  on CIN2  l e s i o n s  s i nce  t hey  show a v a r i a b l e  
c l o n a l  p a t t e r n .  Our  r e s u l t s  d e m o n s t r a t e  t h a t  p a t i e n t s  w i th  
m o n o c l o n a l  C IN2  l e s i o n s  have  e i t he r  d i s e a s e  p e r s i s t e n c e  or 
p r o g r e s s i o n  d e s p i t e  t r e a t m e n t ,  wh i l e  t h o se  w i t h  p o l y c l o n a l  
CIN2  l e s io n s  b e ca m e  n e g a t i v e  and r e m a i n e d  d i s e a s e  f ree  
a f t e r  t r e a t m e n t .  T he r e  was  no a p p a r e n t  d i f f e r e n c e  in the  
t r e a t m e n t  m o d a l i t y  b e t w e e n  m o n o c l o n a l  and p o l y c l o n a l  
CIN2 .  H o w e v e r ,  a p r o p o r t i o n  of  p o l y c l o n a l  C IN2  l e s i o n s  
we re  n e g a t i v e  for  h igh  r i s k  HPV.  It  is p o s s i b l e  t ha t  the 
d i f f e r e n t  c l i n i c a l  b e h a v i o u r  b e tw e e n  the  two g r o u ps  r e f l e c t s  
t h e i r  i n t r i n s i c  g e n e t i c  m ak e up  as we l l  as t he  HPV s t a tu s .
The  i n c i d e n c e  of  d i s e a s e  r e l a p s e  in t h i s  s e r i e s  was  r e l a t i v e l y  
h igh .  Thi s  may  r e f l e c t  our  s e l e c t i o n  b i a s  t o w a rd  t hose  
l e s i o n s  t ha t  c o n t a i n e d  a b u n d a n t  d y s k a r y o t i c  c e l l s .  H o w ev e r ,  
our  r e s u l t s  i n d i c a t e  t ha t  c l o n a l i t y  a n a l y s i s  of  c e r v i c a l  smea r s  
is p o t e n t i a l l y  v a l u a b l e  in t he  d e t e c t i o n  o f  t r ue  n e o p l a s t i c  
l e s i o n s  and p r e d i c t i o n  of  the  c l i n i c a l  b e h a v i o u r  of  
p r e n e o p l a s t i c  l e s i o n s  in p a r t i c u l a r  CIN2.
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In e ach  of  the  6 c a se s  e x a m i n e d ,  bo th  t he  o r i g i n a l  C IN2  and 
s u b s e q u e n t  l e s i o n s  (CIN2  in 3 c a se s  and  CIN3  in 3) show ed  
an i d e n t i c a l  m o n o c l o n a l  p a t t e r n ,  s u g g e s t i n g  a c l on a l  l i nk .  
T hus ,  it is l i k e l y  t ha t  the  r e c u r r e n t  l e s i o n s  in t he se  ca se s  
we re  due to the  r e l a p se  of  the  o r i g i n a l  CIN r a t h e r  t han  
e m e r g e n c e  o f  a new n e o p l a s t i c  c l o ne .  It  r e m a in s  to be 
i n v e s t i g a t e d  w h e t h e r  t u m o u r  r e l a ps e  r e s u l t s  f r om i n c o m p l e t e  
e x c i s i o n  o f  a CIN l e s io n  or f rom the  g r o w t h  of  o c cu l t  
n e o p l a s t i c  c e l l s  in o t h e r  pa r t  o f  the c e r v i x .  E n o m o t o  et  al 
e x a m i n e d  the  c lo na l  c o m p o s i t i o n  of  m u l t i p l e  CIN and 
c a r c i n o m a  in s i t u  l e s i o n s  in 6 c a se s  and d e m o n s t r a t e d  in 
e ach  case  t ha t  the  m u l t i p l e  l e s i o n s  o r i g i n a t e d  f rom a s i ng l e  
c l o ne  (E n o m o t o  et al  , 199 7 ) .
S i m i l a r l y ,  Guo et  al s t u d i e d  the  c lona l  r e l a t i o n s h i p  b e t w e e n  
a s y n c h r o n o u s  CIN l e s i o n  and i n v a s iv e  c a r c i n o m a  tha t  we re  
t o p o g r a p h i c a l l y  we l l  s e p a r a t e d  and s h o w e d  t h a t  the 
p r e i n v a s i v e  l e s i o n  was  c l o n a l l y  r e l a t e d  to t he  i n v a s iv e  
c a r c i n o m a  in the  m a j o r i t y  o f  c a se s  (Guo  et al,  2000 ) .  
N o n e t h e l e s s ,  u n r e l a t e d  CIN l e s i o n s  in d i f f e r e n t  p a r t s  of  the 
same  c e r v ix  hav e  been  r e p o r t e d  ( E n o m o t o  et  al ,  1997 ) .  The 
p o s s i b i l i t y  t ha t  the  r e c u r r e n t  CIN l e s io n  r e s u l t s  f r o m a c lone  
d i f f e r e n t  f rom the  o r i g i n a l  C IN e x i s t s .
-100-
The f i n d i n g  t h a t  m o n o c l o n a l  CIN2 l e s i o n s  t end  to r e l a p s e  
d e s p i t e  t r e a t m e n t  s u g g e s t s  t ha t  t hey  s h o u l d  be t r e a t e d  m ore  
“ a g g r e s s i v e l y ” . C u r r e n t l y ,  CIN2  l e s i o n s  are  t r e a t e d  by 
v a r i a b l e  a p p r o a c h e s ,  such  as l a s e r  a b l a t i o n ,  cone  b i o p s y  and 
l oop  e x c i s i o n  at  c o l p o s c o p y .  For  s u c c e s s f u l  t r e a t m e n t ,  i t  is 
c r i t i c a l  to a c c u r a t e l y  e s t i m a t e  t he  e x t e n t  o f  the  l e s i o n  in the  
c e rv i x .  A s y s t e m a t i c  e x a m i n a t i o n  of  CIN l e s i o n s ,  
p a r t i c u l a r l y  t h o se  sh o w in g  m o n o c l o n a l i t y ,  at b o t h  the 
h i s t o l o g i c a l  and  m o l e c u l a r  l e v e l s  w ou l d  y i e l d  c r i t i c a l  
i n f o r m a t i o n  to he lp  g y n e c o l o g i s t s  to m a n a g e  t h i s  d i s e a s e  
a p p r o p r i a t e l y  and  avo id  ove r  t r e a t m e n t .
In l i ne  w i t h  p r e v i o u s  r e p o r t s ,  h i g h - r i s k  s u b t y p e s  o f  HPV 
we re  s i g n i f i c a n t l y  a s s o c i a t e d  w i th  CIN3 and CIN2  l e s i o n s  
( P a rk  et  f l / , 1 9 9 6 ; K a u fm a n  et al,  1999) .  H o w e v e r ,  the  p r e s e n c e  
of  h i g h - r i s k  HPV su b t y p e s  does  no t  d i s t i n g u i s h  m o n o c l o n a l  
C IN2  f r om  p o l y c l o n a l  C IN2 ,  a l t h o u g h  t h e i r  i n c i d e n c e  is 
much  h i g h e r  in m o n o c l o n a l  CIN2 than  in p o l y c l o n a l  C IN 2 .  
C l o n a l i t y  a n a l y s i s  o f  c e r v i c a l  sm e a r s  is p o t e n t i a l l y  u s e f u l  as 
an a d d i t i o n a l  f a c t o r  in the  p r o g n o s i s  of  C IN2 .
The  s i g n i f i c a n t  c o r r e l a t i o n  b e t w e e n  c l o n a l i t y  and  c l i n i c a l  
b e h a v i o u r  o f  CIN l e s i o n s  s t r o n g l y  s u g g e s t s  t h a t  g e n e t i c  
m a r k e r s  c an  be  u sed  in p r o g n o s i s  o f  CIN.  H o w e v e r ,  
a p p l i c a t i o n  o f  t he  c l o n a l i t y  a s s ay  in r o u t i n e  p r a c t i c e  is
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h i n d e r e d  by i t s  r e q u i r e m e n t  of  a h igh ly  p u r i f i e d  DNA sa m p le  
and a r e l a t i v e  l a rge  n u m b e r  of  c e l l s ,  as we l l  as by the  l a ck  
of  a h igh  t h r o u g h p u t  a p p ro a c h .  Thus ,  r e s e a r c h  for  o t he r  
g e n e t i c  m a r k e r s  are  d e s i r e d .
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CHAPTER 5 
CIN PROGNOSIS BY COMBINED LOH 
ANALYSIS OF MULTIPLE LOCI
5.1 Introduction
As discussed in the general  in t roduct ion and Chapter  4, CIN 
l es ions  show markedly  var iable  c l inical  behaviour  despi te  their  
apparent  morphologi ca l  homogenei ty  wi thin the same group 
(Ci r isano,  1999).  This  present s  a chal lenge  for cl inical  
management  of  pa t i ent s  wi th CIN i.e.  to ident i fy  those l ikely to 
pers i s t  and progress .  Using PCR based c lonal i ty  analysis  of the 
X-chromosome l inked AR gene,  we showed (Chapter  4) a 
s igni f icant  cor re l a t ion  be tween c lonal i ty  and c l in ica l  behaviour ,  
in pa r t i cu lar  of  CIN2 les ions .  However ,  the appl ica t ion  of  the 
c lonal i ty  assay in rout ine  prac t ice  is hindered by its requi rement  
for  the highly pur i f ied  DNA samples  and a rela t ive  large number  
of  cel ls ,  as well  as by lack of  a high throughput  approach.  Thus,  
other  molecular  prognos t ic  markers  are needed.
The prognos t ic  value of  HPV typing has been extens ive ly  s tudied.  
Despi te  that  high r isk HPV infec t ion  is s t rongly impl ica ted  in the 
genes i s  of cervica l  carc inoma,  the role of HPV typing at single 
points  alone in CIN prognos i s  is l imi ted.  This  is mainly  due to 
f requent  presence  of  high r i sk HPV in normal  cervica l  smears  (2- 
10%) (Lor incz et al,  1992; Kjaer  et al,  2002) ,  border l ine  (10-
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50%) and CIN1 (20-80%) les ions (Lor incz et  al,  1992;Kjaer  et al,  
2002) .  In addi t ion,  HPV infect ion may be t rans ient  (Nobbenhuis  
et al,  1999).  On the other  hand,  pers i s tent  i nfec t ion  of high risk 
HPVs has been shown to be associated wi th pers i s tence  and 
progress ion  of  CIN les ions  (Nobbenhuis  et al,  1999).  Moni tor ing 
HPV infec t ion every 6 months  may help to ident i fy  CIN les ions  
having a high risk of progress ion.
There  is s t rong evidence  that  HPV infect ion alone is insuf f ic ient  
to cause mal ignant  t rans format ion .  Growing evidence  indicates  
that  genet ic  changes play a cr i t ical  role in the t ran sfo rma t ion  of 
HPV infected cel ls and may account  for  the i r revers ible  
progress ion  of  CIN. A number  of chromosomal  regions  i nc luding 
3p l4 .1 -p22 ,  4 p l 6 ,  4q21-35,  5 p l 3 -1 5 ,  6p213-22,  6q21-25,  l l p l 5 ,  
1 l q23 ,  1 3 q l 2 . 3 - q l 3 ,  17p l3 .3  and 18q l2 .2 -22  show LOH in 
cervica l  carc inoma (Lazo,  1999).  LOH at 3 p l 4 .2 ,  3p21-22,  6p21 
and l l q 2 3  is f requent  in cervica l  carcinoma (Ke r semaeke r sa et  al,  
1998; Ke rsemaeke rsa et al ,  1998; Skomedal  et al,  1999; 
Kersemaekers  et  al,  1999; Chung et al,  2000;  ; Pul ido et al,  2000 
Guob et  a / ,2000 ;Chuaqui  et al,  2001;  Har ima et al,  2001;  
Chat ter jee  et al,  2001;Acevedo et al,  2002;Senchenko  et a l , 2003)  
and occurs  more of ten in invas ive  carc inoma,  CIN3 and CIN2 
than CIN1 (Guob et al,  2000;Chat te r j ee  et al,  2001) .  LOH at 
3 p l 4 . 2  has been repor ted to be s igni f icant ly  h igher  in r ecur rent  
CIN les ions  (Linb et al,  2000) .  In addi t ion,  LOH at 3p21 
pos i t ive ly  corre la tes  wi th mi to t ic  act ivi ty of  tumour  cel ls
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(Ke r semaeke rsa et al,  1998).  Delet ion at 6p21 is s igni f icant ly  
assoc ia ted  wi th poor  overal l  and di sease- f ree  survival  in pat ients  
wi th cervical  carc inoma (Har ima et al,  2001).
Funct iona l  s tudies  have shown that  chromosome 11 carr ies  genes 
that  suppress  t umour igenic  proper t i es  of  human cervical  
carc inoma cel l  l ines (Saxon et  al,  1986).  LOH analysis  of
cervica l  carc inoma and study of in vi t ro immor t a l i sa t ion  of
human kera t inocytes  by HPV16 indicate  that  the TSGs are located 
at l l q 2 3  (Steenbergen et al,  1996;Pul ido et al,  2000) .  A
corre l a t ion  be tween LOH at l l q  23.3 wi th extens ive  
l ymphovascula r  space invas ion in radical  hys t er ec tomy specimens 
have been shown by Huet tner  et al. (Hue t t ner  et  al,  1998).  
Addi t iona l ly  a s i gni f icant  assoc i a t ion  be tween t umours  wi th LOH 
at l l q 2 1 . 2 ,  18q22 and shor t  survival  has been repor ted
(Kersemaekers* et al,  1998;Har ima et al,  2001).
In view of  the above evidence ,  we hypothes ized  that  a l lel ic  
de le t ion  at 3p l4 .2 ,  3p21-22,  6p21, and l l q 2 3  is cr i t ical  for 
deve lopment  of  CIN les ions  and may inf luence  thei r  c l inical  
behaviour  and thus have p rognos t ic  value.  To test  this ,  we
screened 12 microsa te l l i t e  markers  including 10 from the above 
chromosomal  regions  for LOH in 164 cases of  CIN and evaluated 
thei r  value as p rognos t ic  markers .
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5.2 Materials Aud Methods
5 .2 .1  Patient Material
164 cases of CIN (54 CIN1,  59 CIN2 and 51 CIN3)  were re t r i eved 
from the Depar tment  of  His topa thology,  Univers i ty  Col lege 
London Hospi ta l  (UCLH).  They were chosen according to the 
avai labi l i ty  of  d i agnos t ic  specimens  and c l inical  f ol low-up data 
except  in the case of  cervical  smears  where those wi th abundant  
clumps of  dyskaryot ic  cel ls  were selected in p r eference  for 
microdissect ion .  The c l inical  fol low-up per iod ranged be tween 6 
to 387 months ,  wi th an average  of 34.8 months .  The diagnos is  of 
CIN was based on hi s t ologi ca l  t i ssue biopsy.  Al l  pa t i en t s  were 
t reated according to the same protocol  at UCLH.
5.2.2 Microdissection And DNA Preparation
The morphology of cervica l  smears  and b iops ies  in all  cases was 
reviewed before  mic rod is sec t ion .  Normal  and dyskaryo t ic  cel ls 
f rom cervical  smears  and cervical  biops ies  were  microdissec t ed  
as descr ibed in Sect ion 2.2.2 of  Chapter  2. Crude DNA samples  
were prepared from the microdissec t ed  cel ls  as de ta i led in 
Sect ion 2.2.3.1 of  Chapter  2.
5.2.3 Detection Of LOH By PCR
Twelve mic rosa te l l i t e  markers  including D3S1566 (3 p l 3 ) ,
D3S1285 (3p l4 .1 ) ,  D3S1300 (3p l4 .2 ) ,  D3S1289 (3p21.1) ,
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D3S1260 (3p22.2) ,  D3S1611 (3p22.3) ,  D5S406 (5p l5 .3 2 ) ,  D6S105 
(6p21.1) ,  D6S265 (6p21.1) ,  D6S277 (6p24.3) ,  D11S35 ( l l q 2 2 . 1 )  
and D11S528 ( l l q 2 3 . 3 ) ,  at which LOH f requent ly  occurs  in 
cervical  carc inoma (Ke r semaeke rsa et al,  1998;  Ke r semaeke rsa et  
al,  1998; Skomedal  et al,  1999; Kersemaekers  et al,  1999;  Chung et  
al,  2000;  Pul ido et al,  2000 Guob et  f l / ,2000;Chuaqui  et al,  2001;  
Har ima et al,  2001;  Chat ter jee  et al,  2001;Acevedo  et al,  
2002;Senchenko et a l , 2003)  were studied.  The pr imers  used for 
PCR of the microsa te l l i t e  markers  are de ta i l ed  in Table 2.3 of 
Chapter  2.
Pr imers  were des igned to immedia te ly  f lank the t andem repeats ,  
thus the f ragment  to be ampl i f ied was smal l ,  a l lowing 
ampl i f i ca t ion  from DNA samples  prepared from archival  f ixed 
specimens .  One of  the pai red pr imers  was f luorescen t ly  l abel led 
and PCR was car r ied out  in a thermal  cycler  using a “ hot -s tar t  
t ouch -down” programme as descr ibed  in Table 2.4 of  Chapter  2. 
The speci f ic i ty  of  PCR product s  was ver i f i ed  on agarose gels and 
products  analyzed on an ABI377  DNA sequencer  using the 
GeneScan sof tware  (Vers ion  3.0) as deta i l ed  in Sect ion 2.3 of 
Chapter  2. Dyskaryo t i c / neop las t i c  and normal  cel ls  from the 
same cases were analyzed in para l le l .  Al le l i c  loss was ident i f i ed  
by a computer  programme when the peak height  rat io of  t umour  to 
normal  al leles  was 0.25 or less as descr ibed pr ev ious ly  (Lakhani  
et  al,  1996),  then conf i rmed by visual  inspec t ion  in each case.
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The molecular  data were genera ted  wi thout  the knowledge  of 
c l inical  fol low-up detai l s .
5.2.4 Detection Of High-Risk HPV
High-r i sk  HPV including 16, 18, 33, 45 and 56 were detected  by 
PCR separa te ly using pr imers  es tabl i shed in previous  s tudies  (The 
pr imers  used for PCR of  HPV are shown in Table  2.3 of Chapter  
2) (Mi l ler  et al,  1994;Ostwald  et al,  1994; Kar l sen et  a l , 1996).  
DNA samples  prepared  from microdis sec t ed  dyskaryot ic  or 
neoplas t ic  cel ls were used for HPV detect ion in each case.  Str ict  
l abora tory  procedures  as de ta i l ed  in Sect ion 2.2 .4 .2  of  Chapter  2, 
including separa te  set -up areas for  DNA preparat ion ,  PCR and 
pos t -PCR analysis  were fol lowed and serial  cont rol s ,  at var ious  
s tages of DNA prepara t ions  and PCR set -up,  were i nc luded in 
each set of  exper iment s  to avoid and detect  potent ia l  cross 
contaminat ion.
5.2.5 Statistical Analysis
Stepwise  analysis  of  the 12 markers  was car r ied  out  using two 
way s tudent  t - test  to obtain group of  markers  that  show 
di f ference  be tween disease  free and disease p rogress ion .  This was 
done by progress ive ly  analys ing  the 12 markers  in s tepwise 
manner  unt i l  a group of markers  of p < 0.05 was obtained.
Student  t - test  on the group of markers  showing s ta t i s t ica l  
s igni f icance  was used for  compar i son  of age and fol low-up t ime
-108-
be tween CIN les ions  showing di f ferent  c l in ica l  behaviour .  %2 
was used to analyse the re la t ionship  be tween LOH and cl inical  
outcome,  HPV status and t rea tment  methods.
5.3 Results
5.3.1 Identification of Loci at which LOH is potentially 
valuable in CIN prognosis
Pr imers  for  microsa te l l i t e  analysi s  were des igned to ampl i fy the
minimum f ragment  conta ining the tandem repeat ,  thus sui table  for
ampl i f i ca t ion  of  DNA samples  prepared from archival  specimens .
PCR was successful  for all DNA samples  prepared  from cervica l
smears  and 95% of those from t issue b iops ies .  For  cases that
were fai led for PCR in the f i rst  ins tance,  repeat  PCR wi th var ious
amounts  of  template  DNA were carr ied out  and those wi thout
success ful  PCR ampl i f i ca t ion  were excluded from the analysis .
To ident i fy  the loci  at which LOH was assoc ia ted  wi th disease  
behaviour  and may thus have prognos t ic  value,  we f i rs t  sc reened 
12 microsa te l l i t e  markers  and corre la ted LOH wi th c l inical  
outcome in 71 cases of  CIN (15 CIN1,  22 CIN2 and 34 CIN3)  
us ing d i agnos t ic  cervical smears .  Pat ients  were divided into two 
groups:  those that  became disease free (DF) wi th in  6 month after  
the f i rst  t rea tment  and those that  showed disease pers i s t ence  (DP) 
at the same or a h igher  CIN grade 6 months  af ter  the ini t ial  
t rea tment .  The average  t ime showing the disease  recur rence  was
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26 months ,  ranging from 6 to 90 months .  As resect ion margin 
could not  be rel iably evaluated in each case,  no a t tempt  was made 
to correlate  the extent  of tumour  i nvolvement  wi th the outcome of 
t rea tments .
As the number  of cases examined from each CIN group was 
re la t ive ly  smal l ,  we corre la ted LOH wi th c l inical  outcome 
i r respect ive  of  CIN grade.  Among the 12 markers  inves t igated,  
D3S1300 (3p l4 .2 ) ,  D3S1260 (3p22.2)  and D11S528 ( l l q 2 3 . 3 )  
showed LOH at s igni f icant ly  h igher  f requencies  in the DP than 
the DF group (p<0.01,  Figure  5.1A).  D11S35 ( l l q 2 2 . 1 )  exhibi ted 
the next  h ighes t  s t a t i s t i ca l  d i f ference  be tween the two groups 
a l though not at a s igni f icant  level .  Using a s tepwise  s ta t i s t ica l  
analysis ,  var ious  combina t ion  of the 12 markers  were t es ted and 
the above four  markers  col lec t ive ly  gave the highes t  s ta t i s t ica l  
s igni f icance  (p<0.02)  be tween the two groups and were selected 
for  fur ther  analysi s .  As the value of using these loci  alone as 
prognos t ic  markers  was l imi ted,  we tes ted the 4 makers  together  
(Figure  5 . IB) .  By s tepwise  examina t ion of  the sens i t iv i ty  and 
speci f i c i ty  of  the combined  4 LOH markers ,  i .e.  1 or 2 or 3 or all 
of  the 4 loci  showing LOH, the best  cu t -of f  point  was when 2 of 
the 4 loci  showing LOH was appl ied.  At  this threshold ,  around 
45-58% of CIN les ions  in the DP group but  none in the DF group 
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Figure 5.1: I d e n t i f i c a t i o n  o f  L O H  l o c i  t h a t  ar e  p o t e n t i a l l y  v a l u a b l e  in
C I N  p r o g n o s i s .  ( V a l u e s  i n b l a c k  r e p r e s e n t  p e r c e n t a g e  L O H  a n d  i n red  
r e p r e s e n t  n u m b e r  o f  c a s e s )
A:  F r e q u e n c i e s  o f  L O H  at  12 m i c r o s a t e l l i t e  m a r k e r s  b e t w e e n  C I N  l e s i o n s  s h o w i n g  
d i s e a s e  f r e e  ( D F )  or  d i s e a s e  p e r s i s t e n c e  ( D P )  a f t e r  i n i t i a l  t r e a t m e n t .  * T h e  
i n c i d e n c e  o f  L O H  at D 3 S 1 3 0 0  ( 3 p  1 4 . 2 ) ,  D 3 S 1 2 6 0  ( 3 p 2 2 . 2 )  a nd  D 1 1 S 5 2 8
( l l q 2 3 . 3 )  i s  s i g n i f i c a n t l y  h i g h e r  i n t he  D P  t h a n  t h e  D F  g r o u p  ( p < 0 . 0 1  i n e a c h ) .  
D 1 1 S 3 5  ( l l q 2 2 . 1 )  e x h i b i t e d  t h e  n e x t  h i g h e s t  s t a t i s t i c a l  d i f f e r e n c e  b e t w e e n  t h e  
t w o  g r o u p s ,  a l t h o u g h  n o t  at  a s i g n i f i c a n t  l e v e l .  U s i n g  a s t e p w i s e  s t a t i s t i c a l  
a n a l y s i s  t e s t i n g  v a r i o u s  c o m b i n a t i o n  o f  t h e  12  m a r k e r s ,  t h e  a b o v e  f o u r  m a r k e r s  
c o l l e c t i v e l y  g a v e  t h e  h i g h e s t  s t a t i s t i c a l  s i g n i f i c a n c e  ( p < 0 . 0 2 )  b e t w e e n  t h e  t w o  
g r o u p s  a n d  w e r e  f u r t h e r  a n a l y s e d  as  d e t a i l e d  i n  F i g u r e  I B .
B: P r o g n o s t i c  v a l u e  o f  c o m b i n e d  L O H  a n a l y s i s  at  t h e  a b o v e  4 l o c i .  B y  s t e p w i s e
t e s t i n g  t h e  s e n s i t i v i t y  a n d  s p e c i f i c i t y  o f  t h e  c o m b i n e d  4 L O H  m a r k e r s  i n C I N  
p r o g n o s i s ,  i . e .  1 or  2 or  3 or  4 o f  t h e  4 l o c i  s h o w i n g  L O H ,  t he  b e s t  c u t - o f f  p o i n t  
i s  L O H  at 2 o f  t h e  4 l o c i .  At  t h i s  t h r e s h o l d ,  b e t w e e n  4 5 - 5 8 %  o f  C I N  l e s i o n s  in 
t h e  D P  g r o u p  but  n o n e  i n t h e  D F  g r o u p  s h o w  L O H .
- I l l  -
5.3.2 Prognostic Value Of LOH At D3S1300 (3pl4.2),  
D3S1260 (3p22.2), D11S35 ( l lq22.1)  And D11S528 
( l lq23.3)  In CIN
To fur ther  conf i rm the prognos t ic  value of  LOH at the above 4 
markers  in CIN,  we examined a fur ther  93 cases using diagnos t ic  
t i ssue biops ies  since it was easier  to microd issec t  neoplas t ic  cel ls 
f rom biops ies  than cervical  smears.  LOH was cor re l a t ed  with 
c l inica l  fo l low-up as above.  The data f rom these addi t ional  cases 
were compat ible  to those obtained from the cervica l  smears  in the 
pi lot  s tudy a l though the LOH frequency in the DP group was 
h igher  in the cervica l  smears  than t issue b iops i es  par t icu l ar l y  for 
the CIN1 and CIN2 les ions  (Figure  5 . IB and Figure  5.2C) .  This 
most  l ikely ref lec ted the se lec t ion of cervica l  smears  with 
abundant  c lumps of dyskaryot ic  cel ls,  which may bias se lect ion 
of those pa t ient s  wi th extens ive  disease,  and the number  of the 
cases  examined in the pi lot  s tudy was smal l .  No s ta t i s t ica l  
d i f ferences  were  found be tween the age,  HPV sta tus ,  t r ea tment  
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F i g u r e  5 .2 :  P r o g n o s t i c  v a l u e  o f  L OH at D 3 S  1 3 0 0  ( 3 p l 4 . 2 ) ,  D 3 S 1 2 6 0
( 3 p 2 2 . 2 ) ,  D 1 1 S 3 5  (1 1 q 2 2 . 1 )  a nd  D 1 1 S 5 2 8  ( 1 1 q 2 3  . 3 ) .  ( V a l u e s  in b l a c k  
r e p r e s e n t  p e r c e n t a g e  LOH a n d  i n red r e p r e s e n t  n u m b e r  o f  c a s e s ) .
A: C o r r e l a t i o n  o f  LOH w i t h  C I N  g r a d e .  L O H  at  D 3 S 1  3 0 0 ,  D 3 S 1 2 6 0  a nd  D 1 1 S 3 5
c o r r e l a t e s  p o s i t i v e l y  w i t h  t he  g r a d e ,  w h i l e  t he  i n c i d e n c e  o f  L O H  at D 1 1 S 5 2 8  i s  s i m i l a r
a m o n g  d i f f e r e n t  CI N l e s i o n s .
B: C o m p a r i s o n  o f  L O H  b e t w e e n  C I N  l e s i o n s  s h o w i n g  d i s e a s e  f r e e  ( D F )  or  d i s e a s e
p e r s i s t e n c e  ( D P ) .
C: By  s t e p w i s e  t e s t i n g  t he  s e n s i t i v i t y  and s p e c i f i c i t y  o f  t he  c o m b i n e d  4 L OH m a r k e r s
in C I N  p r o g n o s i s ,  i . e .  1 or  2 or  3 or  4 o f  t he  4 l o c i  s h o w i n g  L O H ,  t he  b e s t  c u t - o f f  
p o i n t  i s  L O H  at 2 o f  t he  4 l o c i .  At  t h i s  t h r e s h o l d ,  b e t w e e n  2 2 - 4 7 %  C I N  l e s i o n s  o f  t he  
DP  g r o u p s  c a n  be  i d e n t i f i e d  w i t h  1 0 0 % s p e c i f i c i t y .
-  1 1 3 -
In tota l ,  we examined 164 cases of CIN (54 CIN1,  59 CIN2 and 
51 CIN3).  The f requency of LOH at D3S1300,  D3S1260 and 
D11S35 pos i t ive ly  corre la ted  wi th CIN grade,  whi le  the incidence  
of  LOH at D11S528 was s imi lar  among d i f fe rent  CIN groups 
(Figure  5.2A).  As expected,  the f requency of  LOH at these loci  
was  s i gni f icant ly  h igher  in the DP than the DF group (p<0.0005,  
Figure  5.2B).  By combining  the 4 markers  t oge ther  as above,  
22% of  CIN1,  28% of CIN2 and 47% of CIN3 of  the DP group but  
none of  the DF group showed LOH at 2 or more of  the 4 loci  
examined (Figure  5.2C) .  Thus,  LOH analys is  at these loci  could 
ident i fy  22-47% of CIN les ions  that  showed di sease  pers i s tence  
despi te  t rea tment .
The percentage  of  infec t ion  of  high r isk HPV was s igni f icant ly  
h igher  in the DP (90%) than in the DF group (43%) (p<0.0005)  
(Table  5.1A).  Among d i f ferent  high r isk HPV, HPV16 infec t ion 
was s i gni f icant ly  assoc ia ted wi th the DP group (p<0.001)  despi te  
the fact  that  we may have underes t imat ed  i ts real  incidence,  
par t i cu l a r ly  in samples  prepared  from paraf f i n- embedded t issue 
spec imens ,  since the f ragment  to be ampl i f i ed  is re la t ive ly  large 
(398bp) .  I n teres t ingly ,  only HPV16 was s ign i f i can t ly  associated 
wi th  LOH at each of the four loci  examined (p<0.01) ,  par t icu l ar l y  
D3S1300  (p<0.0005)  (Table 5 . IB) .  Trea tment  informat ion  was
avai lab l e  in 102 cases  i nc luding  47 and 55 from the DF and DP 
group respec t ive ly .  Laser  abla t ion was more f requent ly  used in 
the DF than the DP group (p<0.02) ,  whereas  large  loop exci s ion
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of  the t rans format ion  zone (LLETZ) was appl ied more of ten to 
the DP (62%) than the DF group (21%) (p<0.005)  (Table5.1A).  
There  were no s igni f icant  di f ferences  in other  t rea tment  
modal i t i es ,  age and fol low-up t ime between the two groups.
T ab l e  5.1A: Cl inical  features  of CIN les ions be tween the DF and 
the DP group.
DF DP




High r isk HPV infec t ion
Number  of  cases wi th high r isk HPV* 32 43% 80 90%
HPV16* 1 1% 26 29%
HPV18 9 12% 18 20%
HPV33 15 20% 18 20%
HPV45 5 7% 9 10%
HPV56 1 1% 2 2%
Double vi rus 1 1% 7 8%
Treatment
Number  of  cases wi th avai lable  data 47 55
Cold Coagula t ion 1 2% 0 -
Laser  ablat ion* 15 32% 3 6%
Cone biopsy 21 45% 18 32%




* S i g n i f i c a n t  d i f f e r e n c e  b e t w e e n  D F  and DP g r o u p s .  
L L E T Z :  L a r g e  l o o p  e x c i s i o n  o f  the  t r a n s f o r m a t i o n  z o n e
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T a b l e  5 . IB:  Cor re la t ion of HPV16 infec t ion wi th the four 
markers .
Marker LOH +ve LOH -ve p-value
D11S528 HPV +ve 24 24 0.002152
HPV -ve 36 87
LOH +ve LOH -ve p-value
D11S35 HPV +ve 20 30 0.002326
HPV -ve 28 106
LOH +ve LOH -ve p-value
D3S1300 HPV +ve 27 24 0.000653 *
HPV -ve 32 102
LOH +ve LOH -ve p-value
D3S1260 HPV +ve 23 29 0.004165
HPV -ve 26 100
* M a r k e r  w i t h  the  m o s t  s i g n i f i c a n t  a s s o c i a t i o n  b e t w e e n  H P V  and L O H .
T h e  a n a l y s i s  i s  c a r r i e d  o u t  u s i n g  x2 (Chi-squared) between LOH and HPV for each marker.
To fur ther  evaluate  the assoc ia t ion of LOH wi th cl inical  outcome 
of  CIN,  we examined both d iagnos t ic  and fol low-up b iops ies  in 
22 cases from the DP group.  Of these cases,  5 (numbers  1-5) 
became disease  free after  the f i rs t  f ol low-up biopsy (7-15 
months)  and none of  them showed accumulat ion  of LOH in the 
fol low-up biopsy (Table 5.2) .  The remaining 17 cases showed 
disease  pers i s tence  at the same (8 cases)  or h igher  CIN grade (9 
cases)  dur ing fol low-up,  and 13 cases (numbers  9-21)  d i splayed 
LOH at addi t ional  loci  (Figure  5.3).  The average  t ime to gain 
LOH at an addi t ional  locus was 30 months ,  ranging from 5 to 93 
months .  Except  case 22, the LOH observed in the d iagnos t ic  
sample  was always seen in the fol low-up biopsy (Table 5.2) .  In
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case 22, LOH was seen at D3S1260 and D11S35 in the diagnos t ic  
biopsy but  not  in the fol low-up biopsy three years later ,  
sugges t ing  that  the two CIN les ions  may not be c lona l ly  related.
In 6 cases (numbers  12-14,  16-18),  the diagnos t ic  b iopsy showed 
no LOH or LOH at only 1 of the 4 loci ,  but  the fo l low-up biopsy 
d i sp layed LOH at 2 or more of the 4 loci ,  r eaching the threshold 
of  p rognos t ic  s i gni f i cance  as de ta i led above.  I nt eres t ingly,  two 
of  these cases (numbers  17 and 18) also showed infec t ion by an 
addi t ional  h igh- r i sk  HPV.
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Table  5.2A: C o m p a r i s o n  o f  L OH  a n d  H P V  s t a t u s  b e t w e e n  d i a g n o s t i c  a n d  f o l l o w u p  s p e c i m e n s .
D ia g n o s is Time(year-month) Treatment HPV D 3 S 1 3 0 0 D 3 S 1 2 6 0 D 1 1 S 3 5 | D 1 1 S 5 2 8
1
CIN3 19 95 -6 Cone bio psy 33 + H - H
CIN3 1996-3 Cone biopsy 33 + II - H
2
CIN2 1999-5 LLETZ 45 - H - -
CIN2 1 9 9 9 -1 2 NA 45 - H - -
3
CIN1 19 98 -9 No 18 - - - +
CIN1 1 9 9 9 -1 2 NA 18 - - - +
4
CIN1 19 89- 8 No 33 - + - -
CIN2 19 90 -6 LLETZ 33 - + - -
5
CIN 1 1 9 9 7 -1 0 LLETZ 33 - - II -
CIN 1 1998-6 LLETZ NA - - H -
6
CIN2 1994 -1 1 LLETZ 33 - - + -
CIN2 1995-5 NA 33 - - + -
7
CIN2 1998-1 1 No 16 - + - -
CIN3 2 0 0 0 -2 LLETZ 16 - + - -
8
CIN 1 1 9 94 -7 LLETZ 18 + - H -
CIN1 1995-3 NA 18 + - II -
9
CIN2 1 99 2- 2 Cone biopsy 18 - H - -
CIN2 1998-1 1 NA 18 - H - +
10
CIN1 19 97-9 NA 18 - - H -
CIN2 19 99- 4 NA 18 - - H +
11
CIN 1 19 97-4 LLETZ 33 - H - -
CIN3 2 0 0 0 -9 Cone biopsy 33 - H - +
12
CIN 1 1 9 9 1 -1 0 No 16 - - + -
CIN3 1995-1 LLETZ 16 + - + -
13
CIN2 19 9 5 -7 No 16 + - - -
CIN3 19 98-4 LLETZ 16 + _ - +
14
CIN1 19 95-3 No NA - - - -
CIN 1 19 9 6 -1 0 No NA - + + +
15
CIN 1 19 89-4 No 16 + - - +
CIN3 1992-8 LLETZ 33 + - + +
16
CIN2 1 9 88-1 1 Cone bi ops y 16 - - - +
CIN3 1992-2 Cone biopsy:  16 - + + +
17
CIN3 1991-5 Cone biopsy 18 - - + -
CIN3 1 9 94 -11 Cone biopsy 18 + 16 - + + -
18
CIN2 1 9 9 1 -1 0 Cone bi op sy 16 + II - -
CIN3 1 9 9 7 -1 0 LLETZ 16 + 45 + II + -
19
CIN3 19 89-1 1 Cone biopsy 16 + - + -
CIN3 19 91-4 NA 16 + 18 + + + -
20
CIN1 1 9 89 -6 NA 18 + - - +
CIN1 1 9 8 9 -1 2 LLETZ 18 + - + +
CIN1 19 90 -4 NA 16 + - + +
21 CIN2 1994-4 NA 16 + - + +
CIN3 199 4 -9 NA 16 + + + +
22
CIN3 1990-1 NA 33 - + + -
CIN3 1993-1 NA 33 NA - - -
Cases  1-5 became  d i s ea se  f ree a f t e r  the f i r s t  f o l l ow -up  b io p sy ;  Cas es  7-21 c o n t i n u a l l y  
sho wed  d i s e as e  p e r s i s t e n c e  o r  p r o g r e s s i o n  a f t e r  the f i r s t  fo l low-up  b io p s y  (da ta  show n 
in t a b le  5 .2 B) .  NA: no t  a v a i l a b le ;  + : LOH po s i t iv e ;  -: LOH n e g a t i v e ;  H: h om o z y g o u s .
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Tab le  5 . 2 B :  C a s e s  w i t h  “ w o r s t  r e c u r r e n c e ” a f t e r  s e c o n d  b i o p s y .




7 C1N3 2000 LLETZ
CIN3 2001
CIN1 1994 LLETZ
8 CIN1 1995 NA
CIN1 1995







10 CIN2 1999 NA
CIN2 1999
CIN 1 1997 LLETZ
11 CIN3 2000 Cone bio psy
CIN3 2001
CIM1 1991 No
12 CIN3 1995 LLETZ
CIN3 1996
CIN2 1995 No
13 CIN3 1998 LLETZ
CIN 1 200 0 Cervica l  b iopsy
Cl Ml 1995 NA
14 CIN1 1996 NA
Cl Ml 1997
CIN1 1989 No
15 CIN3 1992 LLETZ
CIN2 1993
CIN2 1988 Cone biopsy
16 CIN3 1992 1 Cone bio psy
CIN3 1993
CIN3 1991 Cone bio psy
17 CIN3 1994 Cone bio psy
CIN3 1995















20 CIN1 1989 LLETZ
CIN 1 1991
CIN I 1990 NA
CIN2 1994 NA
21 CIN2 1994 LLETZ
CIN3 1995
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CIN1 15 15 5
CIN2 0 9 26
CIN3 0 0 13
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Figu re  5.3: E x a m p l e  o f  L O H  a n a l y s i s .  T h e  d i a g n o s t i c  b i o p s y  ( C I N 3 )  o f
c a s e  19 s h o w s  L O H  at D 3 S 1 3 0 0  and D 1 1 S 3 5 .  D e s p i t e  t r e a t m e n t ,  t he  
p a t i e n t  c o n t i n u a l l y  p r e s e n t e d  w i t h  C I N 3 .  T h e  f o l l o w - u p  b i o p s y  17 m o n t h s  
a f t e r  d i a g n o s i s  d i s p l a y s  a d d i t i o n a l  L O H  at D 3 S 1 2 6 0 .  N:  n o r m a l  c e l l s ;  T: 
t u m o u r  c e l l s .
-  120 -
5.3.3 Putative Tumour Suppressor Genes At D3S1300 
(3pl4.2), D3S1260 (3p22.2), D11S35 (l lq22.1)And  
D11S528 ( l lq23.3)
Bioinformat ic  analysi s  of the genomic  regions  at D3S1300,  
D3S1260,  D11S35 and D11S528 ident i f i ed  puta t ive  genes  that  
may be target  of the dele t ions .  LOC152071 (an EST c lone) ,  FHIT 
( f ragi le  h i s t idine  t r iad gene) and NPCR (nasopharyngea l  
car cinoma rela ted protein)  are at or in the v i cin i ty  of  D3S1300.  
Since FHIT is f requent ly  dele ted in a var ie ty  of  human 
car cinomas  i nc luding cervical  carc inoma (Yoshino et al,  
2000;But l er  et al,  2000;Hel land et al, 2000) ,  it is a l ike ly target  
of  the dele t ion.  Among the genes in the vic in i ty  of D3S1260 
i ncluding ORCTL (organic  ca t ionic  t r anspor t er - l ike  4) and XYLB 
(Xylukokinase  homolog) ,  DLEC1 (dele ted in lung and esophageal  
carc inoma 1) may be re levant  as it is assoc i a t ed  wi th carcinoma.  
AD031,  PR (proges te rone  receptor)  and TRPC6 ( t rans ient  
receptor  potent ia l  cat ion channel ,  super fami ly  C, member  6) are 
at or in the vic in i ty  of D11S35.  PR appears  to be the most  
re levant  given its role in inhibi t ion of  human endometr ia l  
carcinoma.  Final ly ,  TRIM29 ( t r ipar t i te  mot i f - cont a in ing  29) and 
several  hypothet ica l  genes  are around D11S528.  TRIM29 has 
mul t ip le  zinc f inger  mot i f s  and a leucine z ipper  mot i f  and may 
act  as a t ranscr i pt i ona l  regula tory  factor .
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5.4 Discussion
Al l e l i c  de le t ions  at several  chromosomal  loci  inc luding  3p l4 .2 ,  
3p21-22,  6p21 and l l q 2 3  are s igni f icant ly  assoc ia ted  wi th high 
grade CINs and invasive cervical  carc inomas  (Ke rsemaeke r s3 et  
al,  1998; Ke rsemaeke rs3 et al,  1998; Skomedal  et al ,  1999; 
Kersemaeker s  et al,  1999; Chung et al,  2000;  ; Pul ido et al,  2000 
Guob et  a / ,2000 ;Chuaqu i  et al,  2001;  Har ima et al,  2001;  
Cha t ter jee  et al,  2001;Acevedo et al,  2002;Senchenko  et a l , 2003) 
However ,  whether  LOH at these loci  can be used to de te rmine  the 
pr ognos i s  of  CIN is l argely unknown.  We inves t iga ted  
r e t rospec t ive ly  the prognos t ic  value of LOH markers  in CIN 
l es ions  based on archival  cell  and t issue mater ia l .  The molecular  
analyses  were per formed wi thout  the knowledge  of c l inical  data 
and LOH was recorded by a computer  programme es t abl i shed  in 
previous  s tudies  (Lakhani  et al,  1996),  thus avoiding subject ive  
bias .  All  cases were re t r i eved  from a s ingle t eaching  hospi tal  
and were managed c l in ica l ly  according to the s tandard  t rea tment  
pro tocol .  There was no s igni f icant  d i f ference  in the age,  nature 
of  the specimen (cervica l  smear  or t issue b iopsy)  and fol low-up 
t ime be tween the two groups.
To ident i fy  the loci  at which LOH may have prognos t ic  value in 
CIN,  we f irst  screened 12 mic rosa te l l i t e  markers  and corre la ted  
LOH wi th c l inical  behaviour  of CIN les ions  in a pi lot  study.
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D3S1300,  D3S1260, D11S35 and D11S528 showed potentia l  
p rognos t ic  value and were fur ther  inves t iga ted  in a la rger  cohort .  
A l though  independent ly  LOH at these loci did not al low a clear  
separa t ion  be tween the DF and the DP groups,  combined analysis  
of the four LOH markers  permit ted  iden t i f ica t io n  of a s ign if ican t  
p ropor t ion  of the DP group with high spec i f ic i ty .  The best  c u t ­
off  point  was 2 of 4 loci  showing LOH. At this  th reshold ,  22- 
47% of CIN les ions  in the DP group could be iden t i f ied  with 
100% spec i f ic i ty .
The assoc ia t ion  of  LOH at these loci  with c l in ica l  behaviour  of 
CIN was fur ther  re in forced  by analysis  of fo l low -up  b iops ies  in 
cases from the DP group. None of the 5 cases that  became 
d isease  free after the f i rs t  fo l low-up b iopsy  exhib i ted  
a ccum ula t ion  of LOH in the fo l low-up specim ens .  In contras t ,  13 
of the 17 cases that  had disease  pe rs is tence  or p rogress ion  
showed,  accumulat ion  of LOH at addit ional  loci  in the fo l low-up 
specim ens and in 6 cases the p rognos t ic  value of LOH reached the 
th resho ld  of  s ign if icance .  The resul ts  s t rongly  ind ica te  that  LOH 
analys is  of fo l low-up  specimens could fu r ther  seg rega te  CIN 
les ions  with d if fe ren t  c l in ica l  outcome.  It remains  to be 
de te rm ined  when is the best  in te rval  to implem ent  such analys is  
a l though our study showed that  an average  of  30 months was 
required  for acqu is i t ion  of an addit ional  LOH at the 4 loci  
examined.
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In fec t ion  of  h igh-r isk  HPV is s ign i f ican t ly  assoc ia ted  with 
increased  risk of cerv ica l  carc inom a development .  In support  of 
this , our resul ts  showed that  the percen tage  of in fec t ion  of high 
risk HPVs, pa r t icu la r ly  HPV16 and double v i ruses ,  was higher  in 
the DP than the DF group. Fur therm ore ,  HPV16 infec t ion  
s ign i f ican t ly  co rre la ted  with LOH at each of the four markers  
examined,  pa r t icu la r ly  D3S1300 as shown in table  5 . IB. HPV16 
in teg ra t ions  in cerv ica l  carc inomas p re fe ren t ia l ly  ta rge t  common 
frag i le  s i tes  inc luding  FRA3B ( 3 p l4 .2 )  where  the FHIT gene and 
D3S1300 are loca ted ,  and are accompanied  by de le t ion  of cel lu lar  
genes (Wilke et al,  1996;Thor land et al,  2003). Thus, LOH at 
these  loci  may be d irec t ly  a t t r ibu ted  to HPV16 infec t ion  in some 
cases.
The s ign i f ican t  assoc ia t ion  of LOH at D3S1300 ( 3 p l4 .2 ) ,
D3S1260 (3p22.2) ,  D11S35 ( l l q 2 2 . 1 )  and D11S528 ( l l q 2 3 . 3 )  
with poor p rognosis  of CIN s t rongly  suggests  that  these markers  
may be at or in the v ic in i ty  of tumour suppresser  genes.  
B io in fo rm at ic  analysis  of the genomic region at these  loci  
iden t i f ied  several  genes inc lud ing  two known genes FHIT and PR, 
which  could be the target  of de le t ions .
FHIT, spanning the FRA3B frag i le  site and the b reakpo in t  of 
t (3 ;8)  of famil ia l  renal  carc inoma, has been proposed  as a tumour
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suppresser  gene (Ohta et al,  1996). Dele t ion  and reduced or 
absent  express ion  of the FHIT gene occur in a wide range of 
human carc inom as including  cervical  carc inom a (Birrer  et al,  
1999;Yoshino  et al,  2000;Butle r  et al,  2000 ;H el land  et al,  2000). 
In CIN les ions ,  LOH and reduced or absent  FHIT express ion 
posi t ive ly  corre la te  with the h is to log ica l  grade. Moreover ,  LOH 
is assoc ia ted  with reduced FHIT express ion  (B ir re r  et al,  1999; 
Connolly  et al,  2000;Butle r  et al,  2002) . Our resul ts  re inforce  
the assoc ia t ion  of FHIT gene de le t ion  with p rogress ion  of CIN 
and fur ther  indica te  that  de le t ion  of the gene has p rognost ic  
value.
PR, encodes two isoform s,  PR-A and PR-B, func t ion ing  as l igand 
act iva ted  t ranscr ip t iona l  fac tors .  PR-A and PR-B have d if fe ren t  
t ransc r ip t ion  ac t iva t ion  proper t ies  and play d is t inc t ive  roles  in 
d i f fe ren t  t is sues  (Connol ly  et al,  2000). PR-B acts as a 
t ransc r ip t iona l  ac t iva to r  and is importan t  for normal  p ro l i fe ra t ive  
response  of  mammary glands to p roges te rone ,  while  PR-A 
funct ions  as a t ransc r ip t iona l  repressor  and is c r i t ica l  for 
p roges te rone  dependent  rep roduct ive  responses  in u terus  and 
ovary (Connolly  et al ,  2000). PR-A represses  the ac t iv i ty  of 
PR-B and other  s te ro id  recep tors  including  oes t rogen  receptor  
a lpha (Connolly  et  al,  2000),  which may underl ie  the mechanisms 
of p roges terone  m edia ted  an t ip ro l i fe ra t ive  e f fec t  in endometr ia l  
carcinoma. Dele t ion  of the PR gene and loss of its express ion  are
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assoc ia ted  with aggress ive  endometr ia l  carc inom a and ep i the l ia l  
ovarian  tumours .  In cervica l  carcinoma, reduced PR express ion  
has been found in cervica l  carcinoma in com par ison  with normal 
cervix.  Taken these data together ,  PR is l ike ly  to be the target  of 
de le t ion  at D11S35. This  is in line with the sugges t ion  by both 
ep idem io log ica l  and labora tory  studies  that s te ro id  hormones play 
a role  in development  of squamous carc inom a of the cervix 
(Moodley et al,  2003).
In summary, we have iden t i f ied  four m arkers  at which LOH is 
s ign i f ican t ly  a ssoc ia ted  with the c l in ica l  behav iour  of  CIN 
les ions .  Combined analys is  of  LOH at these  loci  could ident i fy  
at least  a third of CIN les ions  that  pers is t  or p rogress  despite  
t rea tm ent .  In v iew of the enhanced power of  combined LOH 
analysis  of mult ip le  loc i ,  addit ion  of other  m olecu la r  markers  of 
p rognos t ic  s ign i f icance  should fur ther  improve the sens i t iv i ty  of 
the current  assay and eventual ly  allow developm ent  of a 
p rognos t ic  test  for CIN les ions ,  Leading to improved  pa t ien ts  
management .
Hence the p rognos t ic  markers  wil l only be e f fec t ive  if  used at 
c r i t ica l  t imes of  the evolu t ion  of the les ion .  It is yet to be 
de termined when is the best  in te rval  to im plem ent  such analysis .  
A l though  our study showed that  average t ime for  the les ion  to 
show recurrence  was 26 months (6-90 months) .  W hereas  average 
time to gain LOH is 30 months (5-93 months) .  So for a les ion  to
-126-
progress  many genet ic  changes should occur;  LOH being one of 
them according to our resul ts .
It is in te res t ing  to note that  LOH was seen in a p ropor t ion  of 
CIN1 les ions ,  suggest ing  that  these CIN1 les ions  maybe 
monoclonal .  This appears  to be d ifferent  from the observa t ion  of 
c lona l i ty  analys is  with  the X-l inked androgen  recep tor  gene 
where po lyclonal  pa t tern  was shown in 3 of the 3 CIN1 les ions 
examined.  The d isc repancy  is most  l ikely due to: 1) the number 
of cases s tudied by c lonal i ty  analysis  is small ,  and 2) LOH 
analysis  is more sens i t ive  than c lonal i ty  analys is  in de tec t ion  of 




The overa l l  ob jec t ive  of this  thesis  was to f ind a p rognost ic  
marker  for CIN. The spec i f ic  aims were threefo ld :  1) to
inves t iga te  the su i tab i l i ty  of archival  cerv ica l  smears for PCR- 
based m olecu la r  inves t iga t ions ;  2) to exam ine  the prognost ic  
value of PCR-based  c lonal i ty  analysis  of  the X-l inked  androgen 
recep tor  gene in CIN; and 3) to screen a se r ies  of m ic rosa te l l i te  
markers ,  which show high f requencies  of  LOH in cerv ica l  
carc inoma,  in a large cohort  of  CIN, iden t i fy  those assoc ia ted  
with CIN pers is tence  and/or  p rogress ion  and examine their  
combined value in prognosis  of  CIN.
Curren t ly ,  there is no b iochem ica l  or m o lecu la r  marker ,  which 
can d is t ingu ish  same grade CIN with d if fe ren t  c l in ica l  behaviour .
The p rognos t ic  value of HPV typing  has been ex tens ive ly  s tudied.  
Despi te  that  high risk HPV in fec t ion  is s t rongly  im pl ica ted  in the 
genesis  of cerv ica l  carc inom a,  the role of HPV typing alone in 
CIN prognosis  is l im ited .  This is m&inly due to f requent  
presence  of high risk HPV in normal  cerv ica l  smears  (Lorincz  et  
al,  1992;Kjaer  et al,  2002),  and border l ine  les ions  (Lorincz  et al,  
1992;Kjaer  et al,  2002). In addit ion ,  HPV in fec t ion  may be 
f requent ly  t rans ien t  (Nobbenhuis  et al,  1999).
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To iden t i fy  poten t ia l  molecular  markers that  may serve as a 
p rognos t ic  marker  for  CIN, we have carr ied  out a ser ies  of 
s tud ies  based on a rchival  cervica l  smears conta in ing  CIN les ions ,  
for  which appropr ia te  c l in ica l  fo l low-up data  were avai lable .  
F irs t ,  we have es tab l ished  and opt imized  several  molecular  
m ethods  on archival  cervica l  smears ,  which provided  a basis  for 
subsequen t  inves t iga t ions .
By sys tem at ica l ly  tes t ing  d if fe ren t  DNA ex trac t ion  methods,  we 
have demonstra ted  that  PCR ampl i f ica t ion  of  genomic  DNA 
sequences  can be applied  to crude DNA prepa ra t ion  from minute 
cel ls  m ic rod issec ted  from archival  smears .  When the DNA 
segment  to be amplif ied  is res t r ic ted  to 250 bp or less,  most  if 
not all  a rchival  smears ,  are su i tab le  for PCR. If  it is necessa ry  to 
ta rge t  a s l igh t ly  larger  f ragment ,  a rchival  cerv ica l  smears are 
s t i l l  a va luab le  resource  because  major i ty  of cases can be used 
for  PCR up to 460 bp. In fact ,  the quali ty  of DNA samples 
prepared  from archival  cerv ica l  smears is much be t te r  than those 
p repared  from arch ival  fo rm al in - f ixed  and pa ra f f in -em bedded  
t is sues ,  from which it is of ten  d i f f icu l t  to amplify  f ragm ents  
la rger  than 300 bp (Jackson  et al ,  1990;Coates  et al,  1991). Thus, 
c rude DNA prepa ra t ion  from minute  m icrod issec ted  cells  should 
meet the need of most  common PCR-based  m olecu la r  analyses ,  
such as sc reening  for gene muta t ion ,  LOH, and HPV typing.
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A fter  p u r i f ica t ion ,  DNA samples prepared  from m icrodissec ted  
d yskaryo t ic  cells  can be readi ly  d iges ted  with res t r ic t ion  
enzymes,  such as HapII , are therefore  su i tab le  for PCR-based  
c lona l i ty  analysis  of the X-chromosome inac t iva t ion  pa t tern .  By 
para l le l  analysis  of cerv ica l  smears and m atched cervical  
b iops ies ,  we have shown that  PCR-based  c lona l i ty  analys is  can be 
readi ly  applied  to a rchival  smears with more than 10 years of 
s torage  time (el Hamidi et al,  2003) . Fur therm ore ,  we have 
shown that  m ic rod issec ted  dyskaryot ic  cel ls  from archival  
cerv ica l  smears are su i tab le  for RT-PCR. However ,  the f ragment  
to be amplif ied  by RT-PCR should be res t r ic ted  to less than 150 
bp (Hamidi  et al,  2002;Liu  et al,  2002).
Having es tab l ished  the methods for m olecu la r  inves t iga t ions  of 
archival  cerv ica l  smears , we have re t ro spec t ive ly  examined the 
prognost ic  value of c lona li ty  in archival  cerv ica l  smears .  Our 
resul ts  from cerv ica l  smears  are in line with prev ious  f ind ings  
from studies  based on cerv ica l  carcinoma b iops ies :  CIN3 and the 
major i ty  of CIN2 les ions  are monoclonal ,  whereas  CIN1 les ions  
are po lyclonal  (Enomoto et al,  1994; Park et al,  1996; Enomoto et  
al,  1997;Ko et al ,  1997 ;G uob, et al. 1998).
Im portan t ly ,  we have shown that  c lonal i ty  may be va luab le  in 
prognosis  of CIN2 les ions .  All pa t ien ts  with m onoclonal  CIN2 
les ions  showed e i ther  pe rs is tence  or p rogress ion  of the disease  
during fo l low-up,  despi te  t rea tm ent .  In con tras t ,  pa t ien ts  with
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polyc lona l  CIN2 les ions became negat ive  after  t rea tm ent  and 
remained disease free during fol low-up.
It is in te res t ing  to note that  the presence  of  h igh -r isk  HPV 
subtypes  did not d is t ingu ish  m onoclonal  CIN2 from po lyclonal  
CIN2, a l though their  incidence  is much h igher  in monoclonal  
CIN2 than in po lyclonal  CIN2.
The s ign i f ican t  corre la t ion  between c lona l i ty  and c l in ica l  
behav iour  of CIN2 les ions  s trongly  indicates  that  gene t ic  markers  
can be used for CIN prognosis .  However,  app l ica t ion  of the 
c lona l i ty  assay in rout ine  p rac t ice  is h indered  by its need for 
h ighly  pur if ied  DNA samples,  a re la t ive ly  large number  of  cells ,  
and a lack of high th roughpu t  approach.  Thus, o ther  genet ic  
markers  are desired .  We there fore  re t rospec t ive ly  inves t iga ted  the 
p rognos t ic  value of  LOH markers  in CIN.
To ident i fy  the loci  at which LOH may be of p rognos t ic  value in 
CIN, we reviewed the l i te ra tu re  and iden t i f ied  the chromosomal  
reg ions  and m ic rosa te l l i te  markers  that  show high inc idences  of 
LOH in cerv ica l  carc inom a,  and where poss ib le  in CIN les ions .  
We have se lec ted  12 m ic rosa te l l i te  markers  inc lud ing  10 from 
3 p l4 .2 ,  3p21-22,  6p21 and l l q 2 3 ,  which show high f requency 
LOH in cervica l  carc inom a,  and screened them for  LOH in 
var ious  CIN les ions  (K e rsem aeke rs8 et al,  1998; K e rsem aek e rs8 et  
al,  1998; Skomedal  et al ,  1999; Kersemaekers  et al ,  1999; Chung et  
al,  2000; ; Pul ido et al ,  2000 Guob et  <*/,2000;Chuaqui et al,  
2001; Harima et a l ,2001; Chatter jee  et al,  2001;Acevedo  et al,
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2002;Senchenko  et a l , 2003). The in it ia l  sc reen ing  was based on 
71 cases of  CIN (15 CIN1, 22 CIN2 and 34 CIN3) using cervica l  
smears .  The f requency of LOH at various m ic rosa te l l i te  markers 
was compared between CIN that  showed d isease  free and those 
that  showed disease  pers is tence  or p rogress ion  after t rea tment.  
The aim of the p i lo t  s tudy was to ident i fy  m ic rosa te l l i te  markers  
that  may have po ten t ia l  p rognost ic  value for CIN.
Among the 12 markers  examined,  D3S1300 ( 3 p l 4 . 2 ) ,  D3S1260
(3p22.2)  and D11S528 ( l l q 2 3 . 3 )  showed LOH at s ign if ican t ly  
h igher  f requencies  in the DP than DF group (p<0.01) ,  (Figure  
5 .1A).  D11S35 ( l l q 2 2 . 1 )  exh ib i ted  the next h ighes t  s ta t i s t ica l  
d i f fe rence  between the two groups although not at a s ign i f ican t  
level .
Using a s tepwise  s ta t i s t ica l  analys is  tes t ing var ious  combinat ion  
of the 12 markers ,  the above four markers co l lec t ive ly  gave the 
h ighes t  s ta t i s t ica l  s ign i f icance  (p<0.02)  be tween  the two groups 
and were se lec ted  for fu r ther  analysis .  Given that  the value of 
using these loci a lone as p rognos t ic  markers  was l imited ,  we 
tes ted  the four markers  together  (Figure 5 . IB) .  By stepwise 
exam ina t ion  of the sens i t iv i ty  and spec i f ic i ty  of  the combined 4 
LOH markers ,  i .e.  1 or 2 or 3 or all of the 4 loci  showing LOH, 
the best  cu t-o f f  point  was when 2 of the 4 loci  showing LOH was 
applied .  At this th reshold ,  a round 45-58% of CIN les ions  in the 
DP group but none in the DF group were iden t i f ied .
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Having iden t i f ied  the four m ic rosa te l l i te  markers  that  are 
po ten t ia l ly  va luab le  in CIN prognosis ,  we have fur ther  va l ida ted  
the p rognos t ic  value of these markers  in add i t iona l  93 cases of 
CIN. To make the exper iment  easier ,  we have used d iagnos t ic  
b iops ies  ra ther  than cerv ica l  smears since it was much easier  to 
m ic rod issec t  neop las t ic  cells  from the former.  The resu l ts  
ob ta ined  from b iops ies  were compatib le  to those  from the 
cerv ica l  smears in the p i lo t  s tudy.
In to ta l ,  we have screened 164 cases of CIN includ ing  54 CIN1, 
59 CIN2 and 51 CIN3 for  LOH at D3S1300, D3S1260,  D11S35,  
and D11S528.  The f requency  of LOH at D3S1300,  D3S1260,  and 
D11S35 posi t ive ly  corre la ted  with CIN grade,  while  the inc idence  
of LOH at D11S528 was s im ila r  among d i f fe ren t  CIN groups 
(F igure  5.2A). As expec ted ,  the frequency of LOH at these  loci  
was s ign i f ican t ly  h igher  in the DP group (p<0 .0005 ,  Figure  5 .2B). 
By combining  the 4 m arkers  toge ther ,  22% of CIN1, 28% Of CIN2 
and 47% of CIN3 of  the DP group but none of  the DF group 
showed LOH at 2 or more of the 4 loci exam ined  (Figure  5 .2C).  
Thus, LOH analysis  at these loci  could iden t i fy  22-47% of CIN 
les ions  that  showed disease  pers is tence  despi te  t rea tm ent .
To fur ther  evaluate  the a ssoc ia t ion  of  LOH with c l in ica l  outcome 
of CIN, we have examined both d iagnos t ic  and fo l low -up  b iops ies  
in 22 cases from the DP group.  None of the 5 cases that  became 
d isease  free after  the f i rs t  fo l low-up b iopsy  exh ib i ted
-133-
accum ula t ion  of LOH in the fo l low-up specim ens .  In contras t ,  13 
of  the 17 cases that  had disease p e rs is tence  or p rogress ion  
showed accum ula t ion  of LOH at add it ional  loci  in the fo l low-up 
specimens .  In 6 cases,  the prognost ic  va lue  of LOH was not 
s ign i f ican t  in the d iagnos t ic  specimens but reached the threshold  
of s ign i f icance  in the fo l low-up biopsies  (Table  5.2). The resul ts  
s t rongly  indicate  that  LOH analysis  of fo l low -up  specimens could 
fu r ther  segrega te  CIN les ions  with d i f fe ren t  c l in ica l  outcome. 
However ,  it remains to be dete rmined  when is the best  in terval  to 
implement  such analysis .  Our p re l iminary  study showed that an 
average  of  30 months was required  for  acqu is i t ion  of an 
add i t iona l  LOH at the 4 loci  examined.
The f ind ing  of a s ign i f ican t  assoc ia t ion  of LOH at D3S1300 
( 3 p l4 .2 ) ,  D3S1260 (3p22.2) ,  D11S35 ( l l q 2 2 . 1 )  and D11S528 
( l l q 2 3 . 3 )  with poor p rognosis  of  CIN s t rongly  suggests  that  these 
m arkers  may be at or in the v ic in i ty  of TSGs.  We have performed 
b io in fo rm at ic  analys is  of the genomic  region  at these  loci 
a t tem pting  to iden t i fy  the po ten t ia l  genes ta rge ted  by de le t ion .  
We have found two known genes FHIT and PR,  which could be 
the target  of de le t ions  as shown by LOH at D3S1300 and D11S35 
respec t ive ly .
FHIT has been p roposed  as a TSGs (Ohta et  al ,  1996).  Dele t ion  
of the gene and reduced or absent  of its p ro te in  express ion  have 
been found in a wide range of human carc inom as  inc luding
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cervica l  carc inom a (Birrer  et al,  1999;Yoshino et al,  2000;Butle r  
et al,  2000; Helland et al,  2000;Baykal ,  2003).  In CIN, LOH and 
reduced or absent  FHIT pro te in  express ion  posi t ive ly  corre la te  
with  the h is to log ica l  grade.  Moreover,  LOH is assoc ia ted  with 
reduced FHIT prote in  express ion  (Birrer  et al ,  1999; Connolly  et 
al,  2000;Butle r  et al,  2002). In te res t ing ly ,  HPV16 in tegra t ions  in 
cerv ica l  carc inomas p re fe ren t ia l ly  target  common fragi le  si tes 
inc lud ing  FRA3B (3 p l4 .2 )  where the FHIT gene and D3S1300 are 
loca ted ,  and are accompanied  by dele t ion  of ce l lu la r  genes (Wilke 
et al,  1996;Thor land et al,  2003).  We have found that  HPV16 
infec t ion  s ign i f ican t ly  corre la tes  with LOH at D3S1300.  Taken 
together ,  our resu l ts  re in force  the assoc ia t ion  of FHIT gene 
de le t ion  with p rogress ion  of  CIN and fur ther  ind ica te  that  
de le t ion  of  this  gene has a p rognos t ic  value.
Dele t ion  of the PR  gene and loss of its express ion  are assoc ia ted  
with aggress ive  endom etr ia l  carcinoma and ep i the l ia l  ovarian  
tumours .  Reduced PR express ion  has been found in cerv ica l  
carc inoma in compar ison  with normal cervix .Taken these data 
together ,  PR is l ike ly  to be the target  of de le t ion  at D11S35.
In summary, 1) We have es tab l ished  and op t im ized  severa l  PCR 
based  m olecu lar  methods on archival  cerv ica l  smears ,  which 
prov ides  a basis  for  m olecu la r  inves t iga t ions  of a rchival  
pa tho log ica l  specimens;  2) We evaluated  the p rognos t ic  va lue  of 
c lona li ty  in archival  cerv ica l  smears, and found a s ign i f ican t
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corre la t ion  be tween c lona l i ty  and cl in ica l  behav io r  of CIN2 
les ions ;  3) We iden t i f ied  four m ic rosa te l l i te  markers  at which 
LOH is s ign i f ican t ly  assoc ia ted  with the c l in ica l  behav iour  of 
CIN.
6.1 Future work
Using m olecu lar  markers  in large cohort  of CIN les ions  may 
iden t i fy  new groups of CIN les ions with  d i f fe ren t  c l in ica l  
behaviour .  This may help in updating  the m orpho log ica l  grading 
system and making it more c l in ica l ly  re levant .  Inves t iga t ing  the 
D6S277 LOH marker  by carry ing  out LOH analys is  in s imilar  
manner  to the 4 LOH markers  done in this  thes is .  Testing the 
combined p rognos t ic  va lues  of the LOH m arkers  by develop ing  a 
robust  high th roughpu t  assay.
Also,  pe rform ing  ex tens ive  b io in fo rm at ics  study to ident i fy  the 
gene t ic  ne tw ork  that  l inks  the genes a ssoc ia ted  with  the LOH 
markers ,  once the ne tw ork  is ident i f ied ,  a pa thway would be 
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